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ABSTRACT 
It is clear that dendritic cells (DCs) are essential for priming of T cell responses against 
tumors. However, the distinct roles DC subsets play in regulation of T cell responses in 
vivo are largely undefined. In this study, we investigated the capacity of ovalbumin 
(OVA)-presenting CD4–8–, CD4+8–, or CD4–8+ DCs (OVA-pulsed DC (DCOVA)) from 
mouse spleen in stimulation of OVA-specific T cell responses. Our data show that each DC 
subset stimulated proliferation of allogeneic and autologous OVA-specific CD4+ and CD8+ 
T cells in vitro, but that the CD4–8– DCs did so only weakly. Both CD4+8– and CD4–8+ 
DCOVA induced strong tumor-specific CD4+ Th1 responses and fully protective CD8+ 
cytotoxic T lymphocyte (CTL)-mediated antitumor immunity, whereas CD4–8– DCOVA, 
which were less mature and secreted substantial transforming growth factor (TGF- ) upon 
coculture with T cell receptor (TCR)-transgenic OT II CD4+ T cells, induced the 
development of interleukin-10 (IL-10)-secreting CD4+ T regulatory 1 (Tr1) cells. Transfer 
of these Tr1 cells, but not T cells from cocultures of CD4–8– DCOVA and IL-10–/– OT II 
CD4+ T cells, into CD4–8+ DCOVA-immunized animals abrogated otherwise inevitable 
development of antitumor immunity. Taken together, CD4–8– DCs stimulate development 
of IL-10-secreting CD4+ Tr1 cells that mediated immune suppression, whereas both 
CD4+8– and CD4–8+ DCs effectively primed animals for protective CD8+ CTL-mediated 
antitumor immunity.  
Different DC subsets play distinct roles in immune responses. CD4-8- DCs secreting 
TGF-β stimulate CD4+ regulatory T type 1 (Trl) cell responses leading to inhibition of 
CD8 CTL responses and antitumor immunity.  In this study, we explored the potential 
effect of three stimuli CpG, lipopolysaccharide (LPS) and anti-CD40 antibody in 
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conversion of CD4-8- DC-induced tolerance. We demonstrated that when CD4-8- DCs 
were isolated from overnight culture and cultured for another 8 hrs in AIM-V plus 
recombinant mouse granulocyte-macrophage colony-stimulating factor (rmGM-CSF) 
(15-20 ng/ml) and OVA (0.1 mg/ml) with CpG (5 ug/ml), LPS (2 ug/ml) and anti-CD40 
antibody (10 ug/ml), their phenotype became more mature compared with the freshly 
isolated ones. CpG is the only agent that stimulates the DCs to secrete significant level of 
interleukin-6 (IL-6) and interleukin-15 (IL-15); DNA array analyses also indicate that 
CpG stimulates higher expression of IL-6 and IL-15 mRNA. CpG treatment most 
efficiently converts the tolerogenic DCs into immunogenic ones which stimulated the 
OTII CD4+ T cell to become T helper type 1 (Th1) and T helper type 17 (Th17) rather 
Tr1, while the other two stimulator-treated DCs could not induce Th17 response.  Their 
vaccination also induced the strongest antitumor CTL responses and protective immunity 
against tumor cell challenge.  When CD4-8- DCs were isolated from IL-6 knock out 
(IL-6-/-) mice, CpG-treated DCOVA vaccination almost completely lost their animal 
protection capacity. Wild type B6 DCOVA-vaccinated IL-15 receptor knock out (IL-15R-/-) 
mice can only provide up to 30% protection against tumor challenge. Those results 
indicate that IL-6/ IL-l5-induced Th17 plays a critical role in their conversion. Taken 
together, our findings indicate that CpG treatment is the most efficient agent that can 
convert tolerogenic DCs into immunogenic ones and induce long-lasting antitumor 
immunity.  
We previously demonstrated that the nonspecific CD4+ T cells can acquire 
antigen-specific DC-released exosomes (EXO) and these CD4+ T cells with acquired 
exosomal MHC I peptide complex (pMHC I) can stimulate antigen-specific CD8+ CTL 
responses. In my project we have found that CD4-8-DCs could induce regulatory T cell 
type 1(Tr1) response, thus it would be very necessary to know whether regulatory T cells 
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would change their antigen specificity if they got the membrane complex from DC 
through coculture or DC-derived exosome pulsing. During the beginning of my 
regulatory T cell project, we found that CD8+CD25+ Tr were much more easily 
expanded, while CD4+CD25+ Tr usually began to die just after 3 days in vitro culture and 
it’s very hard to get enough cells for further research. Therefore, CD8+CD25+ were used 
as a model Tr cells in the following project. To assess whether the nonspecific 
CD8+CD25+ Tr cells can acquire antigen-specificity via acquired exosomal pMHC I, we 
purified CD8+CD25+ Tr cells from wild-type C57BL/6 mice and OVA-pulsed 
DCOVA-released EXOOVA expressing pMHC I complexes. We demonstrated that the 
nonspecific CD8+CD25+ Tr cells expressing forkhead box P3 (Foxp3), cytotoxic 
T-Lymphocyte Antigen 4 (CTLA-4), glucocorticoid-induced tumor necrosis factor 
receptor (GITR), perforin and granzyme B inhibited in vitro T cell proliferation and in 
vivo OVA-specific CD4+ T cell-dependent and independent CD8+ CTL responses and 
antitumor immunity. CD8+CD25+ Tr cells’ suppressive effect is possibly mediated 
through its inhibition of DC maturation, down-regulation of secretion of Th1 polarization 
cytokines by DCs and its induction of T cell anergy via cell-to-cell contact.  The 
nonspecific CD8+CD25+ Tr cells acquired antigen specificity by uptake of 
DCOVA-released EXOOVA expressing pMHC I and enhanced its effect on inhibition of 
OVA-specific CD8+ T cell responses and antitumor immunity by 10-folds. The principles 
elucidated in this study may have significant implications not only in antitumor 
immunity, but also in other sectors of immunology (e.g, autoimmunity and 
transplantation).  
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1.0 LITERATURE REVIEW  
 
 
1.1 Introduction on dendritic cells 
     
   Dendritic cells (DCs), first recorded as Langerhans cells (LCs) in the skin in 1868 and 
initially characterized about 35 years ago as accessory cells for antibody production, are 
now found to be the strongest and unique antigen-presenting cells (APC) ever reported.  
Their ability to recognize, acquire, process and present antigen to naïve, resting T cells 
for the induction of antigen-specific immune responses surpass that of any other kind of 
APCs including macrophage, B cells, other leukocytes (1-5). DCs can even directly kill 
some tumor cells by expressing Fas ligand (FasL), granzyme B, perforin, tumor necrosis 
factor alpha (TNF-α) and TNF-related apoptosis-inducing ligand (TRAIL) (6-9); Very 
recently a new type of DCs called interferon-producing killer DCs, which share some 
characteristics of DC and natural killer (NK) cells and produce substantial amounts of 
type I interferons (IFN) and interleukin (IL)-12 or IFN-gamma (IFN-γ), depending on 
activation stimuli, was identified (10-13), although later this kind of cells were further 
confirmed to be activated natural killer (NK) cells (14, 15).  Although DCs comprise 
only a small proportion (0.1-1%) of the cells in different lymphoid and non-lymphoid 
tissues (5), they are widely distributed in the body and divided into numerous subsets.  
Currently they are classified as conventional (c)DC (CD11chigh and MHCIIhigh) and 
plasmacytoid (p)DC (CD11cintMHCIIlowCD11b-CD205-CD123+) (16), with conventional 
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DC further grouped into CD8α+, CD8α-, dermal, monocyte-derived DC based on their 
function and marker differences (17). A third population of DCs, uniquely present in the 
lymph node but absent from the spleen or thymus, corresponds to migratory DCs 
including Langerhans cells and interstitial DCs that migrate from peripheral tissues 
through the lymphatics (18).  DCs were first grouped as myeloid and lymphoid DCs 
according to whether they have markers related to lymphocytes (1).  However, this 
lineage-based classification system has been discarded because both CD8α+ and CD8α- 
DCs can arise from clonogenic common myeloid progenitors in both thymus and spleen 
(19, 20).  CD8-CD11c+ precursor in the spleen could be committed to CD8α + dendritic 
cells (21, 22), and DC subsets with function similar to spleen CD8+ and CD8- dendritic 
cell could be induced in bone marrow cultures with Fms-like tyrosine kinase 3 ligand 
(Flt3 L), not just isolated from spleen (23).  Both plasmacytoid and conventional 
dendritic cell subtypes could be developed from single precursor cells derived in vitro 
and in vivo (24, 25).  Cross-priming, the ability of certain antigen-presenting cells to 
take up, process and present extracellular antigens with MHC class I molecules to CD8 T 
cells, has been credited to conventional myeloid DCs with the exception of  the pDCs, 
meaning that DCs have the capacity to take up, process, and present exogenous antigens 
in association with MHC class I molecules (4).  pDCs have been reported to have little 
or no T cell–stimulatory ability (26), but to promote the generation of regulatory T cells 
(27, 28), depending on the time after activation that pDC function is assessed.  
However, other contradictory results have shown that pDCs have the same capacity to 
stimulate anti-virus CD4+ and CD8+ T cells responses (29) and that pDCs use 
‘ready-made’ stores of major histocompatibility complex (MHC) class I to rapidly 
present exogenous antigen to CD8+ T cells. This meant that pDCs can also do the cross 
presentation (30). Even the antigen specific B cells has also been reported to 
cross-present immune-stimulating complex-associated cognate antigen (31) and cross 
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present the CpG-OVA to naive CD8 T cells (32); which means that cross-priming is 
widely existed among different APCs. Traditionally DCs have been considered to be an 
end-stage cells which only survive several days after activation and maturation (33), but 
this concept has been challenged by the report that culture-generated mature DCs can 
further differentiate under the influence of stromal cells (34).  
   DCs are the most potent antigen presenting cells that exist in virtually every tissue. 
However, most DCs that reside in lymphoid organ are phenotypically and functionally 
immature, most likely for the purpose of maintaining peripheral tolerance (35, 36) . 
Langerhans cells (LCs), which were the first characterized DC, capture antigens in the 
periphery during their immature stage, migrate to the lymphoid organs and present those 
captured  antigens during their mature stage. When DCs are immature, they express 
very low level of MHC class II molecules, and costimulatory and adhesion molecules 
such as CD40, CD54 [inter-cellular adhesion molecule 1 (ICAM-1)], CD80 (B7.1) and 
CD86 (B7.2), etc.  After meeting with exogenous and endogenous stimulation, they 
become mature and up-regulate the expression of above –mentioned antigen presentation 
machinery.  They interact with antigen specific CD4 and CD8 T cells through the 
binding of MHC peptide with TCR, CD80/86 with /CD28 (37-40), CD54 with 
lymphocyte function-associated antigen-1 (LFA-1) (41, 42), CD40 with CD40L (43-46), 
OX40 with OX40L (47), 4-1BB with 4-1BBL (5, 48),  and CD70 with CD27 (49-54), 
etc, and activate the naive T cells  with the help of cytokines such as IL-2, IL-4, IL-12 
and many more.  
   For the activation of naive CD8+ T cells by APC, currently there are two popular 
mechanisms: cross-priming and direct priming. The major differences between 
cross-priming and direct priming are the source of Ag and the cell type that presents the 
Ag to the responding CD8+ T cells. In cross-priming, professional APCs, such as DCs 
acquire exogenous Ag by endocytosis, pinocytosis and phagocytosis, process the Ag into 
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peptides and load them onto MHC I, then finally present them to the antigen specific 
CD8+ T cells.  In direct priming, the APCs, which may or may not be DC, synthesize, 
process their endogenous Ag, and present it by themselves to CD8+ T cells.  Recently a 
third mechanism, called cross-dressing was reported (55).  DC directly acquire MHC 
class I-peptide complexes generated by other dead donor cells by a cell contact-mediated 
mechanism, and present the intact complexes to naive CD8+ T cells. The activated CD8+ 
T cells are restricted to the MHC class I genotype of the donor cells and are specific for 
peptides generated by the donor cells. In vivo studies demonstrate that the cooperation 
between cross-priming and cross-dressing are required for the optimized priming of 
CD8+ T cells. Thus, cross-dressing might be an important mechanism by which DCs 
process inefficiently cross-presented antigens for priming of naive CD8+ T cells. When 
DCs were injected in vivo, people found that a majority of resident DCs expressed donor 
MHC molecules and that a proportion of injected DCs acquired host MHC molecules. 
The bidirectional MHC molecule exchange between migratory and resident DCs (56) 
might provide a new clue for how DCs exchange antigen-MHC complexes and amplify 
the antigen presentation in vivo, and also showed that DC could acquire MHC class 
I-peptide complex from live cells, contrary to the Dolan et al’s conclusion (55).   
 
1.2 Mouse dendritic cells 
 
  Mouse DCs  were first discovered in mouse spleen and named as DCs based on 
their unique morphology (57).  However, because DCs are normally present in 
extremely small numbers in the circulation and tissue, their research didn’t make 
significant progress for almost two decades until the development of in vivo and in vitro 
expansion of DCs.   Recent advances in DC biology have allowed the development of 
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methods to generate large numbers of these cells in vitro (58-65).  Because preparing 
dendrite cells preparation from bone marrow (BM) was the most efficient and popular 
way, most studies on DCs were based on this type of DCs.  At the beginning of DC in 
vitro cultures, people used a cocktail of McAbs including anti-CD4, CD8, B220 and Ia 
antibody and rabbit complement to eliminate lymphocytes and I-a positive cells.  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was used as the only 
growth factor to promote the formation of DC from bone marrow progenitors.  After 1 
week, more than 5 x 106 DCs  from precursors within the large hind limb bones of a 
single animal can be produced;  however, other cells such as granulocytes and 
macrophages were also generated and the DCs yield was relatively low (58).  Scheicher 
et al first used anti-Ia antibody coated beads to isolate the cultured DC with low 
concentration of GM-CSF and cell purity up to 95% could be obtained (63).   Lutz et al 
improved upon the above standard method to propagate 1–3 x 108 BM-DCs per mouse at 
90–95% purity after 10–12 days. The achievement of higher cell yields is based on 
several modifications of the standard culture conditions: i) Avoid any antibody and 
complement treatment to preserve more precursors, ii) Reduce the plating density of bone 
marrow cells, iii) Extend the culture period to 10–12 days, iv) Decrease the concentration 
of GM-CSF from 200U/ml to 30-100U/ml from day 8 or 10 onwards to reduce 
granulocyte contaminations (60). Garrigan et al first used GM-CSF and IL-4 to culture 
mouse bone marrow DCs and found that BM DCs were superior to spleen DC in 
processing native protein (66).   Labeur et al compared different combination of 
cytokines to culture BM DCs and found that DCs cultured in GM-CSF alone were 
immature.  They found that lipopolysaccharide (LPS) and CD40L can make cells 
become mature, while DCs under GM-CSF+IL-4 with or without Flt3 ligand (Flt3L) 
exhibited intermediate maturation. When cells were further treated with CD40L, this 
group exhibited strongest antitumor capacity (67), which indicated generation of tumor 
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immunity by bone marrow-derived DCs is closely related to the DC maturation stage. 
DCs derived in GM-CSF plus IL-4 express cell-surface antigens typically associated with 
DCs, including DEC205, MHC class II, CD80, and CD86, and demonstrate potent 
allo-stimulatory activity (67). Son et al directly used BM cells without removing those 
attached cells as Labeur did (67) and did not use antibody and complement to remove 
other cells (58, 68). Culturing BM precursors using GM-CSF+IL-4 and six-well plates, 
around 30–40 x 106 /mouse DCs with 85–95% purity and more mature phenotype were 
obtained on day 7 (65).  Although bone marrow cultures in the presence of GM-CSF 
with or without IL-4 resulted in the differentiation of DCs with phenotypical and 
functional characteristics that are similar to those described for human monocyte-derived 
DCs, there are still differences.  In order to get data directly related to the human 
monocyte-derived DCs, research on DCs from mouse peripheral blood was very much 
needed, but there are very few reports because of limited amount of mouse blood.  One 
paper claimed that from the blood of one mouse 1x106 DC can be generated with 
GM-CSF (69).  Another paper compared the mouse monocyte-derived DCs (MODC) 
prepared with GM-CSF and IL-4 as growth factors with bone marrow-derived DC and 
found that they displayed similar morphology, phenotype and immunostimulatory 
activity (70). The isolation and characterization of mouse MODC will provide more 
information on fundamental aspects of DC biology and which DC subsets are most 
suitable to induce anti-tumor immunity. 
    Mouse pDCs express low level of CD11c along with B220 and Gr1, and after 
treatment with Flt3L, mouse pDCs can also become CD123 positive(71, 72).  They have 
also been found in the spleen, BM, and LN of naive animals and their number could be 
increased by the in vivo injection of Flt3L or Flt3L and GM-CSF.   Mouse 
CD11c+B220+ pDCs could be cultured with BM cells cultured in medium supplemented 
with 200 ng/ml recombinant human FL (23, 73) or M-CSF (74).  They are immature 
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APCs with very low level expression of MHC class II and activation markers; they don’t 
express IL3R (CD123)  which is reported to be expressed by human pDCs (75). 
Although being poor T cell stimulators, they could differentiate into cDCs when cultured 
in medium containing CpG plus CD40L plus GM-CSF (73). Thus, the in vitro generation 
of murine pDCs may serve as a useful tool to further investigate pDC biology as well as 
the potential role of these cells in viral immunity and other settings. 
A few researches have been done to use Flt3L as a single growth factor to culture 
mouse BM DCs and produce different subsets similar to those isolated from spleen (61).   
Although the expression of CD4 and CD8 markers were not detected before adding 
maturation modulators, function and systemic phenotype analysis including mRNA and 
protein level indicated that CD45RAhigh plasmacytoid DC, CD24high and CD11bhigh cDC 
subsets were generated in the culture.   The last two subsets functionally correspond to 
CD8+ and CD8- DCs in the spleen, indicating that we can culture spleen DC subsets using 
BM precursors without the need of time-consuming and cost ineffective isolation from 
the spleen (23). 
   For the studies on the DCs from tissues such as thymus, spleen, lymph node and liver, 
collagenase and/or DNase digestion were exploited to separate the DCs.  During the 
purification, some added EDTA in the buffer to keep the cells from attaching to each 
other.  However, some DC subsets might be very sensitive to the EDTA treatment and 
may become damaged.   After red blood cells lysis, people use short time plate culture 
and prewarmed PBS washing to crudely separate the splenic DCs from most T and B 
cells. They harvest the attached cells and purify CD11c+ DCs by using MACS beads 
technology, or by directly staining the cells and using the FACS sorter to isolate the 
CD11c+ DCs or different subsets (76-78).  
   One way of increasing the number of DCs in the tissue is in vivo injection of the DC 
growth factors, such as GM-CSF, G-CSF, progenipoietin-1 (ProGP-1), or Flt3L into the 
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mice (78-80).  Among the above growth factors, ProGP-1 is the strongest factor in 
increasing the overall DC numbers.  The effects on the ratio change of DC subsets 
among spleen depend on the specific growth factor; ProGP-1 and Flt3L selectively 
expanded CD8+ DCs, whereas GM-CSF mainly increased the number of CD8- DCs.  
However, all the growth factors except G-CSF expanded DCs have some functional 
differences compared with its counterparts in the wild type mice (80). 
    By studying  the relationship of CD8+ and CD8- DCs, It was found that both 
common lymphoid progenitors (CLP) and common myeloid progenitors (CMP) could 
differentiate into CD8+ and CD8- DCs, thus DCs could be derived from two distinct 
differentiation pathways-myeloid or lymphoid (19).  Various cytokines or growth 
factors such as GM-CSF, IL-4, TNF-α, and Flt3L have been reported to be involved in 
DC development.   The first three were later found to be dispensable, while Flt3L 
remained critical to the development of DCs (81). GM-CSF and stem cell factor (SCF) 
were essential growth factors for the generation of DCs from CMP, whereas IL-7 was an 
essential cytokine for inducing the differentiation of CLPs into DCs (20).  DCs located 
in peripheral lymphoid organs are renewed from circulating bone-marrow-derived 
precursors while Langerhans cells are derived from proliferating precursors that are 
present in the skin.   However inflammatory changes in the skin can induce the 
recruitment of blood-borne progenitors with Langerhans-cell differentiation potential 
(82).  Induction of T-cell immunity against microbial infection involves the recruitment 
of DC precursors to lymphoid tissues and their local differentiation into DCs (83).  
Recently more evidences have indicated that DCs could differentiate from either 
lymphoid or myeloid precursors depending on the environmental conditions, such as the 
location and the presence of different exogenous and endogenous stimuli (23, 83). Now 
the early precursors for all DC subtypes are thought to be within the BM Flt3+ precursor 
populations, regardless of their lymphoid or myeloid lineage orientation (84).  In mouse 
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blood, a CD11c+ MHC class-II- DC-restricted precursor population, which can fully 
reconstitute splenic CD8-, CD8+ and plasmacytoid B220+ DC subpopulations, and lack 
lymphoid- or myeloid-differentiation potential, has been recently described (85). More 
recently a clonogenic common DC precursor (CDP) in mouse bone marrow was 
identified for the first time. The CDPs can develop and become, at a single-cell level, 
cDCs and pDCs, but not other cell lineages, in vitro. Phenotypically, CDPs express the 
receptor for Flt3L, the receptor for macrophage colony-stimulating factor (M-CSFR) and 
the receptor for stem cell factor (c-Kit), but they don’t express specific lineage markers 
(Lin-), CD11c and MHC-II. After transfer to nonirradiated 'steady-state' mice, CDPs 
develop exclusively into CD8+ DCs, CD8- DCs and pDCs in the peripheral lymphoid 
organ such as spleen and in the lymph node. Under in vitro culture condition, Flt3 ligand 
alone could make CDPs differentiate into DCs and pDCs, but M-CSF, a cytokine that is 
essential for macrophage differentiation(18), could not support the survival or 
differentiation of CDPs. In addition, when Flt3L were co-injected into the animal, CPDs 
expand and differentiate into all DC subsets in vivo (25). A clonal DC precursor (pro-DC) 
that closely resembles the CDP phenotypically and functionally was also identified in the 
mouse bone marrow lately.  Pro-DCs are defined phenotypically as 
Lin-CD11c-MHC-II-Flt3+M-CSFR+c-Kit+ similar to CDPs. Pro-DCs give rise at a 
single-cell level to pDCs and cDCs in vitro, whereas pro-DCs injected into nonirradiated 
mice give rise to pDCs, CD8+ and CD8- DCs not only in peripheral organs such as spleen, 
but also in the bone marrow (24). Therefore, the direct precursors of DCs were identified, 
which might solve the dilemma of the identities of haematogenous DC precursors.  
  For the mouse DC research, two phenotypically and functionally distinct 
subpopulations- CD8- and CD8+ DCs were identified at the beginning.  They are located 
at different areas in spleen and Peyer’s patches, where CD8- DCs reside in antigen uptake 
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zone and CD8+ DCs stay in T cell area.  Only CD8- DCs could induce B-cell activation 
and plasmablast differentiation (86, 87).  Although only CD8+ DCs could internalize 
apoptotic cells (88), CD8- DCs have higher capacity of endocytosis and pahgocytosis 
than CD8+ DCs (89).  In vivo CD8+ DCs secrete much higher level of IL-12 to induce 
strong Th1 response, while CD8- DCs mainly elicit Th2 response (90, 91). However, 
other studies have found that the ability of driving Th1 and Th2 response is not totally 
depending on specific DC subsets. Both subsets reside in the spleen as immature cells and 
become mature upon culture in vitro in GM-CSF-containing medium or in vivo in response 
to lipopolysaccharide. Only after maturation can DCs acquire their T-cell priming 
capacity.   Matured CD8+ DCs and CD8- DCs can activate naïve CD4+ and CD8+ T cells 
with equal potency and efficiency; thus environmental factors may have the ability to 
influence the Th responses of DC subsets qualitatively (92). These factors include the 
activation state of the DCs, the nature of the antigen, the concentration of antigen, the type 
of receptor that is responsible for antigen uptake and specific cytokines, such as IL-10 and 
IFN-γ (83, 93). For example, CD8- DCs could produce IL-12 and induce the production of 
Th1 cytokines under defined experimental conditions, such as in the absence of IL-10 or 
after CD40L-mediated activation.   At low antigen doses CD8+ DCs induced the 
production of Th2 cytokines, and at high antigen dose, CD8- DCs could also induce Th1 
response like CD8+ DCs (94, 95).    In the spleen, exogenous antigen is preferentially 
presented by CD8+ DCs to CD8+ T cells and by CD8- DCs to CD4+ T cells. CD8-CD11b-  
DCs in mesenteric lymph node (MLN) and CD8+CD11b+ DCs in peripheral lymph nodes 
(PLN)  mainly cross-present OVA to CD8+ T cells in their respective tissues in MLN and  
other PLN.   Regardless of tissue origin, CD8-CD11b+ DCs generally present OVA to 
CD4 T cells.  CD8-CD11b+ DCs in MLN and CD8+CD11b+ DCs in PLN present OVA to 
both CD4+ T and CD8+ T cells. Therefore, DCs’ anatomical environment as well as their 
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phenotypes might also determine the antigen-presenting capacity of each distinct DC 
subset (96). 
In spleen, DCs comprise around 1% of the total splenocytes.  Among them, 
approximately 80% are cDCs and the remaining 20% are pDCs. Those cDCs have been 
classified into three subsets based on CD4 and CD8α expression on their surface and are 
named as CD4+8- DC, CD4-8+ DC and CD4-8- DC (76) ;  each represents about 50%, 25% 
and 20-25% of the spleen cDCs, respectively. CD4-8+ DC are located in T cells areas and 
require interferon response factor (IRF8/ISCBP) and Id2  for their  normal development 
and function, while CD4+8- DC reside in non-T cell zone and need IRF4, IRF2, Relb and 
PU.1 for their normal development and function (83, 97, 98).   
CD4–8+ DCs have been reported as variably effective stimulators of allogeneic CD8+ T 
cell responses and CD4–8– and CD4+8– DCs as more effective in stimulating CD4+ T cell 
responses (99, 100). When splenic CD8α+ DCs isolated from mice infected with 
Chlamydia muridarum were transferred into the naive mice, they induced better 
protective immunity than CD8α- DC (101).   CD4–8+ and CD4–8– DCs can efficiently 
prime male Ag-specific CTLs, whereas CD4+8– DCs do so only weakly (99). The 
CD4–8+DC makes itself unique among cDCs by having the exquisite cross-presentation 
ability to constitutively present exogenous cell-associated or soluble proteins very 
efficiently in the context of MHC I (100, 102). However, when antigen was presented as 
immune complex and DCs were activated via FcR ligation, CD8- DCs could also do the 
cross presentation (102). Different subsets have also been reported to play some 
inhibitory role in certain type of immune response. CD4+8– DCs mediate tolerance or 
bystander suppression against diverse T cell specificities and support effective 
suppression of autoimmunity (103), while CD4–8+ DCs can induce tolerance to 
tissue-associated Ags and inhibit the transplantation rejection (104, 105). However, the 
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differences in inducing antitumor immunity among the three DC subsets remain to be 
explored. 
    During my research on this specific area, we found that bulk spleen DCs induced 
lower antitumor immunity when compared with the CD4+8- DC and CD4-8+ DC subsets 
indicating that there are some interactions among those three subsets. The CD4-8- DCs 
were found to be less mature even after overnight culture, and primed CD4+ T regulatory 
1(Tr1) cells to suppress the antitumor immunity (106), despite reports that spleen DCs 
will mature after culturing in vitro for 6 hrs or longer (66, 107, 108).  The other two 
subsets stimulated strong Th1 response and resulted in immunoprotection from tumor 
challenge when those DC subsets were pulsed with low, physiological similar 
concentrations of OVA protein.  The above data strongly suggested that DCs should be 
made functionally homogeneous and mature in order to be used as vaccine against tumor 
challenge or cancer treatment.    
 
1.3 Human dendritic cells 
   Human DCs mostly originate from bone marrow-derived leukocytes (109); but 
Follicular DCs are of stromal origin and don’t belong to leukocytes. Follicular DCs have 
no role in T cell, NK cell, or NKT cell immunity like conventional or plasmacytoid DCs.  
They mainly activate B cells in the germinal center without the need of T cell help  
through  engagement of CD21 in the B-cell coreceptor complex by complement-derived 
CD21 ligand (110).  
   Different human DCs might have different phenotypes or functions depending on the 
culture conditions including the growth factors and time in vitro. At least four types of 
human DCs have been described such as conventional or "myeloid" DCs: i) CD14+ blood 
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monocyte-derived DCs (MODCs); ii) dermal DCs or interstitial DCs (DDC-IDCs); ii) 
Langerhans cells (LCs); and iv) plasmacytoid DCs (31).  Another special blood CD11c+ 
DCs could be prepared by cell sorting from peripheral blood mononuclear cells and 
cultured just overnight in RPMI 1640 medium supplemented with autologous or pooled 
AB serum without adding any specific growth factors. Those DCs are lineage negative, 
CD11c+, CD86+, and HLA-DRbright and express CD83 after activation by brief overnight 
culture; unlike MODC, they don’t express CD209. Blood CD11c+ DCs present low dose 
of antigen more efficiently and induce stronger Th1 response than MODC; therefore, 
blood DCs may be a better DC choice for clinical trials (111). 
   Because of the limitation of the quantity of human DCs, many studies on in vitro 
cultures have been carried out. Sallusto et al first combined interleukin-4 (IL-4) and 
GM-CSF to culture human peripheral blood mononuclear cells (PBMC) to prepare DCs 
and found that this kind of DCs can efficiently present soluble antigen, which means DCs 
were further activated and enriched by the presence of IL-4 (112). Functional human DCs 
were even generated from adherent peripheral blood monocytes by CD40 ligation in the 
absence of granulocyte-macrophage colony-stimulating factor (113). Later, 
immunomagnetic selection using a semi automated clinical scale immunomagnetic 
column was used to purify CD14+ monocytes from PBMC as more specific source for 
human DC cultures (114, 115).  Other have used human CD34+ haematopoietic 
progenitor cells of the bone marrow and peripheral blood (116) cultured with c-kit ligand, 
GM-CSF, and TNF-α (117) or with Flt3L, c-Kit Ligand, GM-CSF, IL-4, and TNF-α 
(118) and adherent cells of cord blood by culture with GM-CSF, IL-4, and TNF-α  (119) 
to generate functional antigen-presenting cells resembling mature monocyte-derived 
DCs.   
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    Recently people are very interested in short-term culture DCs (FastDC). This type of 
mature DCs derived from human CD14+ monocytes could be prepared within 48 hours: 
first 24hrs with GM-CSF(1000 U/ml) and IL-4 (500 U/ml), and next 24 hrs with addition 
of proinflammatory mediators (TNF-α, IL-1β, IL-6, PGE2) (120, 121), or uses 
calcium-mobilizing agents to drive differentiation of fully mature DCs from CD14+ 
monocytes in only 2 days (122, 123).   In the beginning, people were doubtful about 
short term culture DCs’ ability to induce antitumor immunity; however, many studies 
have since confirmed that they could be as powerful as standard cultures 
monocyte-derived DCs (121, 124, 125).  As such, the cost of research and clinical trials 
could be significantly decreased. 
   Human plasmacytoid pre-DCs (pDCs) are lineage-negative CD11c-CD33-IL3R+ DCs 
with high power of IFN-α production. Their precursors in the circulation were identified 
as lineage negative, HLA-DR bright, BDCA-2+, BDCA-4+ and CD123bright cells (75, 126).  
CD11c+B220+ pDCs express TLR7 and TLR9, while classical CD11c+B220- DCs 
preferentially express TRL2, TLR3, and TLR4. Although being poor T cell stimulators, 
they could differentiate into cDCs when cultured in medium containing IL-3 and CD40 
ligand (CD40L) (75).     
 
1.4 Dendritic cell maturation 
 
      DCs exist in vivo mostly as immature cells expressing very low level of CD80/86, 
CD40, and MHC II.   Only under certain conditions such as inflammation can DCs 
become mature. When DCs are immature, they have a strong capacity of phagocytosis, 
and can therefore efficiently uptake antigen.    However, at this stage, they have a very 
weak ability to present antigen, and thus usually induce tolerance. In order to provoke 
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effective immune responses such as anti-intracellular pathogen and tumor immunity, it’s 
very necessary for DCs to become mature and develop strong antigen presenting 
machinery by increasing the expression of co-stimulatory molecules (CD40, CD80/86), 
adhesion molecules (CD54) and MHC II.  They also need to secrete type I cytokines 
such as IL-12 to induce Th1 response resulting in high levels of antigen specific CTL to 
finally eliminate the pathogen or tumor cells.  
      DCs express the broadest repertoire of TLRs through which they can recognize a 
plethora of microbial compounds. After challenge with microbial or inflammatory 
stimuli, immature DCs undergo a complex process of maturation, resulting in their 
migration from tissues to secondary lymphoid organs and up regulation of MHC and 
costimulatory molecules that are essential for naïve T cell priming (127, 128). There are 
many different environmental stimuli that can mature DCs in different ways. Microbial 
products including lipid, polysaccharide, DNA, RNA, and protein are now recognized as 
various TLR ligands. They can react with different TLRs on both plasmacytoid and 
conventional DCs and induce maturation (127). CD40L (CD154), either expressed by 
activated T cells or as a multimeric recombinant protein, or agonistic anti-CD40 antibody 
can also mature DCs (129-131).  Special formulas for culturing the matured and 
Th1-polarized DCs (Th1 DC) have been also explored.  IL-1β (25 ng/ml)，TNFα (50 
ng/ml), IFNγ (1,000 units/ml)，IL-6 (1,000 units/ml)， PGE2 (10–6 mol/L)， poly-I:C 
(20 µg/ml)，IFNα (3,000 units/ml)，and LPS (250 ng/ml) were added to the PBMC 
culture started with rhu GM-CSF and IL-4 (both 1,000 IU/ml) at day 6 until day 8.  A 
single round of in vitro sensitization with the above DCs induced up to 40-fold higher 
numbers of long-lived CTLs against melanoma-associated antigens (132).  Another Th1 
DC cocktail [CpGs (1 µmol/L), poly(I:C) (20 µg/ml), and/or IFN-  (20 ng/ml)] was 
added to 5-day cultured BM DCs with GM-CSF and IL-4 for culturing another 18 hrs.  
Those DCs secreted high level of IL-12p70 and its maturation and polarization were not 
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affected even coculture with live B16 melanoma tumor cells, and tumor-loaded DCs 
induced delayed-type hypersensitivity responses in vivo. When DCs were loaded with 
B16 melanoma cells and injected into tumor-bearing mice, Th1-skewed tumor-specific 
CD4+ T cells and a significant reduction in tumor growth were observed (133).  One 
notable point is that IL-12 secretion level is not always related to the Th1 and CTL 
response, because data in vitro and in vivo have demonstrated that robust immune 
response could be induced with DCs matured in the presence of PGE2, even though 
PGE2 matured DCs secrete much lower level of IL-12 than CD40L matured ones (134, 
135). However, the vaccination of cancer patients with DCs matured in the presence of 
IL-1β, TNF , IL-6, and PGE2  can expand their FOXP3+ Treg cell population (136).  
Recent findings suggest that DCs matured with cocktail containing PGE2 will have stable 
Tr-attracting properties mediated by CCL22, which could be further elevated after 
secondary stimulation of DCs in a neutral environment. IFN , a mediator of acute 
inflammation, could restore the ability of the PGE2-exposed DCs to secrete the 
Th1-attracting chemokines: CXCL9, CXCL10, CXCL11, and CCL5 by decreasing the 
secretion of CCL22 inudced by PGE2;  therefore, any formula for culturing MODC better 
contain IFN-  in order to reduce the ability to attract and induce Tr cells (137). 
   Very recently, people have been paying more attention to what maturation stage is 
better for the induction of antitumor immunity in vivo. Through directly analyzing their 
IL-12 secretion or by using microarray, people found that after in vitro activation by LPS, 
or by poly(I)-poly(C), and TNF-  plus IL-1β,  DCs produced IL-12, a cytokine directly 
involved in the generation of CTL responses (138).   This occurred only for a limited 
period with a peak between 5 and 8 h, and after 18 h there is no more IL-12 secretion 
from DCs.  Those DCs become resistant to further stimulation by CD40L, and later this 
phenomenon was called DC exhaustion (139, 140). Animal studies also further support 
the above conclusion. 3 h anti-CD40 or 8 h LPS stimulated BM DCs induced 100% 
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protection, while 24 h anti-CD40 or 48 h LPS DCs didn’t induced any protection at all 
(141-143). 
In addition, suitably matured DCs represent a critical source of interleukin 6 (IL-6), 
IL-12, IL-15, IL-18, IL-23 and IFN-α – all of  which are key members in innate immune 
responses and drive T helper type 1 (Th1) polarization (144-146). Under certain 
conditions, IL-12 secretion might not be the key polarization cytokine in these specific 
DC subsets (145, 147, 148).   Macrophage-derived DCs have strong Th1-polarizing 
potential mediated by beta-chemokines rather than IL-12 (149).  IL-12 production by 
DCs is tightly controlled, as it requires first a priming signal provided by microbial 
products or IFN-γ and then an amplifying signal provided by T cells through CD40 
ligand (CD40L). IL-6 has been found to inhibit the function of regulatory T cells (150, 
151); IL-6, IL-15 and IL-23 are among those key cytokines involved in the development 
and maintenance of a new T cell subsets Th17 (115, 152).  Although Th17 has been 
confirmed to be the major player in autoimmunity and anti-bacterial infection instead of 
Th1 (153), there are still reports that Th17 need  to synergize with Th1 to induce EAE 
(154).  Th17, which secrete IL-21 (155), has been indirectly linked to antitumor 
immunity (156, 157), suggesting that Th1 and Th17 might cooperate in antitumor 
immunity.  Very recently, Tumor-specific Th17-polarized cells have been found to be 
able to eradicate large established melanomas, providing direct evidence of Th17 
involvement in antitumor immunity (158).  Thus, DCs are capable of integrating signals 
from pathogens, cytokines and T cells, leading to the generation of an adaptive immune 
response of the appropriate class (144).    
         
1.5 Antigen loading onto dendritic cells 
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   With the availability of  large number of cultured DCs from bone marrow precursor, 
CD14+ peripheral blood monocyte and CD34+ progenitor cells, various ways of antigen 
loading onto DCs have been tested in animal studies and clinical trials. 
 
1.5.1 Synthetic CTL peptide 
 
    Tumor-antigen(s)-pulsed DCs have been demonstrated to induce MHC-class I- and 
class II-specific T cell responses in vitro and in vivo. DCs pulsed with peptide antigen in 
vitro and administered to animal induce antigen-specific, cytotoxic T lymphocyte 
(CTL)-mediated protection against a lethal tumor challenge and sustained regression of 
established tumors (159). Peptide-pulsed DCs can also convert the in vivo CTL-tolerizing 
potential of the peptide into specific immunostimulation (160).  
1.5.2 Tumor lysate/acid-eluted peptides 
 
   Most cancer patients lack an identified tumor antigen and/or cannot provide sufficient 
tumor tissue for antigen preparation.  They would lose the chance of treatment with 
cancer vaccines based on using either specific tumor antigens or mixtures of 
tumor-derived antigens in the form of peptides or proteins isolated from tumor cells. 
Compared with vaccination strategies directed against a single tumor antigen peptide, 
tumor lysates or acid-eluted tumor peptide as a better source of antigen could induce wide 
range of epitope-specific CTL and might be another choice for those tumors which 
antigen have not been characterized yet. Vaccines using antigens present in tumor cell 
lysates induce protective immunity with strong memory against distantly related tumor 
variants; however, it’s possible to induce autoimmunity at the same time. The existence 
of a class of antigens shared among tumor variants provides an attractive target for 
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vaccine development (161). Electroporation (EP) has been used to achieve the safe, 
consistent, and efficient loading of DCs with whole tumor lysate and induced much better 
animal protection than conventionally coincubation protocols (162).  
1.5.3 Tumor RNA  
 
   In addition to tumor peptides and lysates, DCs can also be pulsed or transfected with 
ribonucleic acid (RNA) coding for a tumor-associated antigen or whole tumor RNA to 
induce potent antigen and tumour-specific T-cell responses directed against multiple 
epitopes. Antigen in form of RNA carries the advantage of encoding multiple epitopes for 
many HLA alleles, thus permitting the induction of CTL response among many cancer 
patients independent of their HLA repertoire. Vaccination with the mRNA of tumor cells 
would extend the scope of vaccination to this group of patients as well because tumor 
mRNA, isolated from murine tumor cell lines or from primary human tumor cells 
microdissected from frozen tissue sections, can be amplified without loss of function  
(163-165).  Conventional RNA/DC co-culture or liposome mediated loading for RNA 
transfection leads to very low ratios of transfected DCs.  However, the recent developed 
square-wave electroporation technique for RNA transfection has significantly improved 
its efficiency with up to 90-99% of the viable cells transfected (166, 167). Proteasomal 
targeting of mRNA encoding cotranslationally ubiquitinated antigen was found to 
enhance intracellular degradation of target protein, and result in more efficient priming 
and expansion of TAA-specific CD8+ T-cells (168).  
1.5.4 Apoptotic tumor cells 
 
   Another way of pulsing DCs is using the apoptotic tumor cells induced in vitro with 
drugs or irradiation, because DCs express specific receptors for recognizing and uptaking 
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dying cells, such as αVβ5, CD36, or phosphatidylserine receptors for apoptotic cells  
(169, 170) and CD91 receptor for heat shock proteins exposed on necrotic cells (171, 
172).  After phagocytosing apoptotic/necrotic tumor cells in vitro, DCs can become 
mature and efficiently induce antitumor immunity (173).  The advantage of using dying 
tumor cells as a source of tumor antigens are: (i) that DCs can present or cross-present 
both MHC class I and II epitopes of a defined tumor antigen (174)) or multiple tumor 
antigens (e.g., MAGE3 and gp100 of melanoma tumors) (169, 175);  and (ii) unlike the 
case with peptide-pulsed DCs, this type approach is independent of HLA halotype and 
can thus be applied equally to all patients.  Although the apoptotic cells are processed 
and presented through classical pathways for MHC II presentation to CD4+ T cells and 
also are cross-presented through a phagosome-cytosolic pathway or released into the 
cytosol for presentation to CD8+ T cells, uptake and ingestion of apoptotic cells mainly 
promotes an immunosuppressive environment that avoids inflammatory responses to 
self-antigens (176).   It appears that the continuous presentation of self-peptides is 
required for active maintenance of T cell tolerance and prevents the occurrence of 
autoimmunity (177). 
 
1.5.5 Tumor and dendritic cell fusion 
 
   DC/tumor fusions, like the tumor RNA pulsed DCs, might express a broad array of 
tumor Ags presented in the context of DC-mediated costimulation. One concern regarding 
the DC/tumor cell fusions is that tumor cells in the vaccine preparation may interfere the 
function of DCs as APC.  People have recently found that fusions of breast carcinoma 
with DCs expanded regulatory T cells.  They needed to add exogenous IL-12, and CpG 
during their DCs and T cells coculture to decrease the formation of Tr and to promote the 
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expansion of activated tumor specific T cells (178).  This indicate that even after fusion 
with tumor, DCs still need the Th1 adjuvant to help them to form a Th1 response, 
although fusioned DCs have a matured phenotype and even secrete high amount of IL-12. 
 
1.5.6 Targeting antigen to the dendritic cells  
 
   Recently DCs modified with genes such as tumor (associated) antigens and /or 
immunomodulatory proteins, and combined with cytokines further improved their 
capacity to promote the antitumor response (179). The more promising advance in DC 
vaccine against cancer is to target antigen directly to in vivo DCs or their specific subsets. 
This strategy is directly exploiting in vivo antigen presentation cells without the need of 
expansion and other treatment of APCs in vitro. Antibody response has been known to 
enhance the specific T cell response by promoting the opsonization of antigen via Fc 
receptor (FcR)-mediated recognition by APCs.  Accordingly, targeting antigen to the 
APC’s surface molecules is another potential route to enhance the immune response 
mediated by T cell such as antitumor and intracellular pathogen immunity.  Several 
targeting delivery methods have been reported.  One way is using the bispecific 
antibody which can bind the specific antigen and the receptor on the APC simultaneously 
(180).  Other methods similar to this procedure use genetic methods to: (i) express the 
single chain antibody against APC surface molecules and antigen as a fusion protein 
(181, 182),  (ii) to conjugate the antibody and antigen together (183-185), and (iii) to 
insert the antigen peptide into the constant region of the single chain antibody (186, 187).   
Apart from Ab targeting technology, cell-penetrating peptides (CPP) such as HIV TAT 
protein transduction domain (PTD), HSV-1 VP22 (188) and  adenylate cyclase (CyaA) 
(189) have also been used to conjugate with antigen peptides or generate fusion protein to 
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target DCs (190, 191).  People have compared the CPP and antibody targeting strategy 
using in vitro study and found that there is no advantage of cell-penetrating peptides over 
receptor (DC-SIGN)-specific antibodies in targeting antigen to human DCs for 
cross-presentation (192).  Another strategy is to directly express antigen only in DCs by 
using mouse dectin-2 gene promoter to construct a lentivector.  Potent CD8+ and CD4+ 
T-cell responses were also effectively induced after immunization with the optimal dose 
of the dectin-2 lentivector (193). The first eight targeting methods need the help of 
adjuvants to promote the maturation of DCs and induce desired Th response; the other 
four methods don’t need the help of adjuvants to elicit effective immune response, though 
the response could be enhanced by simultaneous administration of them. 
 
1.5.6.1 CD11c 
 
   A variety of different receptors on APCs have been exploited for targeting antigens, 
which may allow optimization for specific immune responses.  The complement 
receptor CD11c/CD18, a surface receptor expressed almost exclusively on DCs and 
related to antigen internalization, is believed to play a crucial role in the process of 
antigen capture and presentation.  A novel chelator-lipid, 3(nitrilotriacetic 
acid)-ditetradecylamine (NTA3-DTDA) anchoring histidine-tagged forms of single chain 
full-length variable Ab fragments (ScFv), which target the CD11c of DCs , onto either  
tumor-derived plasma membrane vesicles (PMV) or onto antigen and 
LPS/IFN-γ-containing stealth liposomes were used to immunize mice, strong 
antigen-specific CTL responses in splenic T cells and a marked protection against tumor 
growth were obtained (194). When antigen was linked with anti-CD11c antibody and 
used for vaccination, fast and high antibody response were induced as well (195).  
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1.5.6.2 DEC205 (CD205)   
 
    DEC-205 is an endocytic receptor with 10 membrane-external, contiguous C-type 
lectin domains and is expressed at high levels on CD8+ DCs in the T cell areas of 
lymphoid organs.  It mediates the efficient processing and presentation of antigens on 
MHC class II products in vivo.  Small doses (<1 µg/mouse) of anti-DEC-205 antibodies 
can be used to target antigens for presentation by DCs in vivo. When an antigenic peptide 
from hen egg lysozyme was engineered into form a fusion protein with anti-DEC-205 
antibody, the antibody and peptide is selectively delivered to DCs (181). When protein 
antigen was targeted to the DC receptor DEC-205 in the steady state, antigen was 
presented through major histocompatibility complex class I and leads to peripheral CD8+ 
T cell tolerance (183).  However, if agonistic anti-CD40 antibody was injected into mice 
to mature DCs at the same time with targeted antigen, a single low dose of 
antibody-conjugated ovalbumin initiated immunity from the naive CD4+ and CD8+ T cell 
repertoire,  and antigen presentation on MHC I was extended up to 2 weeks.  These 
immunized mice showed better resistance to an established, rapidly growing tumor 
challenge and showed therapeutic effects on grown tumor with size of 0.7-1cm in 
diameter.  Improved resistance to viral infection at a mucosal site was also seen.  This 
suggests that antibody-mediated antigen targeting via the DEC-205 receptor increased the 
efficiency of stimulating T cell mediated immunity, including systemic and mucosal 
resistance in disease models (184). When the melanoma antigen tyrosinase-related 
protein (TRP)-2 was conjugated to anti-DEC-205 antibodies, mice immunized with these 
conjugates together with DC-activating oligonucleotides (CpG) showed long-lasting 
antitumor immunity (185).  
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1.5.6.3 MR (CD206) 
 
   The mannose receptor (MR; CD206) is a member of the calcium-dependent lectin 
receptor (CLR) family which have characteristic carbohydrate recognition domains with 
selective binding to specific glycans.  Because of its strong role in endocytosis and 
phagocytosis, MR has been suggested to play a dual role in host defense and homeostasis. 
In vivo MR is primarily expressed on tissue macrophages (M ) and lymphatic and hepatic 
endothelia in humans and mice, and also by subsets of DCs, especially interstitial DCs.  
In vitro cultured DCs from human monocytes and mouse BM also express this type 
glycan receptor, which indicates that this type of receptors could be used as a target for in 
vivo antigen delivery. By using hMR transgenic (hMR Tg) mice, anti-hMR 
antibody(B11)-OVA(B11-OVA) fusion proteins were found to be efficiently presented to 
OVA-specific CD4+ and CD8+  T cells in MR Tg, but not in non-Tg, mice. TLR agonist, 
CpG, significantly enhanced effector differentiation of responding T cells in MR Tg mice. 
Administration of both CpG and B11-OVA to hMR Tg mice induced OVA-specific 
tumor immunity while unimmunized WT mice remained unprotected.  This confirmed 
that antigenic targeting of the human mannose receptor induced strong antitumor 
immunity (196).  
 
1.5.6.4 Langerin (CD207) 
 
   Langerin/CD207 is a type II transmembrane protein, which was first detected on the 
Langerhans cells (197).  Later its expression was also found at lower levels on DCs, 
especially CD8+ DEC205+ DCs in spleen and skin draining lymph nodes, although 
different species have varying expression levels (198).  Langerin recognizes various 
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sugars such as mannose and sulfated sugars and are involved in endocytosis (197). Abs to 
Langerin can be internalized, which indicated that langerin could be used as a target for 
antigen delivery to DCs.  Very recently, a fusion protein containing antibody against 
extracellular domain of langerin and OVA (model antigen) selectively and systemically 
targets appropriate DC subsets in draining lymph nodes and spleen. When injected in 
vivo, naive CD8+ and CD4+ T cells undergo 4–8 cycles of division in 3 days which 
indicated that OVA is efficiently presented. Compared with DEC205 antibody and OVA 
hybrid, antigen presentation detected by in vivo T cell proliferation could last a little 
longer, around 14 days, and is more efficient on MHC II (199).  This means langerin 
can effectively mediate Ag presentation and is another candidate for targeting antigen to 
the DCs in vivo. However, there is no data on whether DC maturation stimuli are needed 
for better antigen presentation. 
 
1.5.6.5 DC-SIGN (CD209) 
     DC-specific intercellular adhesion molecule 3 (ICAM-3) – grabbing nonintegrin 
(DC-SIGN) is a member of the type II C-type lectin family and an endocytic receptor 
mediating antigen presentation.  In humans, DC-SIGN is exclusively and highly 
expressed on professional APCs such as DCs residing in lymphoid tissues, skin, mucosal 
surfaces, and also on specialized macrophages in placenta and lung (200, 201).  This 
makes DC-SIGN a good candidate for targeting antigen to APCs in vivo. When a 
humanized antibody, hD1V1G2/G4 (hD1), directed against DC-SIGN was cross-linked to 
a model antigen, keyhole limpet hemocyanin (KLH), people found that the chimeric 
antibody-protein complex (hD1-KLH) bound specifically to DC-SIGN and was rapidly 
internalized and translocated to the lysosomal compartment. TLR ligands such as LPS 
were required to stimulate hD1-KLH pulsed DCs to become mature because the 
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conjugates themselves could not induce DC maturation. Autologous DCs pulsed with 
hD1-KLH induced 100-fold stronger proliferation of immunized patient peripheral blood 
leukocytes (PBLs) than KLH-pulsed DCs. hD1-KLH–targeted DCs also induced 
proliferation of naive CD4+ and CD8+ T cells, thus, targeting of antigen to DCs via anti- 
DC-SIGN antibody effectively induced antigen-specific primary and secondary response 
(201). Because of the significant differences between human and mouse homologue 
[CD209a (CIRE)], no animal study data is available (202). 
 
1.5.6.6 Dectin-1 
 
   Dendritic cell-associated C-type lectin-1 (Dectin-1) is an NK cell receptor-like C-type 
lectin-like receptor (CLR), originally thought to be DC specific, but subsequently 
demonstrated to be expressed on other cells, including certain macrophage populations, 
neutrophils, and monocytes. Dectin-1 was shown to be expressed on CD8α-CD4-CD11b+ 
DCs found in spleen and lymph nodes and dermal DCs present in skin and s.c. lymph 
nodes. In human, Dectin-1 has been found to be involved in uptake and 
cross-presentation of cellular antigens (203). Injection of Ag-anti-Dectin-1 conjugates 
with poly I:C induced CD4+ and CD8+ T cell and Ab responses at low doses where free 
Ag failed to elicit a response. Compared with antibody targeting Ag to CD205, 
anti-Dectin-1 conjugates stimulated a much stronger CD4+ T cell response and a much 
weaker CD8+ T cell response, whereas anti-CD205 conjugates stimulated no antibody 
response.  This indicated that Dectin-1 might be a better potential targeting molecule for 
immunization to promote Th2 or antibody response (204). 
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1.5.6.7 Dectin-2  
 
   Dectin-2 is a C-type lectin-like receptor encoded in the natural killer complex of 
C-type lectin genes and is expressed on cells of the myeloid lineage including spleen DCs 
and peritoneal macrophages.  It recognizes high-mannose structures and acts as a pattern 
recognition receptor for fungi. A lentivector expressing the human melanoma antigen 
NY-ESO-1 under the control of dectin-2 promoter was constructed and injected into the 
HLA-A2 transgenic mice.  Most of the cells expressing the model antigen were CD11c+ 
DCs.  A NY-ESO-1-specific CD8+ T-cell response was primed and a CD4+ T-cell 
response to a newly identified NY-ESO-1 epitope presented by H2 I-Ab was also induced 
simultaneously. Optimized immunization with the dectin-2 lentivector can induce similar 
responses like those stimulated by a lentivector containing a strong constitutive viral 
promoter, thus, targeting antigen expression to DCs can provide another way of antigen 
preparation and direct delivery to the APCs in vivo (193).  
1.5.6.8 DNGR-1  
 
   NK lectin group receptor-1 (DNGR-1) is a C-type lectin of the NK cell receptor 
group expressed in mice at high levels by CD8+ DCs, at low levels by plasmacytoid DCs, 
and not by other hematopoietic cells.  Its expression is also restricted to a small subset 
of human blood DCs that have similarities to mouse CD8α+ DCs.  In vivo study, antigen 
epitopes covalently coupled to an antibody specific for mouse DNGR-1 were found to be 
selectively cross-presented by CD8α+ DCs and induced potent CTL responses.  It also 
prevented development or mediated eradication of B16 melanoma lung pseudometastases 
when given with adjuvants.  Because of its selective expression pattern and endocytic 
activity, DNGR-1, a novel, highly specific marker of mouse and human DC subsets, 
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could be used as a specific candidate for antigen targeting to DCs and be exploited for 
CTL cross-priming and tumor therapy (205). 
 
1.5.6.9 CD36 
 
   CD36 is a Type BI scavenger receptor family member, which was thought to be 
expressed exclusively on the CD8 + subset of blood-derived conventional DCs (206, 
207), is also expressed by other APC including monocytes/macrophages and B 
lymphocytes (208).  CD36 is involved in phagocytosis of apoptotic bodies and 
presentation of antigen to the CD8+ T cells (209), and probably presentation of  Ags 
derived from apoptotic bodies on MHC class II molecules (210).  CD36 was originally 
reported to be unessential for MHC class I cross-presentation of cell-associated antigen 
by CD8α+ murine DCs (206, 207).  When antibody against CD36 and OVA protein 
hybrid (anti-CD36-OVA) was tested in Ag presentation assays in vitro and in vivo, people 
found that anti-CD36-OVA was capable of delivering exogenous Ags to the MHC class I 
and MHC class II processing pathways. After immunization with anti-CD36-OVA, 
strong naive CD4+ and CD8+ Ag-specific T lymphocytes activation and the 
differentiation of primed CD8+ T cells into long-term effector CTLs were induced. 
Compared with anti-DEC205-OVA, anti-CD36-OVA was much better at inducing 
long-term persistence of effector CTLs and did not require the addition of exogenous 
maturation stimuli.  Anti-DEC205-OVA was however more efficient in inducing early 
events of naive CD8+ T cell activation. Vaccination with anti-CD36-OVA also provides 
protection against Ag-specific tumor challenge, which is mediated through both humoral 
and cell-mediated immunity (182). The results indicated that CD36 could be a novel and 
better potential target receptor for delivery antigen to CD8α+ DCs.  
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1.5.6.10 LOX-1 
 
   LOX-1(Lectin-like oxidized low-density lipoprotein receptor-1) is one of the 
scavenger receptors for HSP binding on human DCs. A neutralizing anti-LOX-1 McAb 
has been reported to inhibit Hsp70 binding to DCs and Hsp70-induced antigen 
cross-presentation. Using anti-LOX-1 McAb to target tumor antigen to LOX-1 in vivo 
could completely prevent the tumor growth without administration of additional 
maturation stimuli. Thus, the scavenger receptor LOX-1 is another promising candidate 
for targeting tumor antigen to in vivo DCs for cancer immunotherapy (211) 
 
1.5.6.11 Mac-1 
 
   Mac-1 is present on myeloid DCs, macrophages, neutrophils, and NK cells.  
Bordetella pertussis adenylate cyclase (CyaA) delivers directly its N-terminal catalytic 
(adenyl cyclase (AC)) domain into the cytosol of eukaryotic cells bearing the αMβ2 
integrin (CD11b/CD18) (Mac-1). Both in vitro and in vivo studies have shown that CD8+  
and CD4+ T cell epitopes inserted into the AC domain of a genetically detoxified CyaA 
could be delivered into the cytoplasm of CD11b+ DCs (212, 213). This kind of vaccine 
could induce robust Th1 type responses (214). CD8+ T cell activation does not require 
CD4+ T cell help, nor the CD40 signalling (212), but TLR ligands (CpG, poly I:C and 
polyuridine, not R484) and cyclophosphamide enhance the therapeutic efficacy of 
CyaA-E7 fusion protein on advanced tumors. Thus, CyaA appears to be a safe and potent 
vehicle for in vivo Ag delivery to CD11bhigh DCs, leading to Th1 polarized CD4 and 
CD8+ T cell priming (189, 213). 
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1.5.6.12 Other targets 
 
   Using chemokine ligands to target antigen to the DCs has also been reported. 37-kDa 
immature laminin receptor protein (OFA-iLRP) and MIP3α/CCL20 or β-defensin mDF2β 
(chemoattractant ligands of CCR6) fusion protein could induce antitumor immunity even 
without additional DC maturation stimulation (215). By preparing immune-complexes 
(IgG-antigen) (IC) to target the FcγR on the DCs, mouse DC maturation and  efficient 
MHC class I/II-restricted presentation of peptides from exogenous, IgG-complexed 
antigens were induced (216).   ICs should efficiently sensitize DCs for priming of both 
CD4+ helper and CD8+ cytotoxic T lymphocytes in vivo.  
 
 
1.6 Dendritic cell polarization 
 
   For cancer immunotherapy, Th1 response is preferred because it promotes CTL 
formation and finally kills the tumor cells.  In order to induce Th1 immune responses, 
DCs must be first polarized meaning that they must be treated to become optimally 
mature, otherwise Th2 or Tr response will be induced, inhibiting antitumor immunity.  
During the process of DC maturation, interactions between CD40 (DC) and CD40L (T 
cells) and/or TLR and TLR ligands play a critical role in the polarization of DCs and their 
induced immune response.  Therefore, CD40L or agonistic anti-CD40 Ab, TLR ligands, 
and their combination have been extensively explored to promote BM DCs 
maturation/polarization and induction of Th1 type antitumor immunity. 
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1.6.1 CD40 ligand and agonistic anti-CD40 antibody 
 
   CD40, the receptor for CD40 ligand (CD40L), is expressed on APCs such as B cells, 
macrophages, and DCs with its expression increasing with maturation. CD40L is a 
member of the TNF family and is expressed primarily on activated Th cells.  The CD40 
and CD40L interaction induces the maturation and activation of DCs, and helps TLR 
ligands to stimulate DCs to secrete cytokines such as IL-12, which are essential for the 
development of the Th1 response (217, 218).  Agonistic anti-CD40 Ab can function as 
CD40L and modulate DCs to drive naive CD8+ T cells, while ligation of CD40 on DCs 
restores CTL activity in CD4+ depleted mice. In addition, mice treated with anti-CD40L 
Ab had impaired induction of Ag-specific CTLs. These data indicate that CD40-CD40L 
interactions play a key role in modulating APC function so that these cells can prime 
CD8+ T cells in vivo (219). 
 
1.6.2 Toll-like receptor ligands 
 
   Different TLRs share the same or exploit distinct signaling pathways and result in 
various cellular responses. TLR3 induce IFNF-β only through TRIF- and IKK-related 
kinase and activation of TRAF3 and IRF3 and seems to be independent of MyD88 
pathway. Other TLRs such as TLR1, 2, 4, 7/9 induce cytokine production and activation 
of molecules via MyD88 recruited IRAKs and TRAF6. The TRAF6 resulted in activation 
of TAK1 that phosphorylates and activates the IKK-complex, causing NF-κB to be 
released and translocated to the nucleus. At the same time, TAK1 activates 
stress-activated protein kinases (SAPK) pathways and c-Jun-NH2-kinases (JNK) and 
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p38, thus culminating in the activation of the transcription factor, activator 
ptrotein-1(AP-1), which plays a crucial role in the induction of inflammatory-response 
genes. TLR4 also activates cells after binding LPS through MyD88-independent pathway 
via TRAM and TRIF.  This makes it a unique TLR and results in some special 
physiological or pathological distinction (220, 221).  Another important recent 
discovery on TLR signaling is that MyD88-dependent pathway also activates some IRFs; 
when plasmacytoid DCs react with TLR7/9 ligands, IRF7 were activated, while when 
conventional DCs react with their own TLR9 ligands, IRF1 were activated.  IRF5 might 
be activated during the reaction of TLR3,4,7/8 ligands with all kinds of DCs (222). 
   Toll-like receptors (TLRs) are characterized as type I transmembrane protein with 
leucine-rich repeats in the extracellular domain and a cytoplasmic Toll/interleukin (IL)-1 
receptor homology (TIR) domain. As innate receptors, they sense microbial products and 
trigger DC maturation and cytokine production, thus effectively bridging innate and 
adaptive immunity.  Around 10 to 13 TLRs have been proposed to be existed in most 
mammalian species. Different TLRs recognize one or more PAMPs (pathogen-associated 
molecular patterns), including lipopolysaccharide (LPS), lipid A, monophosphoryl lipid 
A (MPL), and HSPs (heat shock protein) (by TLR4); Mycobacterial cell wall fractions 
enriched for lipoarrabinomannan, Mycobacteria-derived monoacylated muramyl 
dipeptide derivatives, bacterial lipoproteins and lipoteichoic acids (by TLR2+TLR1, or 
TLR2+TLR6); peptidoglycan (by TLR2); flagellin (by TLR5); herpes simplex virus, the 
unmethylated CpG DNA of bacteria and viruses, insect DNA and vertebrate DNA in 
liposomes (by TLR9); double-stranded RNA (by TLR3); single-stranded viral RNA (by 
TLR7 and TLR8) and Toxoplasma profilin (by TLR11).  Some synthetic ligands can 
also be recognized by certain TLRs, such as tripalmitoyl-cysteinyl-seryl-(lysyl)3-lysine 
(Pam3CSK4) by TLR1/2,  Imidazoquinoline compounds [resiquimod (R-848), 
imiquimod, and oxoribine], 7-Thia-8-oxoguanosine and 7-deazaguanosine, ANA975, an 
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oral prodrug of isatoribine, SM-360320 S-27609, 3M-01 and 3M-03 by TLR7;  3M-01 
and 3M-02, but especially 3M-02 and Poly-G10 by TLR8,  Poly(I:C) and Ampligen 
(poly I:poly C12U) by TLR3,  and CpG ODN, CpG-containing ODN, i.e., IMOs, and 
dumbbell-like covalently closed ODN (dSLIM-30L1) by TLR9. TLR 10, 12 and 13 
ligands have not been identified or confirmed (127, 223). 
   Unlike other TLRs, TLR5 is not expressed on conventional DCs or macrophages in 
mice, but is expressed mainly on intestinal CD11c+ lamina propria cells (LPC). CD11c+ 
LPC detected pathogenic bacteria and secreted proinflammatory cytokines in a 
TLR5-dependent way (224).  TLR10 is expressed in humans but not in mice, TLR8 has 
no function in mice, and TLRs 11, 12 and 13 are only identified in mice.  TLRs 1, 2, 4, 
5 and 6 (present on the cell surface) seem to specialize in the recognition of mainly 
bacterial products that are unique to bacteria and not made by the host. Their detection 
therefore affords a straightforward self-non-self discrimination. TLRs 3, 7, 8 and 9 
(present in the endosomal compartment), in contrast, specialize in viral detection and 
recognize nucleic acids, which are not unique to the microbial world (144, 221, 223, 
225-227).  Like the TLR2 forms complex with TLR1/TLR6, TLR8 can interact with 
TLR7 or TLR9, and TLR9 can also interact with TLR7.  However these interactions 
resulted in antagonistic effects.  The TLR9-TLR7 interaction reduces TLR7 signaling, 
while the TLR8 ligands decrease the TLR7 and 9 induced  signaling cascade (228).  
This indicated that not all the TLR ligands combinations can be used for enhancing APC 
maturation.   Although most TLR ligands will activate DCs to stimulate Th1 response, 
it‘s also very important to remember that some TLR ligands will induce Th2 response.  
TLR2 and TLR5 agonists can provoke Th2 response under certain conditions and LPS at 
low doses will induce Th2   immune responses (229).  Among the spleen DCs, our 
specific DC subset CD4-8-DCs express TLRs from TLR1 to TLR 9, but CD4-8+ DCs and 
CD4+8- DCs don’t have TLR7 and TLR3, respectively (226), which means that almost 
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every kind of TLR ligands could be used to trigger and induce the maturation of 
CD4-8-DCs.  
   In vitro studies of the above mentined have also been confirmed by in vivo 
experiments. Murine renal cell carcinoma (RENCA)-pulsed CpG-ODN-treated DCs were 
able not only to significantly reduce tumor growth but also to prevent tumor implantation 
in 60% of mice (230).  Poly(I:C) and CpGs treated DCs, which secrete very high levels 
of IL-12, loaded with B16 melanoma cells and injected into tumor-bearing mice induced 
Th1-skewed tumor-specific CD4+ T cells and a significant reduction in tumor growth 
(133).   When CpG or plus anti-IL-10 were injected inside the tumor, the tumor 
infiltrated immature DCs matured and induced the regression of established tumor.  If 
the tumor cells were transfected with CCL20 (MIP-3α) or CCL16, chemokines for 
immature DCs, the antitumor immunity was even stronger than that to those tumors 
without transfection of those chemokine genes (231, 232).  Another in vitro study 
showed that tumor-infiltrating DCs (TIDCs) were able to present tumor-associate antigen 
(TAA) in the context of major histocompatibility complex class I but that they were 
refractory to stimulation with the combination of lipopolysaccharide, interferon , and 
anti-CD40 antibody.  However, TIDC paralysis could be reverted by in vitro or in vivo 
stimulation with the combination of a CpG immunostimulatory sequence and an 
anti-interleukin 10 receptor (IL-10R) antibody.  CpG plus anti–IL-10R treatment 
enhanced the TAA-specific immune response,  triggered de novo IL-12 production, 
resulted in robust antitumor therapeutic activity exceeding by far that of CpG alone, and 
elicited antitumor immune memory (233).  Tumor necrosis factor alpha and CD40 ligand 
combination could also antagonize the inhibitory effects of interleukin 10 on T-cell 
stimulatory capacity of DCs (234) 
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1.6.3 Cooperation among CD40L and TLR ligands 
   The cooperation of TLR ligands and CD40L or anti-CD40 in induction of DCs to 
secrete IL-12 is very important in generating CTL from naïve polyclonal CD8+ T cells in 
vitro (219). CpG and PPD need the help of CD40L to stimulate the spleen DC mixture, 
CD4-8-DCs and CD4-8+DCs, but not CD4+8-DCs to secrete IL-12. Peptide antigen could 
also enhance the IL-12 induction capacity of PPD (235). LPS could not efficiently 
stimulate bone marrow or monocyte-derived DCs to secrete IL-12 without the help of 
CD40L or T cell help (217, 236). Various TLR ligand combinations such as R848+LPS, 
R848+poly (I:C), LPS+CpG, and LPS+ poly(I:C), which react with TLRs on the cell 
surface and inside cellular compartments at the same time but separately, have been 
reported to stimulate higher level of IL-12 secretion than single ligand and reach the 
similar level of IL-12 induced by TLR ligands +IFN-γ (144, 237). DCs activated 
simultaneously through TLR-7 ( and TLR 2/6,3,4, 7, 9 to some extent) and anti-CD40 
displayed 10-fold increases in their ability to stimulate CD8+ T cell responses over DCs 
activated through each individual receptor alone (238). Synergistic activation of 
macrophages via CD40 and TLR9 also results in T cell independent antitumor effects 
(239). Simultaneous activation of TLR-3 and TLR-9 on macrophages induced synergistic 
levels of nitric oxide, IL-12, TNF- , and IL-6 production (240). 
 
1.6.4 Antigen dose 
   There have been reports that the Th1 or Th2 response might not depend on the type of 
DCs but rather on the antigen concentration; higher doses stimulate Th1 response, while 
lower doses stimulate a more Th2 response.  After TLR ligand stimulation, more Th1 
responses were induced (93). We also found that high concentration of OVA could 
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switch the CD4-8-DC induced response from Tr to Th1 (241).  However, such high 
concentrations are not practical for clinical trials. 
 
1.7 Dendritic cell vaccine 
 
Since DCs have the most powerful capacity to present antigen via MHC I to activate 
the CD8 T cells to form CTL and attack intracellular pathogen and tumor cells (3, 242, 
243), DCs pulsed with various antigens and modification as described above have been 
used in animal study and/or put into clinical trials (2, 3, 179, 244, 245).  
With the availability of large numbers of DCs cultured in vitro and identification of 
tumor specific or associated peptides, DCs have been pulsed with various human and 
mouse tumor peptide antigens to induce antitumor immunity.  Various specific 
MHC-restricted synthetic peptides derived from tumor-associated antigens such as 
adipophilin protein (246), bcr-abl chimeric nonapeptide [GFKQSSKAL]  (247, 248),  
carcinoembryonic antigen (CEA) (249-251), endogenous retroviral gene products 
gp70/p15E  (252, 253),  folate binding protein (FBP) (254, 255), Heparanase (256), 
hepatocellular carcinoma-associated antigen HCA587 (257), HER-2/neu oncoprotein 
(258-266), HPV 16 E7 (267), melanoma related antigen MART-1/ Melan A, MAGE-1, 
MAGE-3, gp100 (268), or tyrosinase (269-276),  MUC-1 (277-280), multiple myeloma 
(281), NY-ESO-1 (282), ovarian tumor antigen stratum corneum chymotryptic enzyme 
(283), prostate-specific membrane antigen (PMSA) (284-288), regulator of G protein 
signaling 5 (RGS5) (289),  survivin (290-292), and TRAG-3 (293) have been identified 
and/or used for pulsing the DCs for animal study or clinical trials.  Various CTL 
responses and even temporary regression of diseases have been recorded.  However, the 
disadvantage is that specific peptide for certain protein antigens must be first identified 
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and peptide-pulsed DCs induced CTL responses usually are very weak.  Other antigen 
such as autologous lysates may be more effective (275), or DC preparation should be 
improved (276). 
For those tumors in which antigenic peptides were not identified, a lot of studies have 
been carried out with tumor lysate. DCs coincubated with whole-tumor lysate can elicit 
specific antitumor T-cell responses. DCs pulsed with the tumor lysate from fibrosarcomas 
and mammary carcinoma (294), hepatocellular carcinoma BNL 1ME A.7R.1 (BNL) (295, 
296), melanoma (297),  pancreatic carcinoma (298), renal cell carcinoma (162, 299), 
and syngeneic GL261 gliomas (300, 301) have been tested in mice models.  DCs pulsed 
with lysates from human breast carcinoma (302), malignant brain tumor (303, 304), 
myeloma (305), ovarian cancer (306, 307), and pancreatic carcinoma (308) have been 
demonstrated to induce tumor antigen-specific CTL responses in vitro, and the T cell 
response can be enhanced by KLH. Vaccination of patients with cancer using DCs pulsed 
with tumor lysates were also shown to be effective for advanced breast (309, 310),  
advanced gynaecological malignancies (311), hormone-refractory prostate carcinoma 
(312), malignant melanoma (269, 313), parathyroid carcinoma (314, 315), pediatric solid 
tumors (316, 317), renal cell carcinoma (RCC) (318-321), and uterine serous papillary 
cancer (322). 
The mRNA from allogeneic prostate whole tumor (323), autologous melanoma (324), 
whole renal cell carcinoma (325, 326), whole pediatric brain tumor (327),  and whole 
neuroblastoma (328); and synthetic mRNA from lung cancer and breast cancer(CEA) 
(329), prostate[prostate specific antigen(PSA) (330) and telomerase (331) have also been 
used to transfect monocyte-derived DCs for clinical trials. All the above trials indicated 
that this form of vaccination is feasible and safe, but elicited T cell responses varied in 
different trials from 0 to 100% of tested patients.  Cytokine patterns after cancer 
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vaccination may be more complex than indicated by the classic Th1/Th2 dichotomy (332, 
333). 
In animal models, murine multiple myeloma, mastocytoma, breast carcinoma and 
renal cancer cell fusion with DCs have been used to vaccinate the animal and could 
protect against tumor lethal challenge and effectively eradicate established tumor (178, 
334-337). Fusions of patient-derived breast carcinoma cells and DCs stimulated the 
formation of antigen specific CTL and lyse the autologous tumor cells in vitro (338).  In 
a clinical trial for patients with metastatic breast carcinoma, clinical responses were only 
observed in a few of patients, although most patients developed some kind of antitumor 
immunity after vaccination with autologous DC/tumor fusions (337). However, most of 
the ongoing presently clinical studies using multiple rounds of immunizations have been 
reported to induce regulatory CD4+ T cell response (339). Immature DCs or even mature 
DCs have also been claimed to expand the regulatory T cells and induce 
immunosuppression (340-344). Thus, the best conditions for carrying out clinical trials 
still need to be further explored, and more basic researches in this area are in great 
demand.   
 
1.8 Exosomes  
 
  DCs process exogenous antigens (Ags) in endosomal compartments such as 
multivesicular endosomes (345) that can fuse with plasma membrane, thereby releasing 
Ag presenting vesicles called "exosomes" (EXO) (346, 347). Exosomes (EXO) are 50–90 
nm diameter vesicles containing Ag presenting (MHC class I, class II, CD1, hsp70–90), 
tetraspan (CD9, CD63, CD81), adhesion (CD11b, CD54) and costimulatory (CD80 and 
CD86) molecules (348, 349), i.e. the necessary machinery required for eliciting potent 
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CD4+ and CD8+ T cell responses. Moreover, exosomes pulsed with tumor peptides have 
been reported to provoke T cell-dependent antitumor effects, and TLR-3 or -9 ligands 
could significantly increase the intensity of the induced immune response (346, 350). 
Mature BM DCs pulsed with exosomes could more efficiently induce OVA-specific 
cytotoxic T-lymphocyte responses, antitumour immunity and CD8+ T-cell memory in 
vivo than exosomes themselves or DC pulsed with OVA protein. Moreover, exosome 
plused DC could also more efficiently eliminate established tumor (351). 
Both human and mouse tumor cells constitutively secreted these membrane vesicles 
which are similar to DC-derived exosomes in their morphology, density and expression 
of certain membrane markers (MHC I, LAMP1, tetraspanins, HSP70-80). Tumor derived 
exosomes have been confirmed to contain whole native tumor antigens and could induce 
CTL in vitro. They also promote T cell-dependent cross-protection against syngenic and 
allogenic tumors in mice, thus this type of exosomes might be a source of tumor rejection 
antigens and could be used for pulsing DCs to vaccinate the related recipients. One 
clinical trial has found that autologous MODC pulsed with autologous ascites purified 
exosomes could expand tumor specific lymphocytes from peripheral blood cells. 
However, some data suggest that tumor-derived exosomes might have negative effects on 
the host’s immune system.  Tumor derived exosomes might suppress T cells response 
through their inhibitory components such as FAS-L (352), NKG2D ligands (353) or 
HLA-G (354), and they even could promote the tumor  growth by dampening NK 
function (355).  Other data indicated that exosomes released by human tumor can skew 
IL-2 responsiveness in favor of regulatory T cells and away from cytotoxic cells (356) 
and  promote the differentiation of monocytes to myeloid-derived suppressor cells, thus 
support tumoral growth and immune escape (357), therefore exosomes released by 
tumors themselves should not be used alone as tumor vaccine.  
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1.9 T cell subsets (Th1/Th2/Th17/Tfh/Tr) 
 
1.9.1 T helper cell subsets (Th1, Th2, Th17 and, Tfh) 
 
   Among the immune cells, different T cell subsets play a cooperative or inhibitory role 
on one another. CD4+T cells play central roles in the regulation of immune responses by 
activating or suppressing immune cells and tissue cells. Originally, the adaptive immune 
system is thought to be controlled by two subsets of T helper (Th) cells, termed Thl and 
Th2, which preferentially promote cellular and humoral immunity, respectively, with 
their own specific cytokine profiles (358-360). Thl cells make IL-2, IFN-γ, and TNF-α, 
whereas Th2 cells secrete IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13. Thl cells proliferate in 
response to IL-2 in an autocrine fashion, and Th2 cells proliferate similarly in response to 
IL-4. Mostly Th1 and Th2 regulate each other negatively. IL-4 and IL-10 inhibit Thl 
differentiation and proliferation, respectively, while IFN-γ is able to inhibit Th2 
differentiation. Th1 cells enhance the innate and Th1-dependent immune responses of NK 
and CD8+ T cells by secreting IFN-γ, ultimately leading to the elimination of intracellular 
pathogens and tumor cells.   Th1 cells also play a significant role in systemic pathology 
such as autoimmune disease and delayed-type hypersensitivity responses.  Th2 cells 
produce cytokines like IL-4, IL-5, and others which are the major helpers for B cell and 
Ab responses.  These cells might also activate eosinophils (IL-5) to kill the parasite and 
may have a role in allergy and asthma. Recently a new type of Th17 were identified to 
play crucial roles in regulating tissue inflammation and the development of disease in 
several animal models of autoimmunity;  the former culprit for autoimmune disease was 
cleared of its involvement (361). Th17 cells could be differentiated by culturing CD4+ T 
cells with TGF-β and IL-6.  A very recent study using serum-free medium concluded 
that human Th17 like its mouse counterpart also needs the presence of TGF-β for 
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differentiation (362), thus solving the dilemma whether there is any difference in growth 
factors for human and mouse Th17. IL-23 is necessary for the maintenance of the Th17 
response (152).All the above three kinds of Th cells have their own differentiation 
mediated lineage-specific transcription mechanism. IL-12 activates the transcription 
factor signal transducer and activator of transcription 4 (STAT4) to regulate Th1-cell 
differentiation. TCR cross-linking and IL-12 induced signaling cascades finally lead to 
expression of the transcription factor T-bet, which enhances the secretion of IFN-γ and 
decreases the production of Th2 cytokines.  T-bet is thus the master regulator of 
Th1-cell differentiation (363).  By contrast, IL-4 promotes Th2-cell differentiation 
through the action of STAT6.  This up-regulates expression of GATA-binding protein 3 
(GATA3), which is both necessary and sufficient for Th2-cell development.  GATA-3 is 
the key regulator of Th2-cell differentiation (364). Both Th1- and Th2-cell-specific 
transcriptional regulators (STAT1 and T-bet, STAT6 and GATA3, respectively) inhibit 
Th17 cell differentiation (365). For the Th17 cells, TGF-β and IL-6 activate STAT3and 
STAT4(366, 367)  and then upregulated the expression of retinoic acid receptor-related 
orphan receptor gamma-T (RORγt) to differentiate naive T cells into Th17.   RORγt is 
the Th17-specific transcriptional regulator, because expression of RORγt in naive T cells 
was both necessary and sufficient to induce IL-17A, IL-17F and IL-23R expression 
(368).   Rorc-/- mice are not responsive to IL-23 and possess lower numbers of Th17 
cells.  RORα seems to synergize with RORγt to promote differentiation and function of 
Th17 cells, because Rora-Rorc double-mutant mice harbor few Th17 cells and are more 
resistant to inflammatory diseases (367).   
   Another major subset of nonpolarized effector T cells that provides help to B cells has 
been identified through microarray analysis and was named as T follicular helper (Tfh) 
cells. They home to the B cell areas of secondary lymphoid tissue, through interactions 
mediated via the chemokine receptor CXCR5 and its ligand CXCL13 (369).   They 
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have their own specific CD markers such as CD84 and CD200, and the transcription 
factor BCL6.  Tfh cells secrete cytokine IL-10 and IL-21. Tfh cell generation was 
regulated by ICOS ligand (ICOSL) expressed on B cells and was dependent on IL-21, 
IL-6, and signal transducer and activator of transcription 3 (STAT3).   They provide 
cognate help to B cells for high-affinity antibody production in germinal centers (GC) 
through IL-21.  IL-21 was identified as a key cytokine that promotes the development of 
these specialized effector cells. T cell-derived IL-21 promotes themselves expression of 
CXCR5, which directs these cells to interact with B cells in the follicular regions and 
germinal centers (370-372). 
 
1.9.2 Regulatory T cells  
 
   The specific capacity of the immune system to recognize and eliminate various 
foreign invaders by the enormous diversity of antigen-specific receptors on B and T 
lymphocytes has to be balanced by mechanisms preventing reactivity against 
self-antigens. Several tolerance mechanisms are operating in parallel under physiological 
conditions for the silencing of T cells during their development in the thymus or in the 
periphery. Although cell-intrinsic processes leading to deletion or inactivation of 
autoreactive T cells were regarded as the most important tolerance mechanisms before 
1990, regulatory T cells (Tr) are now considered to play a more dominant role in 
tolerance, controlling autoreactive T cells that have escaped deletion in the thymus. 
Those Tr cells are classified into naturally occurring Tr cells and those that can be 
induced by suboptimal antigenic stimulation (373). Naturally occurring CD4+CD25+ and 
CD8+CD25+ Tr cells are believed to be generated in the thymus, possibly by recognizing 
self-antigen on epithelial cells (374).  The presence of the respective self-antigen has 
 42
been shown to be necessary for their survival in the periphery (373). Other types of Tr 
such as TCRαβ+ CD4-CD8- double negative regulatory cells (375), and  TCRαβ+ 
CD4+CD8+ double positive CD25 T regulatory cells (376) which maintain immune 
homeostasis by secreting granzyme B and  perforin were also reported. 
 
1.9.2.1 CD4+CD25+ Tr, Tr1 and Th3 
   Contrary to Th cells,  regulatory T cells (Tr), which suppress the immune system to 
prevent overactive responses and inflammation rather than help the response, have been 
getting more and more attention recently since naturally occurring thymic-derived 
CD4+CD25+ Tr cells were isolated based on their expression of CD25 under steady state 
(377). CD4+CD25+ Tr cells are a T cell population with immunosuppressive properties 
that constitutes 5–10% of the total peripheral CD4+ T cells.  Besides the expression of 
CD25, they constitutively express other several activation markers, such as the 
glucocorticoid-induced tumor-necrosis factor (TNF) receptor-related protein (GITR), 
OX40 (CD134), L-selectin (CD62 ligand (CD62L)), neuropilin-1, and cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4 or CD152). Other markers have also been 
reported to be associated with CD4+CD25+ Tr cells, such as folate receptor 4 (FR-4) 
(378), and CD39 and CD73 (379). The transcription factor forkhead box P3 (FOXP3) 
have been identified as a crucial transcription factor for the development and 
functionality of CD4+CD25+ Tr cells and also a specific intracellular marker for the 
identification of Tr cells (380) (381); however, Foxp3 expression is not always related to 
human CD4+CD25+ Tr cells (382).  Notch and TGF-β signalling pathways cooperatively 
regulate Foxp3 expression and regulatory T cell maintenance both in vitro and in vivo 
(383), although Notch has been reported to be related to Th1.  Currently three kinds of 
CD4+ Tr cells have been proposed; the naturally occurring CD4+CD25+ Tr cells secrete 
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high level of IL-10 and express TGF-β,  CD4+ regulatory T cells of type 1 (Tr1) express 
high levels of IL-10 and moderate levels of IL-5, IFN-γ, and TGF-β, but no IL-2 and IL-4 
(384), and T helper 3 (Th3) regulatory T cells express high levels of TGF-β (385). The 
last two Tr cells usually are induced by antigen specific stimulation, thus they are 
considered antigen specific. The first CD4+CD25+ Tr cells are non-antigen specific and 
need to be activated to exhibit its optimal inhibitory function (386, 387). Neuropilin-1 
contributes to the prolonged interaction of regulatory T cells with DCs (388). CTLA-4, 
TGF-β and IL-10 were the mediators that are reported to be involved in CD4+CD25+  Tr 
cells induced immune suppression, and under most conditions, cell-contact was necessary 
for the CD4+CD25+ Tr cells to exhibit their inhibition. Other membrane molecules or 
soluble factors, however, need to be further explored. The proliferation test of naive 
CD4+ and CD8+ T cells stimulated with T cells-depleted splenocytes and anti-CD3 
antibody has become a classic assay for identifying Tr cells. CD4+CD25+  could 
facilitate the induction of T cell anergy, which T cells lost the ability to produce IL-2 and 
proliferate (389), and express CD73 and FR-4. Naturally occurring CD4+CD25+ Tr cells 
cells have also been reported to directly induce conventional CD4+CD25- cells to become 
suppressive cells by infectious tolerance and the newly formed CD4+ suppressor cells 
inhibited proliferation of CD4+ T cells either via IL-10 or TGF-β production, not via 
cell-contact (390, 391).  CD4+CD25+  Tr cells could inhibit the BM DCs stimulated T 
cell to secrete IL-2, but could not prevent the stimulated proliferation (392).   Human 
CD4+CD25+  Tr cells could increase the B7-H4 expression of human monocyte-derived 
DCs by enhancing its own secretion of IL-10 (393). Contrary to the naive T cells which 
promote the secretion of IL-6 and decrease the production of IL-10 after culture with 
DCs, CD4+CD25+  Tr cells have the opposite effects (394).  Auto-antigen specific 
CD4+CD25+  Tr cells also could inhibit the naive T cells induced mouse spleen DC 
maturation, though spontaneous maturation of DCs was slightly increased (395).  
 44
Human CD4+CD25+  Tr cells reduced the expression of costimulatory molecules such as 
CD83, CD80, CD86, but not CD40 on DCs.  They promoted DCs to secrete IL-10 
directly , thus restraining the maturation and antigen presenting function of the DCs 
(396). When anti-CD25 antibody were injected into the mice to deplete the CD25 
expressing CD4+CD25+ Tr cells, several progressively tumor growth were suppressed 
(397, 398).  In addition, when tumor specific CD8+ T cells were co-transferred with 
CD4+CD25+ Tr cells into the mice, their antitumor immunity was eliminated (399, 400).  
When low dose of cyclophosphamide was used to deplete the Tr cells in vivo, this 
treatment markedly enhance the magnitude of secondary but not primary CTL responses 
induced by DC derived exosome vaccines, and also improved immune response in other 
animal tumor models (401-403) and even in patients with metastatic melanoma (404).  
All the above data indicated that a direct link between Tr cells and reduced tumor 
immunity.  
 
1.9.2.2 CD8+ Tr cells 
   The existence of regulatory CD8+ T cell subsets as an effectors of suppressor in 
models of autoimmune diseases, transplantation, and in protection against cancer has 
been proposed in 1970s and early 1980s (405, 406).  However, because of lack of 
defining markers and difficulties in isolating these cells, those earlier reports proposed 
suppressive mechanisms have been discredited or ignored. Recently, with the discovery 
of CD4+CD25+ regulatory T cells as naturally existed regulatory cells and more advanced 
cell purification techniques, CD8+ Tr cells  again have attracted more and more attention 
among immunologists.  
   The formation of CD8+ Tr cells has been reported to be naturally occurring or 
induced by in vitro cultures, almost using the same mechanism as that of CD4+CD25+ Tr 
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cells.  Although CD8+ Tr cells were proposed to play a very important role in in vivo 
inhibition and infectious immunosuppression as T suppressor, the first phenotypically 
characterized CD8 Tr cells were CD8+CD28- (407) and Qa1-depencent CD8+ regulatory 
cells (408). Multiple priming of human T cells in mixed lymphocyte cultures induced 
allospecific and xenospecific Ts which were CD8+CD28-, not CD8+CD28+.  These 
CD8+CD28-  cells can specifically recognize the MHC class I antigens expressed by 
antigen-presenting cells (APC) used for in vitro immunization and prevent target APC to 
increase expression of CD80 and CD86, thus interfering with the CD28-B7 interaction 
required for T helper (Th) activation. Immature myeloid and CD40L primed 
plasmacytoid DCs were reported to induce the formation of CD8+ Tr cells, which secrete 
IL-10, but mainly rely on cell-contact (340)  or IL-10 (27)  to carry out their inhibitory 
function. Haptenated apoptotic cells can induce CD8+ suppressor T cells without priming 
CD4+ T cells for immunity (409). Tolerogenic treatment of lupus mice with consensus 
peptide induces Foxp3-expressing, apoptosis-resistant, TGF-β-secreting CD8+ T cell 
suppressors (410).  When transgenic CD8+ T cells were activated with OVA expressing 
antigen-presenting cell (APC) in the presence of exogenous transforming growth factor, 
5-15% OT-1 T cells express FoxP3 and could mediate linked suppression of primary 
immune responses and cardiac allograft rejection (411).  In rat, CD8+ CD45RClow T 
cells were also naturally formed and had regulatory properties. They produce mainly 
IL-4, IL-10, and IL-13 cytokines upon in vitro stimulation and expresses Foxp3 and 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). However, they are not cytotoxic 
against allogeneic targets (412). Intestinal epithelial cells (IECs) are able to induce the 
proliferation of a small fraction of CD8+ peripheral T cells. The CD8+CD28- subset of 
IEC-activated CD8+ T cells, which express CD101 and CD103, interact with IECs through 
gp180 and have regulatory functions (413).  Vasoactive intestinal peptide generates 
human tolerogenic DCs that induce CD4+ and CD8+ Tr cells (414).  Stimulation of OT-1 
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CD8+ cells with OVA257+IL-4+IL-12+dexamethasone (DEX) induced IL-10-secreting 
CD8+ T cells. IL-4/IL-12/DEX can even induce an equivalent  IL-10+ phenotype from 
freshly isolated CD44high memory or CD44low naive OT-1 population (415).  
   In 1970, the suppressor T cells were thought to be CD8+ T cells, but the purification 
of this type of T cells was impossible so there is almost no phenotype data about these 
specific T cells. During the past ten years, the progress in cell isolation techniques and 
the discovery of CD4+CD25+ regulatory T cells make it possible for us to know more 
about the phenotype of this rare type of T cells. Most cell surface and intracellular 
markers on  CD4+CD25+  regulatory  T cells such as CTLA-4, TGF-β, PD-1,CD25 
were also detected on CD8+ regulatory cells, and the relation to their function in vitro and 
in vivo were  similar.  CD8+  regulatory T cells also have some specific markers 
which are related to their specific inhibition mechanism. The first phenotypically 
characterized CD8 regulatory cells was CD8+CD28-; by in vitro culture with alloantigen 
stimulation, CD8+ T cells were differentiated into CD8+CD28+ and CD8+CD28-;  the 
CD28- type T cells can inhibit the proliferation of the CD28+ ones, which indicated that 
CD28 is a specific markers for identifying the regulatory cells from the mixed T cells 
culture. CD103 (αEβ7 integrin) was initially described to be expressed on both murine and 
human CD8+ T lymphocytes localized in intestine, bronchoalveolar fluid, and allograft 
tissues. Recently, CD103 was shown to be a target of FoxP3 and was also found to be 
expressed on CD4+ Tr cells.  Now CD103 are found to be specifically expressed on 
alloantigen-induced CD8+ regulatory T cells, not CD8+ effector cells (416). CD122 is 
another marker which could be used to select the CD8+ Tr cells for IL-2 receptor β chain 
deficient mice. CD8+CD122+ have been found in very young mice because of their role in 
prevention of abnormal T cells in CD122-deficient mice (417, 418).  Although 
CD4+CD25+ T cells exist in this kind of  mouse,  they don’t show any inhibitory 
function here (417).  Some CD8+ Tr cells were found to express TRAIL, granzyme, and 
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perforin (419), which are rarely reported ever on CD4+CD25+ Tr cells. A novel 
population of Qa-1-restricted CD8αα+ TCRαβ+ T cells was identified to be one of the 
CD8+ Tr cells. They express higher level of CD69, CD40, CD94, TL-tetramer and 
TL-168(peptide), lower levels of CD122 compared with CD8αβ+ OT-1, and express 
similar level of CD44, CD25 and CD28.  Among them, CD94 is an anti-apoptosis 
molecule (420).  Foxp3 were found to be expressed on naturally occurring CD8+ Tr 
cells such as CD8+CD25+ and CD8+CD28-, those in vitro induced ones are not always 
having this specific transcription factors, which means that Foxp3 to CD8+ regulatory T 
cells is not as important as that to CD4+CD25+ regulatory T cells. Although mRNA for 
GITR are detected in  human CD8+CD25+ regulatory T cells, those molecules were not 
found to be expressed on their surface. With different models and different purification 
methods, phenotypes among those reported CD8+ Tr cells varied significantly. Until now 
there is no single marker expressed on all reported CD8+ Tr cells. 
  With the discovery of induced CD8+ Tr cells, more efforts have been made to find the 
counterparts of CD4+CD25+ Tr cells.   In human thymus, CD8+CD25+ thymocytes 
sharing phenotype, functional features, and mechanism of action with CD4+CD25+ T 
regulatory cells (421) were found.  CD8+CD25+ Tr cells could be expanded by TCR 
stimulation with modified anti-CD3 McAb in diabetic patients (422).  In old (423) and 
MHC II-/- (424) mice, CD8+CD25+ regulatory cells were found in thymus and peripheral 
lymph organs such as spleen and lymph nodes with higher ratios than younger mice 
and/or normal mice. The discovery of CD8+CD25+ Tr cells in human thymus and old 
mouse spleen would indicated that in vivo the development of Tr cells shares the same 
pathway, no matter the type of T cells is CD4+ or CD8+. CD25 marker should be suitable 
for identifying and purifying the Tr cells from the naive animals (421, 423). Although 
human thymus CD4+CD25+ and CD8+CD25+ don’t proliferate and secrete cytokine after 
activation treatment, both show stronger inhibition on Th1 rather than Th2 (374); Mouse 
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thymic CD8+CD25+ Tr cells secrete various cytokines after activation and seems to be 
different from human CD8+CD25+  Tr cells (424). Another study reported that 
CD8+CD25+ T cells might be a type of memory cells in aged mice (425).  With regards 
to its inhibitory mechanism, both human and mouse CD8+CD25+ Tr cells inhibit the 
naive T cell proliferation through cell-contact, but detailed studies are needed to be done 
whether this Tr cells share all the features with CD4+CD25+ Tr cells or they have their 
own special mechanism such as killing activity like Qa-1-restricted CD8αα+ TCRαβ+ T 
cells which kill the “antigen specific” CD4+ T cells.  
     Based on antigen specificity, Tr cells can also be classified into another two groups. 
One is naturally occurring with no antigen specificity while the other is antigen induced 
and shows antigen specificity. However, some termed naturally antigen specific Tr cells 
have also been isolated (373, 426-428). The debates over origins of the antigen 
specificity are still unsolved (429, 430). Trogocytosis is a new name for “fast,cell to cell 
contact-dependent uptake of membranes and associated molecules”.  This phenomenon 
has been reported in almost every kind of cells, such as antigen-presenting cells(APC) 
and T cells.  Cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells 
(431). Double negative (regulatory) T cells in human being and mice could function 
antigen specifically to induce apoptosis and suppress proliferation of antigen-specific 
CTLs by acquiring peptide-MHC complexes (375, 432). CD4+ and CD8+ T cells can also 
acquire MHC-peptide complex from DCs to act as antigen specific APC to stimulate 
other T cells (433-435). We are interested in whether Tr cells can acquire the 
MHC-peptide complex to become antigen specific, and what molecules are key players in 
this antigen specificity transferring. CD8+CD25+ Tr cells (423) (424), which are found to 
be easily amplified in vitro by us, will be the model cells in our project. 
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2.0 HYPOTHESIS AND OBJECTIVES 
  RATIONALE 
   Since DCs have the most powerful capacity to present antigen via MHC I and activate 
the CD8 T cells to form CTL and attack intracellular pathogen and tumor cells (3, 242, 
243),  DCs pulsed with various antigens and modifications have been used in animal 
studies and/or advanced into clinical trials (2, 3, 179, 244, 245). However, most of the 
presently ongoing clinical studies using multiple rounds of immunizations have been 
reported to induce regulatory CD4+ T cell response (339).  Immature or even mature 
DCs have also been reported to expand the regulatory T cells and induce 
immunosuppression (340-344).  Therefore, determing how to make the DC vaccine 
become more efficient in inducing Th1 response and inhibiting the Tr cell formation is 
the key research direction in cancer immunotherapy.  There are three subsets of DC 
based on their expression of CD4 and CD8 in spleen.  They are named as CD4+8– DCs, 
CD4–8+ DCs, and CD4–8– DCs. Inconsistent reports about their functional differences in 
inducing allogeneic T cell response, various immune tolerance  and cross-presentation 
have been published (see review above). The ability of murine DC subsets to direct T 
helper cell differentiation is also dependent on microbial signals (436), which means that 
all three DC subsets could induce Th1 or Th2 under certain conditions. Antigen dose 
could also switch the direction of induced Th responses (93). Thus spleen DCs is a good 
model to study the differences in antitumor immunity induced by different types of DCs. 
 
   The data from this thesis is from the culmination of two research projects, broken into 
Part 1 and 2. The first part relates to spleen DCs subsets.  It studies their functional 
differences in antitumor immunity and how to convert the tolerogenic CD4-8-DCs into 
immunogenic one and induce Th1 response. The second part is based on our discovery 
that CD4-8-DCs induce Tr1 rather than Th1 response.  We are interested to know 
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whether and how Tr cells can acquire their antigen specificity by getting the membrane 
complex (exosomes) from antigen pulsed DCs. 
2.1 Part 1:  Phenotypic and functional characterization of spleen DC subsets and  
conversion of tolerogenic CD4-8-DCs into immunogenic ones 
 HYPOTHESIS:  Although there are a lot of papers published on spleen DCs, none of 
them studied the differences in antitumor immunity among the three subsets. Because 
different subsets have been reported to induce Th1 or Th2 response, some differences in 
inducing CTL response which lead to kill tumor cells might exist. By knowing the 
differences, we can explore various ways to make them become functionally homogenous 
and more efficacious, thus develop a new type of DC-based vaccine against cancer.  
OBJECTIVES:  In this thesis, part 1 focuss on: i) Setting up the methods for purifying 
splenic DCs and their subsets with MACS technology.  ii) Phenotype and functional 
analysis of the three DC subsets and fresh splenic DCs.   iii) Animal study using CD4 
and CD8 knock out mice to study the role of CD4+ and CD8+ T cells in different DC 
subsets induced antitumor immunity.   iv) Phenotype and functional analysis of CD4-8- 
DCs subsets stimulated with different stimuli.  v) Analysis of activated CD4 T cells 
induced by different DC subsets and differentially stimulated CD4-8- DCs.  vi) DNA 
array analysis of the differences between CpG and LPS treated CD4-8- DCOVA.  vii) 
Study on IL-6 and IL-15 effects on the formation of Th17 and Th1 induced by CpG 
treated CD4-8- DCOVA using in vitro and in vivo assay.   
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2.2 Part 2:  Inhibitory mechanism of CD8+ CD25+ regulatory T cells 
HYPOTHESIS:  Membrane transfer and exosomes release and acquisition are found 
between many cells. What happens after one cell receives the membrane molecules is 
attracting more attention. T cells that acquire membrane complexes from DCs can behave 
like APCs and even neutrophil can become APCs after absorbing antigen-MHC complex 
from exosomes. What would happen if the regulatory T cells get the antigen-MHC 
complex from antigen pulsed DCs?   Will they become a DC-like T cells or will they 
become antigen-specific regulatory T cells enhancing its immunosuppressive function? 
OBJECTIVES: In this thesis, part 2 focuses on: i) Purification and expansion of 
CD8+CD25+ T cells from naive mouse.  ii) Characterization of this type T cells and 
confirmation that it’s a type of regulatory T cells (Tr).  iii) Study its effects on splenic 
DCs and naive T cells.  iv) Purification and characterization of exosomes from DC 
pulsed with OVA (model tumor antigen).  v) Study its effects of Tr cells after being 
pulsed with exosomes on CTL formation and function and compare with unpulsed Tr 
cells.   vi) Further confirm the above results by doing animal studies.  
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3.0 MATERIALS AND METHODS (Methods, see details in manuscripts)   
3.1 Reagents and Suppliers  
Table 3.1 lists the reagents used in the experiments presented in this thesis. All of the 
reagents used were molecular biology or research grade. Table 3.2 lists the 
commercially available kits used in this study         
                     
Table 3. 1: List of reagents and suppliers 
                       Reagents                         Suppliers 
Ammonium chloride 
Anit-Biotin MACS Beads 
Anti-CD4 MCAS beads 
Anti-CD8 MCAS beads 
BSA 
CFSE 
Collagenase IV 
CpG 1826(TCCATGACGTTCCTGACGTT) 
DMEM 
DMSO 
Dynal CD4 beads 
Dynal CD8 beads 
FCS  
Gentamicin Solution 
Glutamine solution 
G418 
GM-CSF 
Hydrochloric acid 
IL-2 
ODN 1892(TCCAGGACTTCTCTCAGGTT) 
OVA I(SIINFEKL) 
OVA II(ISQAVHAAHAEINEAGR) 
Mut-1(FEQNTAQP) 
EM Sciences 
Miltenyi Biotec 
 
 
Sigma 
Molecular Probes 
Worthington Biochemical Corp 
Synthesized by Operon 
Invitrogen 
Sigma 
Invitrogen 
 
Hyclone, Invitrogen 
Invitrogen 
Sigma 
Invitrogen 
Peprotec 
EM Sciences 
Peprotec 
Synthesized by Operon 
Synthesized by Multiple Peptide Systems 
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RPMI 1640 
Sodium chloride 
Streptavidin-ECD 
Streptavidin-FITC 
Streptavidin-PE 
Tris 
Trypsin-EDTA 
Tween 20 
2-mercaptoethanol  
Invitrogen 
EM Sciences 
Beckman Coulter 
BD Biosciences 
 
EM Sciences 
Invitrogen 
Bio-Rad 
Bio-Rad 
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Table 3. 2: Commercially available kits used in this study 
 
                    Commercial Kits                 Suppliers 
ELISA Kits for            IFN-γ 
                        IL-2 
                        IL-4 
                        IL-6 
                        IL-10 
                        IL-12 
                        IL-15 
                        IL-17       
                        TGF-β 
                        TNF-α           
Fixation and Permeabilization Solution 
Kit with BD GolgiStop™ 
FoxP3 intracellular staining kit 
PE-labeled H-2Kb/ SIINFEKL tetramer 
TMB Substrate Kit 
BD Biosciences 
 
 
 
 
 
eBioscience 
 
R&D Systems 
BD Biosciences 
BD Biosciences 
 
eBioscience 
Beckman Coulter 
BD Biosciences 
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 3.2 Antibodies  
Table 3.3 lists the various Abs and their respective suppliers used in the presentation of 
this thesis. Abs were labelled with either fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), or biotin. 
Table 3. 3: Antibodies and their suppliers 
 
                Antibodies                    Suppliers 
Anti-mouse B7-H1 
Anti-mouse B7-DC 
Anti-mouse B7-H3 
Anti-mouse B7-H4 
Anti-mouse CTLA-4 
Anti-mouse H-2Kb 
Anti-mouse I-Ab 
Anti-mouse IFN-γ 
Anti-mouse IL-6 
Anti-mouse IL-10 
Anti-mouse IL-15 
Anti-mouse IL-17 
Anti-mouse CD4 
Anti-mouse CD8 
Anti-mouse CD11c 
Anti-mouse CD25 
Anti-mouse CD28 
Anti-mouse CD30 
Anti-mouse CD40 
Anti-mouse CD54 
Anti-mouse CD62L 
Anti-mouse CD69 
Anti-mouse CD73 
Anti-mouse CD80 
Anti-mouse CD86 
eBioscience 
 
 
 
BD Biosciences 
 
 
 
eBioscience 
BD Biosciences 
eBioscience 
BD Biosciences 
eBioscience 
 
BD Biosciences 
 
 
 
 
 
 
 
eBioscience 
BD Biosciences 
 
 56
Anti-mouse FR-4 
Anti-mouse FasL 
Anti-mouse GITR 
Anti-human granzyme B 
Anti-mouse perforin 
Anti-pMHCI 
Anti-mouse TGF-β 
Anti-mouse TLR-4 
Anti-mouse TLR-9 
Anti-mouse TRAIL 
Anti-rat IgG 
Anti-hamster IgG  
eBioscience 
BD Biosciences 
 
Serotec 
BD Biosciences 
Dr. Xiang’s Lab 
 
eBioscience 
 
BD Biosciences 
Jackson ImmunoResearch 
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4.1.1 ABSTRACT 
 
   It is clear that DCs are essential for priming of T cell responses against tumors. 
However, the distinct roles DC subsets play in regulation of T cell responses in vivo are 
largely undefined. In this study, we investigated the capacity of OVA-presenting CD4–8–, 
CD4+8–, or CD4–8+ DCs (OVA-pulsed DC (DCOVA)) in stimulation of OVA-specific T 
cell responses. Our data show that each DC subset stimulated proliferation of allogeneic 
and autologous OVA-specific CD4+ and CD8+ T cells in vitro, but that the CD4–8– DCs 
did so only weakly. Both CD4+8– and CD4–8+ DCOVA induced strong tumor-specific 
CD4+ Th1 responses and fully protective CD8+ CTL-mediated antitumor immunity, 
whereas CD4–8– DCOVA, which were less mature and secreted substantial TGF-  upon 
coculture with TCR-transgenic OT II CD4+ T cells, induced the development of 
IL-10-secreting CD4+ T regulatory 1 (Tr1) cells. Transfer of these Tr1 cells, but not T 
cells from cocultures of CD4–8– DCOVA and IL-10–/– OT II CD4+ T cells, into CD4–8+ 
DCOVA-immunized animals abrogated otherwise inevitable development of antitumor 
immunity. Taken together, CD4–8– DCs stimulate development of IL-10-secreting CD4+ 
Tr1 cells that mediated immune suppression, whereas both CD4+8– and CD4–8+ DCs 
effectively primed animals for protective CD8+ CTL-mediated antitumor immunity. 
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 4.1.2 INTRODUCTION 
 
   DCs efficiently collect, transport, and present Ags to T cells. Although all DCs 
express multiple surface markers related to their Ag processing and T cell stimulatory 
functions (e.g., MHC class II, CD40, CD80), they in fact comprise heterogeneous subsets 
that differ substantially in other surface markers, as well as their developmental origin 
and physiology. Murine splenic CD11c+ DCs were originally characterized as being 
either CD8+ or CD8– cells, with both reportedly priming allogenic CD4+ and CD8+ T cells 
in vitro (90) and Ag-specific CD4+ T cells in vivo (90). Splenic CD8+ DCs reportedly 
elicit Th1 and CTL responses via an IL-12-dependent mechanism in vivo (437), whereas 
CD8– DCs stimulate Th0/Th2 responses through their elaboration of IL-10 (90, 95). CD8+ 
and CD8– DCs from Peyer’s patches similarly induce Th1 and Th2 responses, 
respectively (438).  
   More recently, splenic CD8– DCs have been subdivided into CD4– and CD4+ 
populations (76). Thus, CD11c+ splenic DCs comprise three distinct subsets, with CD4+8– 
cells representing 50% of splenic DCs and CD4–8+and CD4–8– DCs each 25% of the 
total population (76, 439). CD4–8+ DCs have been reported as variably effective (99, 100) 
stimulators of allogeneic CD8+ T cell responses and CD4–8– and CD4+8– DCs as more 
effective in stimulating CD4+ T cell responses (99, 100). In vivo, CD4–8+ and CD4–8– 
DCs can efficiently prime male Ag-specific CTLs, whereas CD4+8– DCs do so only 
weakly (99). Splenic DCs can also express tolerogenic phenotypes; CD4+8– DCs 
reportedly mediate tolerance or bystander suppression against diverse T cell specificities 
(103), while CD4–8+ DCs can induce tolerance to tissue-associated Ags (104). The 
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reasons for the different (i.e., immunogenic vs tolerogenic) results observed using the 
different DC subsets are at present unclear.  
   Based on the known critical roles of DCs in induction of primary immune responses, 
these cells have been used in DC-based cancer vaccines (179). However, given the 
discrepant immunological functions of the various DC subsets, with their potentials for 
adverse effects in the context of tumor immunity, we thought it important to critically test 
the capacity of each DC subset to prime antitumor responses. In this study, we addressed 
the distinct roles of each of these DC subsets in stimulation of OVA-specific CD4+ and 
CD8+ T cell responses in vitro and in priming of OVA-specific CTLs as well as antitumor 
immune responses in vivo. 
4.1.3 MATERIALS AND METHODS 
 
4.1.3.1 Cell lines, Abs, cytokine, peptides, and animals  
 
   The OVA-transfected MO4 cell line was kindly provided by Dr. P. Srivastava 
(University of Connecticut School of Medicine, Farmington, CT). EL4 T cell lymphoma, 
EG7 (i.e., OVA-transfected EL4 cells) and LB27 B cell hybridoma expressing I-ab were 
obtained from the American Type Culture Collection. MO4 and EG7 tumor cells were 
maintained in DMEM plus 10% FCS and 0.5 mg/ml G418 (Invitrogen Life 
Technologies). Biotin- and FITC-conjugated monoclonal anti-mouse I-Ab (AF6-120.1), 
CD4 (GK1.5), CD8 (53-6.7), CD11c (HL3), CD54 (3E2), CD80 (16–10A1), CD86 
(GL1), F4/80 (MCAP497), biotin-conjugated anti-CD25 (7D4), CD69 (H1.2F3), V 2V
5+TCR (MR9-4) Abs, and those related FITC-conjugated isotype Abs described above 
were obtained from BD Pharmingen. FITC- and R-PE-conjugated streptavidin were 
obtained from Caltag Laboratories. Recombinant mouse GM-CSF and IL-4 were obtained 
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from R&D Systems. The H-2Kb- and I-Ab-specific OVAI (OVA257–264, SIINFEKL) and 
OVAII (OVA323–339, ISQAVHAAHAEINEAGR) peptides(440) were synthesized by 
Multiple Peptide Systems. Wild-type, CD4, and IL-10 knockout (KO) C57BL/6, 
wild-type BALB/c, and the OVA-specific TCR-transgenic OT I and OT II mice(440) 
were obtained from The Jackson Laboratory. Homozygous IL-10–/– OT II mice were 
generated by backcrossing the IL-10–/– mice onto the OT II background for three 
generations; homozygosity was confirmed using mouse genomic DNA by PCR according 
to the company’s protocol. All animal experiments were conducted according to the 
guidelines of the Canadian Council for Animal Care.  
4.1.3.2 Isolation of spleen DCs  
   This protocol is a modified version of that described by Livingstone and Kuhn(441). 
Briefly, spleens were injected with DMEM containing 1 mg/ml collagenase (Worthington 
Biochemical), cut into small fragments, and digested in the above-described enzyme 
solution for 45–60 min at 37°C. Single-cell suspension was prepared by pressing the 
digested tissues through a stainless mesh. After the RBC were lysed with Tris-NH4Cl, the 
spleen cells were washed once in PBS and resuspended in RPMI 1640 plus 10% FCS and 
50 µM 2-ME (complete medium) and incubated at 37°C in 100 x 20-mm petri dishes (one 
spleen equivalent per dish). After 90 min at 37°C, nonadherent cells were removed by 
gentle washing three times with prewarmed normal saline. Adherent cells were harvested 
by using trypsin/EDTA (Invitrogen Life Technologies). Spleen DCs were further purified 
from these adherent cells by incubating them with the biotin-conjugated anti-CD11c Ab 
and then the anti-biotin Ab-coupled microbeads, and then passing them over a MACS LS 
column (Miltenyi Biotec) according to the company’s instruction. The microbead-bound 
cells were fresh CD11c+ spleen DCs. For OVA protein pulsing, adherent cells were 
cultured overnight in AIM V medium (serum-free lymphocyte medium; Invitrogen Life 
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Technologies) plus GM-CSF (15–20 ng/ml) and OVA protein (0.1 mg/ml) 
(Sigma-Aldrich). The next day, nonadherent cells were harvested and high-density cells 
were removed by using Histopaque 1083 (Sigma-Aldrich). The cells were washed twice 
in 0.5% BSA in PBS and used for isolation of spleen DC subsets.  
4.1.3.3 Purification of spleen DC subsets  
   DCs subsets were purified as previously described (90) with modification. Briefly, 
purified overnight cultured nonadherent cells were incubated with the biotin-conjugated 
anti-CD8 Ab and then with anti-biotin Ab-coupled microbeads, and passed over a MACS 
LS column (Miltenyi Biotec) according to the company’s instruction. The 
microbead-bound cells were CD4–8+ spleen DCs. The flow-through cells were then 
incubated with biotin-conjugated anti-CD4 Ab and then repeated the same procedure as 
described above for isolation of CD8+ spleen DCs. The bound cells were CD4+8– spleen 
DCs. The flow-through cells were then passed through a LD column to completely 
remove any residual cells expressing CD4 and CD8 markers. The final flow-through cells 
were incubated with the biotin-conjugated anti-CD11c Ab, and the procedure described 
above was repeated. The bound cells were CD4–8– spleen DCs. The purified CD4+8–, 
CD4–8+, and CD4–8– spleen DCs were used for the following studies. DCs pulsed with 
OVA protein were termed as OVA-pulsed DC (DCOVA).  
4.1.3.4 Preparation of DCOVA-activated CD4+ T cells  
   Naive OVA-specific CD4+ T cells from OT II or OT II/IL-10–/– mice were obtained 
by passage of splenocytes through nylon wool columns (173). The T cells were 
fractionated by negative selection using anti-mouse CD8 (Ly2) paramagnetic beads 
(Dynal Biotech) according to the manufacturer’s protocols to yield populations that were 
>98% CD4+/V 2V 5+. For activation, the naive CD4+ T cells (2 x 105 cells/ml) were 
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stimulated for 5 days with purified DCOVA subsets (1 x 105 cells/ml) in the presence of 
IL-2 (10 U/ml) or anti-TGF-  Ab (0.5 µg/ml; R&D Systems) and then isolated from 
Ficoll-Paque (Amersham Biosciences) density gradients(173).  
4.1.3.5 Analyses of phenotype and cytokine profile  
   All fresh spleen DCs, purified overnight-cultured spleen DC subsets, and T cells were 
analyzed by flow cytometry using marker-specific and isotype-matched control Abs as 
noted (173). The values of mean fluorescence intensity (MFI) for the control and the 
sample were measured by flow cytometry. The expression index (EI) representing the 
degree of molecule expression was calculated by dividing the sample MFI with the 
respective control MFI. For assessment of cytokine production, DC subsets were cultured 
in the presence of GM-CSF (20 ng/ml) and LPS (1 µg/ml) (218), while DCOVA 
subset-stimulated CD4+ T cells were restimulated with irradiated (10,000 rad) and OVAII 
peptide-pulsed LB27 tumor cells (442). One day subsequently, the supernatants were 
assayed for IFN- , IL-4, IL-10, TNF- , and TGF-  using ELISA kits (R&D Systems) 
(173).  
4.1.3.6 T cell proliferation assays  
   Standard T cell proliferation assays were conducted using naive CD4+ or CD8+ T 
cells purified from BALB/c, OT I, or OT II mice as responder cells and irradiated (4000 
rad) DCs and DCOVA subsets were used as stimulators, respectively (173).  
4.1.3.7 CTL assay  
   Splenic lymphocytes (5 x 106) from mice vaccinated with the various DCOVA subsets 
were cocultured for 4 days in 24-well plates with irradiated (10,000 rad) EG7 cells (2 x 
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105). The activated T cells were harvested and used as effector cells against radiolabeled 
EG7 or EL4 target cells in 51Cr release assays (173).  
4.1.3.8 Animal studies  
   For investigation of antitumor immunity, C57BL/6 mice (n = 8/group) were 
vaccinated s.c. with 1 x 106 CD4+8–, CD4–8+, or CD4–8– DCOVA and then challenged s.c. 
10 days later with 1 x 105 MO4 tumor cells. When investigating the role of CD4+ and 
CD8+ T cells in antitumor responses, CD4+ and CD8+ T cells were depleted by i.v. 
injection of 0.5 mg anti-CD4 and anti-CD8 Ab at days –3, 0, and 3 relative to the DC 
immunization, respectively (173). In all experiments, irrelevant isotype-matched rat Abs 
were used as controls, and target cell depletion was confirmed by FACS analysis of the 
circulating T cells. To demonstrate that the anti-CD4 Ab effects (above) were not 
dependent on a coincidental targeting of CD4+ DCs, in some experiments CD4 KO 
C57BL/6 mice were used in place of the anti-CD4 Ab-treated mice.  
   In the studies to confirm that regulatory T (Tr) cells generated in vitro and in vivo 
were functional in vivo, OT II or OT II/IL-10–/– CD4+ T cells, which had been activated 
by coculture with freshly purified DCOVA, and CD4+ T cells, which were purified from 
mice immunized with CD4–8– DCOVA for 7–9 days by using the method described above 
for purification of CD4+8– DCs with MACS beads, were injected i.v. into mice (2 x 
106/mouse) vaccinated with a fully protective dose (i.e., 1 x 106) of CD4–8+ DCOVA 9 days 
before. OT II and normal CD4+ T cells activated in vitro and in vivo by CD4+8– and 
CD4–8+ DCOVA were used as controls. These mice were then challenged s.c. with 1 x 105 
MO4 tumor cells 1 day later. Animal mortality was monitored daily for up to 10 wk; for 
humanitarian reasons, all mice with tumors that achieved a size of 1.5 cm in diameter 
were sacrificed.  
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4.1.4 RESULTS 
 
4.1.4.1 Phenotypic characterization of spleen DCs and DC subsets  
   Fresh spleen DCs were prepared as described in Materials and Methods and then 
analyzed for their cell surface expression of a panel of immunologically important 
molecules by flow cytometry. As shown in Fig.4.1. 1A, they mostly express DC marker 
CD11c, indicating their nature of DCs. They displayed a very low expression of MHC 
class II (I-Ab) (EI, 2.6) and costimulatory molecule CD80 (EI, 1.6) and CD86 (EI, 1.4), 
which are closely associated with DC maturation, indicating that they are immature DCs. 
Three subsets of spleen DCs were purified from the overnight-cultured spleen DCs as 
described in Materials and Methods. As shown in Fig. 1B, three purified subsets of DCs 
mostly (>90%) expressed CD11c and all expressed high amounts of I-Ab, CD80, and 
CD86 molecules, indicating that they are mature DCs. There were two distinct peaks of 
I-Ab, CD54 and CD80 expression, indicating that the differentiation stages of DC subsets 
are heterogeneous. There was 6–7% of the CD3-positive T cell population, but no 
F4/80-positive macrophages (443), within the above DC subset preparations as examined 
by flow cytometry (data not shown). Among the three DC subsets, the CD4–8– DC subset 
had less expression of MHC class II (I-Ab) (EI, 8.3) and costimulatory molecules CD80 
(EI, 10.7) and CD86 (EI, 4.0) compared with the other two DC subsets with a 2- to 3-fold 
higher EI (Fig.4.1. 1B), indicating that it is a relatively less mature form of mature DCs. 
As shown in Fig. 4.1. 2, cytokine secretion profiles among DC subsets are significantly 
different. After stimulation with LPS, both CD4+8– and CD4–8+ DC subsets secreted a 
higher level of IFN-  (0.5–1 ng/ml) and TNF-  (0.2 ng/ml) but a very low level of 
TGF- . On the contrary, CD4–8– DC subset secreted a much higher level of TGF-  (0.55 
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ng/ml) (Student’s t test; p < 0.01 vs CD4+8– DCs or CD4–8+ DCs) and a very low level of 
IFN-  and TNF- . 
4.1.4.2 Stimulation of allogeneic T cells in vitro by DC subsets  
   DCs are potent stimulators of primary MLRs and are able to induce the proliferation 
of allogeneic T cells in vitro (173). Thus, we compared the ability of three DC subsets in 
stimulation of primary 3-day MLRs against allogeneic T cells. All three DC subsets 
demonstrated the ability to stimulate purified CD4+ and CD8+ T cells from BALB/c mice 
in the 3-day MLRs. Among them, the CD4–8+ DC is the most effective type of DCs in 
stimulation of proliferation of unfractionated allogeneic T cells, whereas both CD4+8– and 
CD4–8– DC subsets showed similar stimulation activity (data not shown). When testing 
on T cell subsets, CD4–8+ DCs are also the most effective in stimulation of both 
allogeneic CD4+ and CD8+ T cells, whereas CD4+8– DCs are only more effective in 
stimulation of CD8+ T cells than CD4–8– DCs (Fig. 4.1. 3, A and B).  
4.1.4.3 Stimulation of tumor Ag-specific T cells in vitro by DC subsets  
   We next checked and compared their abilities in presentation of tumor Ag OVA 
instead of alloantigens. For this purpose, we used spleen DCs subsets pulsed with OVA 
protein for stimulation of transgenic OT II CD4+ and OT I CD8+ T cells in vitro in the 
3-day T cell proliferation assay. Accordingly, we found that the results were very similar 
to those of MLRs. The CD4–8+ DC subset had a higher capacity of stimulating CD4+ and 
CD8+ T cell proliferation than the other two subsets in the 3-day T cell proliferation assay 
(Student’s t test; p < 0.05). Again, the CD4–8– DC subset is the weakest inducer of T cell 
proliferation, probably due to its relatively low maturity. In addition, we also found that 
the efficiency of T cell proliferation by both CD4+8– and CD4–8– DC subsets peaked at 
day 3 of stimulation, whereas the efficiency of T cell proliferation by the CD4–8– DC 
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subset peaked at day 5 of stimulation. Interestingly, the CD4–8– DC subset became the 
strongest inducer in stimulation of both OT II CD4+ and OT I CD8+ T cells in vitro in the 
5-day T cell proliferation assay (Fig. 4.1. 3, C and D).  
4.1.4.4 CD4+8– and CD4–8+ DCs prime CTL-mediated antitumor immune responses 
in vivo  
   Next, we wished to test the ability of the various DC subsets for in vivo CTL priming. 
Splenic lymphocytes from mice immunized with DCOVA subsets were cocultured with 
irradiated EG7 tumor cells expressing OVA for 4 days and harvested. These T cells are 
called CTLs. To assess their cytotoxic activities, we conducted a chromium release assay 
by using these CTLs as effector cells and the 51Cr-labeled EG7 tumor cells as target cells. 
As shown in Fig. 4.1. 4A, CTLs derived from mice immunized with CD4+8– and CD4–8+ 
DCOVA showed similar cytotoxic activity against EG7 tumor cells. At an E:T ratio of 50, 
the specific killing activities are all 50%, but essentially none of the OVA-negative EL4 
cells. In contrast, T cells derived from mice immunized with CD4–8– DCOVA did not show 
any OVA-specific cytotoxic activity, indicating that the tumor-specific CTL responses in 
this group of mice were inhibited. 
   To examine whether DC subsets are capable of inducing antitumor immunity, we 
vaccinated mice with DCOVA subsets and 10 days later challenged the mice with MO4 
tumor cells (1 x 105 cells per immunized mouse). As shown in Fig. 4.1. 4B, MO4 tumor 
cell challenges were invariably lethal within 4 wk after implantation for the control mice 
vaccinated with PBS, whereas two of eight mice vaccinated with unfractioned splenic 
DCOVA were protected against MO4 tumor challenge. Most (seven of eight) animals 
immunized with either CD4+8– or CD4–8+ DCOVA were protected for at least 9 wk, 
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whereas all of the mice immunized with CD4–8– DCOVA died within 5 wk of tumor 
inoculation.  
    To study the immune mechanisms in the protective immunity, immunized mice were 
depleted of their CD4+ T cells using the anti-CD4 Ab before MO4 tumor challenge. As 
shown in Fig. 4.1. 5, A and B, the immune protections against MO4 tumor challenge 
dramatically dropped from 100% to 25% and 0%, respectively, in CD4+ T cell-depleted 
mice immunized with CD4+8– and CD4–8+ DCOVA. Because the use of anti-CD4 Ab for 
CD4+ T cell depletion in vivo may also affect and eliminate CD4+8– DCs, we then 
repeated the CD4+8– DCOVA immunization experiment in CD4 KO mice. As shown in 
Fig. 4.1. 5B, the immune protection became 25% in this group of mice. These results 
clearly indicate that CD4+ Th cells play an important role in CD4+8– and CD4–8+ 
DC-primed OVA-specific immune responses. In addition, the immune protection against 
MO4 tumor challenge dramatically dropped from 100% to 0% in CD8+ T cell-depleted 
mice immunized with CD4+8– and CD4–8+ DCOVA, indicating that CD8+ CTLs are the 
major effector cells in the antitumor immunity derived from CD4+8– and CD4–8+ DCs.  
4.1.4.5 CD4–8– DCs prime tolerant immune responses against tumors in vivo  
   In contrast, CD4–8– DC vaccination did not show any immune protection against the 
challenge of 0.1 x 106 MO4 tumor cells. All of the mice immunized with CD4–8– DCOVA 
died within 5 wk after tumor inoculation (Fig. 4.1. 5C), confirming that the 
tumor-specific CTL responses in this group of immunized mice were lacking. To 
investigate whether CD4+ Tr cells induced by CD4–8– DCs are responsible for the lack of 
CTL responses, we conducted the above animal studies in CD4+ T cell-depleted mice by 
using the anti-CD4 Ab. Surprisingly, we found that 88% of mice significantly prolonged 
their survival (Student’s t test; p < 0.05) and 50% of mice were eventually protected from 
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tumor challenge in CD4+ T cell-depleted mice immunized with CD4–8– DCOVA, 
compared with the wild-type mice. These results were further confirmed by using CD4 
KO mice, which showed that 75% of the immunized mice were protected from tumor 
challenge. These results clearly indicate that CD4+ Tr1 cells induced by CD4–8– DCs are 
most likely responsible for the in vivo immune suppression against MO4 tumor cells.  
4.1.4.6 CD4–8– DCs induce CD4+ Tr1 differentiation in vitro  
   Since DC subsets may be specialized to prime different CD4+ T cell responses (444), 
we examined the pattern of cytokine secretion of CD4+ T cells activated by OVA 
protein-pulsed DC subsets by ELISA. We first confirmed that these activated T cells were 
CD4 positive and displayed the clonotypic V 2V 5 OVA TCR, as well as the T cell 
activation markers CD25 and CD69 (data not shown). We then examined their cytokine 
profiles. We found that the activated CD4+ T cells from the CD4+8– or CD4–8+ DCOVA 
cocultures secreted similarly high levels of IFN- , but relatively little or no IL-4 or IL-10 
(Fig. 4.1. 6A), indicating a Th1 phenotype. However, the CD4+ T cells activated by 
TGF- -secreting CD4–8– DCOVA secreted high levels of IL-10 (1.75 ng/ml) and 
substantial amounts of IFN-  (2.1 ng/ml), indicating a Tr1 phenotype.  
4.1.4.7 CD4+ Tr1 cells inhibit the antitumor immunity through IL-10  
   Because Tr1 cells suppress immune responses (445), we next assessed whether they 
also inhibit the antitumor immunity in our animal model. We injected these Tr1 cells into 
CD4–8+ DCOVA-immunized mice before tumor challenge. As shown in Fig. 4.1. 6B, 
CD4–8– DCOVA-induced OT II CD4+ Tr1 cells completely inhibited the immune 
protection of CD4–8+ DCOVA immunization, whereas CD4+8– or CD4–8+ DCOVA-activated 
Th1 cells showed enhanced protection against MO4 tumor challenge when compared with 
the CD4–8+ DCOVA control. To confirm the above findings, we also isolated the CD4+ T 
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cells from CD4–8– DCOVA-immunized immunized mice and repeated the same experiment 
as that for in vitro-activated Tr1 cells. As we expected, we found almost identical results 
to those for in vitro-cultured Tr1 cells (data not shown), confirming that CD4+ Tr1 cells 
induced by CD4–8– DCOVA are most likely responsible for the in vivo immune 
suppression against MO4 tumor cells. To assess whether IL-10 was involved in the 
inhibition of CD4–8+ DCOVA-induced antitumor immunity, OT II CD4+ T cells (IL-10–/–) 
were used to coculture with the CD4–8– DCOVA. After 5 days of culture, the Tr1 (IL-10–/–) 
cells were injected into CD4–8+ DCOVA-immunized mice. As shown in Fig. 4.1. 6B, most 
of the immunized mice were protected against the MO4 challenge and no inhibition was 
observed, while the normal Tr1 cells completely inhibited the antitumor immunity of 
CD4–8+ DCOVA.  
4.1.4.8 TGF-β is partially responsible for the induction of Tr1 by CD4–8– DCOVA  
   It has recently been reported that LPS-stimulated B cells expressing TGF-β induced T 
cell anergy via activation of Tr cells (446). To explore the mechanism of Tr1 induction, 
we added anti-TGF-β Ab to the coculture of CD4–8– DCOVA and OT II CD4+ T cells and 
then tested the cytokine profile of activated CD4 T cells. Interestingly, their cytokine 
profile became similar to that of CD4–8+ DCOVA-activated Th1 (Fig.4.1. 6A). Their IL-10 
secretion was decreased nearly 10 times when compared with their controls. Furthermore, 
these T cells were used in in vivo study as described above. No inhibition, but a little 
enhancement of antitumor immune response, was observed in the CD4–8+ 
DCOVA-immunized mice (Fig.4.1. 6B), indicating that TGF-β was involved in promoting 
the formation of Tr1 cells.  
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4.1.5 DISCUSSION 
   Because of the critical roles DCs have in induction of primary immune responses, 
they have been extensively used for DC-based cancer vaccines. It has been shown that 
DCs, when pulsed with tumor-derived MHC class I-restricted peptides and tumor Ags, are 
able to induce significant CTL-dependent antitumor immune responses (179). Because 
the distinct immunological functions of DC subsets may have detrimental effects on the 
host’s immune responses, it is important to assess the capacity of these DC subsets in 
priming antitumor immunity.  
   Splenic DCs have been classified into three subsets (CD8+4–, CD8–4+, and CD4–8– 
DCs). Although the phenotypic and functional differences between CD8+ and CD8– DC 
subsets have been extensively studied (90) (95, 437, 438), the differences between CD4+ 
and CD4– populations within the CD8– DC subset have been less investigated. In this 
study, we conducted a systemic study on the phenotypic characteristics and the functional 
differences in stimulation of T cells among the three DC subsets. For the first time, our 
data showed that CD4–8– DCs secreted marked levels of TGF-  and represent a 
characteristic consistent with a tolerogenic phenotype (446). In contrast, the CD4+8– and 
CD4–8+ DCs secreted moderate and high levels of IFN-  relative to the CD4–8– DCs, 
respectively, but little or no TGF- . We then investigated the capacity of three DC subsets 
pulsed with OVA protein in priming OVA-specific antitumor immune responses in vivo. 
Our data showed that only CD4+8– DCOVA and CD4–8+ DCOVA could induce the 
antitumor response and protect the immunized mice from tumor challenge, whereas 
CD4–8– DCOVA could not stimulate any protective immune response against tumor, 
indicating distinct in vivo antitumor immune responses derived from vaccination of three 
DC subsets.  
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   There is now compelling evidence that CD4+ T cells, specialized in suppressing 
immune responses, play a critical role in immune regulation. Three major populations of 
Tr cells have been identified based on their distinct phenotype (CD4+CD25+) or cytokine 
profile (Tr1 and Th3). The CD4+CD25+ Tr subset mediates immune suppression in a 
non-Ag-specific manner, whereas the latter Tr1 and Th3 mediate immune inhibition via 
production of IL-10 and TGF- , respectively, but both in an Ag-specific way (447). In 
this study, the cytokine profiles of CD4+ T cells activated by DCOVA subsets differed 
markedly. CD4+8– or CD4–8+ DCOVA induce Th1 phenotype response, whereas T cells 
activated by TGF- -secreting CD4–8– DCs secreted high levels of IL-10 and substantial 
amounts of IFN- , a characteristic of Tr1 cells (447). Tr1 cells can also be induced by 
addition of exogenous IL-10 to primary murine T cell cultures or by coculturing T cells 
with TGF- /IL-10-expressing "tolerogenic" DCs (445, 448, 449) or by immature DCs 
(342). In addition, others have also shown that the IL-10-stimulated CD11clow 
CD45RBhigh tolerogenic DCs, which have a phenotype similar to our CD4–8– DCs, also 
induced Tr1 cell differentiation and immune tolerance in vivo (450). LPS-stimulated B 
cells expressing membrane-bound TGF-  have recently been shown to induce T cell 
anergy (446) via the activation of Tr cells (451). Interestingly, in this study, the addition 
of anti-TGF-  Ab to CD4–8– DCOVA coculture with OT II T cells converted the cytokine 
profile of these CD4+ T cells from the Tr1 phenotype to the Th1 phenotype, indicating the 
critical role of TGF-  of CD4–8– DCs in stimulation of the Tr1 response.  
    These Tr1 cells also distinct from Th1 or Th2 cells in that they produce high levels of 
IL-10 and no IL-4, and proliferate poorly upon TCR ligation, suppress immune responses 
in vitro and in vivo through secreted IL-10 (452). In this study, we also characterized the 
functional effect of these Tr1 cells in induction of immune suppression in vivo. The CD4+ 
Tr1 cells from CD4–8– DCOVA/OT II cocultures or purified from CD4–8– 
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DCOVA-immunized mice were transferred into CD4–8+ DCOVA-immunized mice and 
abolished the CD4–8+ DCOVA-induced antitumor immunity. Unlike the wild-type Tr1 cells 
(above), the IL-10–/– CD4 OT II T cells activated with CD4–8– DCOVA had little impact on 
CD4–8+ DCOVA-driven antitumor immunity, clearly implicating the IL-10-producing Tr1 
cells as central to the tolerance observed in this model system, and this is consistent with 
previous reports (452) (451). As expected, when we transferred the control Th1 cells from 
CD4+8– or CD4–8+ DC/OT II CD4+ T cell cocultures or T cells from coculture with 
CD4–8– DCOVA in the presence of anti-TGF-  Ab into CD4–8+ DC-vaccinated animals, 
we observed augmented tumor protection, confirming the critical role of TGF-  of 
CD4–8– DCs in stimulation of the Tr1 response.  
   CD4+ Th and Tr cells play an important role in modulation of immune responses by 
enhancement and suppression of CD8+ CTL responses, respectively (453). In this study, 
we showed that depletion of CD4+ Th and Tr cells significantly reduced and enhanced 
antitumor immune responses in CD4+8– or CD4–8+ DC- and CD4–8– DC-immunized 
mice, respectively. Surprisingly, the immune protection in CD4+ T cell-depleted CD4–8– 
DC-immunized mice is much stronger than that in CD4+ T cell-depleted CD4+8– or 
CD4–8+ DC-immunized mice. The immune mechanism behind this phenomenon is 
currently unknown. The enhanced immunity seen in CD4+ T cell-depleted CD4–8– 
DC-immunized mice may be partially derived from the capacity of CD4–8– DCs making 
more IL-12p70 than CD4+8– DCs when stimulated appropriately (235), which is 
associated with stimulation of CTL responses (454). It has been reported that different 
spleen DC subsets when pulsed with MHC class I-restricted viral peptide can induce 
antiviral immunity mediated by Th-independent CTL responses (455). In this study, we 
also found that our three DC subsets when pulsed with OVAI peptide can all induce 
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protective immunity against MO4 tumor cells, among which the CD4–8– DC subset 
stimulates the strongest immunity (data not shown), also supporting the above finding.  
  Discrepant results regarding immune priming vs tolerance have previously been 
reported for CD4+8– (100, 103) and CD4–8+ DCs (90, 104, 456). In addition, our results of 
tolerogenic CD4–8– DCs in antitumor immunity are also in contrast to a previous report 
wherein CD4–8– DCs efficiently stimulated H-Y Ag-specific CTL responses (99). It has 
been reported recently that the environmental conditions or stimuli under which DCs 
stimulate T cells critically affect the type of immune responses that ensue (173, 436, 456). 
This suggests that the discrepancies between our results and those observed in other 
systems (e.g., autoimmunity, allotransplantation, or antitumor immunity) would likely be 
attributable to the varying antigenic and environmental conditions in each model system, 
where different TLRs are stimulated (457).  
   Taken together, our data unequivocally confirmed that the different DC subsets can 
function either as stimulators or inhibitors of immune responses. CD4–8– DC stimulated 
IL-10-secreting CD4+ Tr1-mediated immune suppression, whereas both CD4+8– and 
CD4–8+ DC induced CD8+ CTL-mediated antitumor immunity. This information has very 
substantial implications for DC-based approaches to the design of cancer vaccines.  
 
Note: This manuscript has been published in 2005 in Journal of Immunology (Zhang, X., 
H. Huang, et al. (2005). "CD4-8- DCs prime CD4+ T regulatory 1 cells to suppress 
antitumor immunity." J Immunol 175(5): 2931-7.), the format was modified to fit the 
current version of thesis. 
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4.1.6 Figure legends for Manuscript 4.1 
 
Figure 4.1.1: Phenotpye analyses of spleen DC subsets. 
A. Fresh spleen DCs were purified with biotin-anti-CD11c and anti-biotin microbeads 
after harvesting those attached cells after 90 min incubation as described in Materials and 
Methods. They expressed very low level of CD80, CD86 and I-Ab.  B.  DC subsets 
were purified as described in. FITC-directed labeled Abs against mouse CD54, CD80, 
CD86, and MHC class II were used to stain the cells described above; corresponding 
isotype Abs were used as controls (thin lines). The values of MFI for the control and the 
sample are shown in the upper right corners. CD4-8-DCs had a lower level of CD54, 
CD80, CD86 and I-Ab compared with other two subsets. 
 
Figure 4.1.2: Cytokine secretion assay for three DC subsets. 
Three purified dendritic cell subsets were cultured with LPS (1 ug/ml) and rmGM-CSF 
(20ng/ml) for 24 hours and DC subset supernatants were measured for IFN- , TNF- , and 
TGF-  secretion by ELISA. All those kits were purchased from BD biosciences 
(Mississauga, ON, Canada). One representative experiment of three is shown.  
 
Figure 4.1.3: In vitro allogeneic and autologous T cell proliferation assays. 
Irradiated (4000 rad) DCOVA subsets (0.1 x 106 cells/well) and their 2-fold dilutions were 
cultured with a constant number (0.1 x 106 cells/well) of allogeneic BALB/c CD4+ (A) 
and CD8+ (B) T cells or autologous OT II CD4+ (C) and OT I CD8+ (D) T cells, 
respectively. After 48 h, thymidine incorporation was determined by liquid scintillation 
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counting. *, p < 0.05 vs cohorts of CD4+8– and CD4–8– DCs (Student’s t test). One 
representative experiment of three is depicted. 
 
Figure 4.1.4: In vitro cytotoxicity and in vivo animal studies. 
 
A, Activated CD8+ T cells from CD4–8+, CD4+8–, and CD4–8– DCOVA-immunized mice, 
respectively, were used as effector cells, whereas 51Cr-labeled EG7 or irrelevant EL4 
cells were used as target cells in 6-h 51Cr release assay. Each point represents the mean of 
triplicate cultures. One representative experiment of three is shown. B, Mice (n = 8) were 
s.c. vaccinated with unfractionated DCOVA or CD4+8–, CD4–8+, and CD4–8– DCOVA 
subsets, respectively, and then s.c. challenged, 10 days later, with 1 x 105 MO4 tumor 
cells. Animal mortality was monitored daily for up to 10 wk. The data are representative 
of two experiments with similar results. 
 
Figure 4.1.5: CD4+ T cells were responsible for CD4-8-DC induced  
immunosuppression.  
 
CD4+ and CD8+ T cell subset depletion experiments were performed in mice by i.v. 
injection of anti-CD4 and anti-CD8 Ab on days –3, 0, and 3 relative to CD4–8+ (A), 
CD4+8– (B), and CD4–8– (C) DCOVA immunizations, respectively. In addition, CD4 KO 
mice were used for replacement of CD4+ T cell-depleted mice in CD4+8– (B) and CD4–8– 
(C) DCOVA immunization groups. Animal mortality was monitored daily. The data are 
representative of two experiments with similar results. 
Figure 4.1.6: CD4-8-DCs induced Tr1 to inhibit antitumor immunity.  
A, The CD4+ T cell supernatants were measured for IFN- , IL-4, IL-10, and TNF-  
secretion by ELISA. One representative experiment of three is shown. B, Mice were 
immunized with CD4–8+ DCOVA (•) or PBS ( ). Mice vaccinated with CD4–8+ DCOVA 9 
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days before were further i.v. injected with OT II CD4+ T cells activated in vitro by 
CD4–8– (OTII (CD4–8– DCOVA); ), CD4+8– (OTII (CD4+8– DCOVA); ), and CD4–8+ 
(OTII (CD4–8+ DCOVA); ) DCOVA, respectively, or OT II/IL-10–/– CD4+ T cells 
activated by CD4–8– DCOVA (OT II/IL-10–/– (CD4–8– DCOVA); ) or OT II CD4+ T cells 
activated by CD4–8– DCs in the presence of anti-TGF-  Ab (OTII (CD4–8– 
DCOVA/anti-TGF- ); *). Ten days subsequent to DCOVA immunization, these mice were 
then challenged s.c. with 1 x 105 MO4 tumor cells. Animal mortality was monitored 
daily. The data are representative of two experiments with similar results. 
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Figure 4.1. 1: Phenotpye analyses of spleen DC subsets. 
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Figure 4.1. 2: Cytokine secretion assay for three DC subsets. 
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Figure 4.1. 3: In vitro allogeneic and autologous T cell proliferation assays. 
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Figure 4.1. 4: In vitro cytotoxicity and in vivo animal studies. 
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        Figure 4.1. 5: CD4+ T cells were responsible for CD4-8-DC induced immunosuppression.  
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            Figure 4.1. 6: CD4-8-DCs induced Tr1 response to inhibit antitumor immunity. 
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  In the first manuscript, we found that CD4+8- and CD4-8+  DCs subsets induced Thl 
cell responses leading to protective antitumor immunity, whereas CD4-8- DC secreting 
TGF-β stimulated responses of Trl cells secreting IL-10 and IFN-γ leading to immune 
tolerance (106). Our research indicated that DCs are usually composed of different 
subsets that might posses different functions leading to antitumor immunity or tolerance. 
However, for the cancer patient, immunotolerance should be avoided or converted to 
improve the efficency of DC vaccine-based cancer immunotherapy. Thus DCs should be 
made functionally homogenous and mature in order to be used as vaccine against tumor 
challenge or cancer treatment.  Research on how to convert the tolerogenic CD4-8- DCs 
into immunogenic ones will shed light on the way of improving DC based cancer 
treatment.  
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4.2.1 ABSTRACT 
 Different DC subsets play distinct roles in immune responses. CD4-8- DCs secreting 
transforming growth factor (TGF)-β stimulate CD4+ regulatory T type 1 (Trl) cell 
responses leading to inhibition of CD8 cytotoxic T lymphocyte (CTL) responses and 
antitumor immunity. In this study, we explored the potential effect of three stimuli CpG, 
LPS and anti-CD40 antibody in conversion of CD4-8- DC-induced tolerance. We 
demonstrated that when CD4-8- DCs were isolated from overnight culture and cultured 
for another 8 hrs in AIM-V plus rmGM-CSF (15-20 ng/ml) and OVA (0.1 mg/ml) with 
CpG (5 ug/ml), LPS (2 ug/ml) and anti-CD40 antibody (10 ug/ml), their phenotype 
became more mature compared with the freshly isolated ones. CpG is the only agent that 
stimulates the DCs to secrete significant level of IL-6 and IL-15; DNA array analyses 
also indicate that CpG stimulates higher expression of IL-6 and IL-15 mRNA. CpG 
treatment most efficiently converts the tolerogenic DCs into immunogenic ones which 
stimulated the OTII CD4+ T cell to become Th1 and Th17 rather Tr1, while the other two 
stimulator-treated DCs could not induce Th17 response.  Their vaccination also induced 
the strongest antitumor CTL responses and protective immunity against tumor cell 
challenge. When CD4-8- DCs were isolated from IL-6-/- mice, CpG-treated DCOVA 
vaccination almost completely lost their animal protection capacity. Wild type B6 
DCOVA-vaccinated IL-15R-/- mice can only provide up to 30% protection against tumor 
challenge. Those results indicate that IL-6/IL-l5-induced Th17 plays a critical role in 
their conversion. Taken together, our findings indicate that CpG treatment is the most 
efficient agent that can convert tolerogenic DCs into immunogenic ones and induce 
long-lasting antitumor immunity.  
 87
 4.2.2 INTRODUCTION 
DCs are specialized antigen-presenting cells (APCs) that recognize, acquire, process 
and present antigen to naive, resting T cells for the induction of an antigen specific 
immune response (244). Immature DCs are widely distributed in the body, although they 
occupy only a small proportion (0.1-1%) of the cells in different lymphoid and 
non-lymphoid tissues (35, 36). Toll-like receptors (TLRs) are innate receptors that sense 
microbial products and trigger DC maturation, thus efficiently bridging innate and 
adoptive immunity (225). DCs express the broadest repertoire of TLRs through which 
they can recognize a plethora of microbial compounds. After challenging with microbial 
or inflammatory stimuli including endogenous (IL-1β, TNF-α, etc) and exogenous 
mediators (LPS and CpG) (2, 36, 340-342) in the micro environments, immature DCs 
undergo a complex process of maturation wherein they up-regulate MHC class II, CCR7 
and co stimulatory molecules that are essential for naive T cell priming (127, 128) and 
migrate to T cell zones of lymph nodes to stimulate T cell responses (2, 36, 340, 341). In 
addition, DCs represent a critical source of IL-6, IL-12, IL-15, IL-1β, IL-23 or IFN-β, 
especially IL-12, which are key members in innate responses and drive T helper type 1 
(Th1) polarization (145, 146, 458). IL-12 production by DCs is tightly controlled, as it 
requires first a priming signal provided by microbial products or IFN-γ and then an 
amplifying signal provided by T cells through CD40 ligand (CD40L) (217, 219). 
Therefore, CD40 and TLR4 or TLR9 signalings triggered by anti-CD40 Ab and LPS or 
CpG have been extensively explored to promote in vitro and in vivo DC maturation and 
induce Th1 type antitumor immunity (144, 217-219, 225, 458).  
In addition to the micro environments wherein DCs acquire their Ag and different 
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stimuli determine their potential immunogenicities, the different DC subsets are also 
capable of inducing distinct Th or Tr cell-mediated immune responses (2, 36, 340-342, 
459).  In mouse spleens, DCs have been classified into three subsets based on CD4 and 
CD8 expression on their surface, which are named as CD4+8- DC representing ~50% of 
splenic DCs and CD4-8+ and CD4-8- DCs each ~25% of the total population (76, 99, 460). 
CD4-8+ DCs have been reported as variably effective stimulators of allogeneic CD8+ T 
cell responses, and CD4-8- and CD4+8- DCs as more effective in stimulating CD4+ T cell 
responses (99, 100). In vivo, CD4-8+ and CD4-8- DCs can efficiently prime male 
antigen-specific CTL, whereas CD4+8- DCs do so only weakly (99). Splenic DCs can 
also express tolerogenic phenotypes; CD4+8- DCs reportedly mediate tolerance or 
bystander suppression against diverse T cell specificities (103), while CD4-8+ DCs can 
induce tolerance to tissue-associated Ags and heart transplant (104, 105). We have 
recently demonstrated that CD4+8- and CD4-8+DCs subsets induced Thl cell responses 
leading to protective antitumor immunity, whereas CD4-8- DC secreting TGF-β 
stimulated responses of Trl cells secreting IL-10 and IFN-γ leading to immune tolerance 
(106). In addition, we have also shown that Trl-induced immune tolerance is mediated by 
its secretion of immunosuppressive IL-10.  
In this study, we investigated whether CD40 and TLR signalings can convert 
tolerogenic CD4-8- DCs into immunogenic ones and what type of CD4+ T cell responses 
is stimulated by the converted DCs. We stimulated CD4-8- DCs with agonistic anti-CD40 
Ab, LPS and CpG and phenotypically and functionally characterized treated DCs. We 
demonstrated that CpG treatment most efficiently converts the tolerogenic DCs into 
immunogenic ones capable of stimulating Thl and Thl7 cell responses leading to 
induction of efficient CTL responses and antitumor immunity.  
 89
 4.2.3 MATERIALS AND METHODS 
 
4.2.3.1 Cell lines, antibodies, cytokines, peptides and animals 
The ovalbumin (OVA)-transfected B16 melanoma cell line BL6-10OVA was generated 
in our lab (461). EL4 T cell lymphoma, EG7 (i.e., OVA-transfected EL4 cells) and LB27 
B cell hybridoma expressing I-Ab were obtained from the American Type Culture 
Collection (Manassas, VA). BL6-10OVA and EG7 tumor cells were maintained in DMEM 
plus 10% FCS and 0.5 mg/ml G418 (Invitrogen, Burlington, ON, Canada). Biotin- and 
FITC-conjugated monoclonal anti-mouse I-Ab (AF6-120.1), CD4 (GK1.5), CD8 (53-6.7), 
CDllc (HL3), CD54 (3E2), CD80 (16-10A1), CD86 (GL1), biotin- conjugated anti-CD25 
(7D4), CD69 (H1.2F3), Vβ5.1,5.2 TCR (MR9-4), and those above related 
FITC-conjugated isotype antibodies were obtained from BD Biosciences (Mississauga, 
ON). Neutralization antibody against mouse IL-6 and IL-15 were purchased from 
eBioscience (San Diego, CA). Streptavidin-FITC was obtained from Caltag (Burlingame, 
CA). Phosphorothioate-modified CpG ODN 1826: 5'- 
TCCATGACGTTCCTGACGTT-3', and the control ODN 1982: 5'- 
TCCAGGACTTCTCTCAGGTT-3' were synthesized by Operon (Huntsville, AL) (462) 
and diluted in PBS. No endotoxin could be detected in ODN preparations (<0.03 EU/ml); 
BioWhittaker, Walkersville, MD). Agonistic anti-CD40 antibody was purified in our lab 
from the FGK 45.5 hybridoma cells (463) culture supernatant. LPS were purchased from 
Sigma (St. Louis, MO). Recombinant mouse granulocyte-macrophage colony-stimulating 
factor (rmGM-CSF) was obtained from R&D Systems Inc. (Minneapolis, MN). 
Wild-type C57BL/6 and OVA-specific T cell receptor transgenic OT I, OT II (440), 
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CD4-/- (464), CD8-/- (465), IL-6-/- (466) and  IL-15R-/- (467) mice were obtained from the 
Jackson Laboratory (Bar Harbor, Maine). All animal experiments were carried out 
according to the guidelines of the Canadian Council for Animal Care.  
4.2.3.2 Isolation of splenic DCs 
This protocol is a modified version of that described by Livingstone et al (441). 
Briefly, spleens from wild type C57BL/6 or IL-6-/- mice were injected with DMEM 
containing 1 mg/ml collagenase (Worthington Biochemical Corp., Freehold, NJ), cut into 
small fragments and digested in the above enzyme solution for 45-60 min at 37°C. Single 
cell suspension was prepared by press the digested tissues through a stainless mesh. After 
the red blood cells were lysed with Tris-NH4Cl, the spleen cells were washed once in 
PBS and resuspended in RPMI-1640 plus 10% FCS and 50 μM 2-ME (CM) and 
incubated at 37°C in 100 x 20 mm petri dishes (one spleen equivalent per dish). After 90 
min incubation, nonadherent cells were removed by gentle washing 3 times with 
pre-warmed normal saline. Adherent cells were cultured overnight in CM plus 
rmGM-CSF (15-20 ng/ml). For OVA protein pulsing, adherent cells were cultured 
overnight in AIM-V® medium (serum-free lymphocyte medium) (Invitrogen, Burlington, 
ON) plus rmGM-CSF (15-20 ng/ml) and indicated concentration of OVA (Sigma 
Chemical Corp., St. Louis, MO). The next day, the non-adherent DCs (DCOVA) were 
harvested and used for isolation of spleen DC subsets.  
4.2.3.3 Purification of splenic CD4-8-DC subset 
DC subsets were purified as previously described (106) with modification. Briefly, the 
above nonadherent DCs were incubated with the biotin-conjugated anti-CD8 and 
anti-CD4 antibody and then with anti-biotin antibody-coupled MACS® microbeads 
(Miltenyi Biotech, Auburn, CA).  All of the cell suspension was then loaded onto LD 
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column to completely remove any cells expressing CD4 and CD8 markers according to 
the company's instruction. The final flow-through cells were incubated with the 
biotin-conjugated anti-CD11 c antibody and then with biotin conjugated microbeads and 
passed over a MACS® LS column. The bound cells were freshly prepared splenic CD4-8- 
DCs and were used for the following study.  
4.2.3.4 Activation and protein pulsing of CD4-8- DC subset 
Purified CD4-8- DCs were cultured in AIM-V containing rmGM-CSF (15-20 ng/ml), 
OVA protein (0.1 mg/ml), 2-ME (50 μM) with CpG (5 μg/ml), LPS (2 μg/ml), or 
anti-CD40 (10 μg/ml) for 8 hrs. Those DCs were harvested for flow cytometric analysis, 
T cell culture and animal study, or purification of the total RNA for DNA array analysis 
using the RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada); their culture 
supernatants were collected for measuring IL-6, IL-10, IL-12, IL-15, IFN-γ and TNF-α 
using ELISA kits from BD biosciences, and TGF-β using ELISA kit from R&D System 
(Minneapolis, MN). When DCs were pulsed with OVA protein, they are termed as 
CD4-8- DCOVA.  
4.2.3.5 Phenotypical characterization of stimulated CD4-8-DCs 
Purified CD4-8- DCs which were cultured as described above were analyzed by flow 
cytometry using a panel of Abs specific for MHC class II, CD40, CD54, CD80,CD86 as 
previously described (106).  
4.2.3.6 DNA array analyses of differentially stimulated CD4-8-DCs 
The DNA array analyses were conducted using commercial GEArray® S Series 
Mouse Dendritic & Antigen Presenting Cells Gene Array (Superarray Biosciences Corp., 
Frederick, MD), comprising the cDNAs of antigen presentation cells-related cytokines, 
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chemokines and their receptors, antigen uptake, antigen presentation, cell surface 
receptors,  and signal transduction genes (described within the SuperArray website, 
www.supperarray.com) double-spotted on a 3.8x4.8 cm nylon membranes. Prior to 
hybridization, the membranes were prewetted with 5ml deionized water, then 
prehybridized for 1-2 h at 60°C with hybridization solution supplemented with 100  
µg/ml heat-denatured salmon sperm DNA (SuperArray).  
To generate the membrane probes for the analyses, total RNA was isolated from the 
activated DCs using RNeasy Mini kit (Qiagen Inc. Mississauga, ON). The concentration 
and quality of the RNA was determined by spectroscopy (OD260) and denaturing agarose 
gel electrophoresis, respectively. The labeled cDNAs were generated according to the 
manufacturer's protocol (SuperArray) using AmpoLabeling-LPR Kit. Briefly, RT primer 
(1ul) were annealed to 5 µg of RNA (final volume, 10 µl) for 3 min at 70°C, and cool to 
37°C and kept for 10 min; then incubated for 25 min at 37°C after adding Buffer BN 4 µ1, 
RNase-free H2O 4 µ1, RNase Inhibitor 1 µl and Reverse Transcriptase 1 µl. RT products 
were then mixed with Mouse Dendritic & Antigen Presenting Cells Gene Array -specific 
primers 9 µl, Buffer L 18 µl, biotin-16-dUTP (Roche Diagnostics, Laval, Quebec) 2 µl 
and DNA polymerase 1 µl for Linear Polymerase Reaction(LPR) Labeling Reaction. 
After being treated at 85°C for 5 min. the LPR were done for 30 cycles using the 
following condition: 85°C, 1 min, 50°C, 1 min, 72°C, 1 min, and then 72°C for 10 min. 
The labeled cDNAs were denatured for 2 min at 94°C and quickly chilled on ice, then 
incubated with the prehybridized array membranes in roller bottles for overnight at 60°C. 
The probed arrays were washed twice in 2 x SSC/1%SDS for 1 hr at 60°C, and then in 
0.1 x SSC/0.5%SDS at 60°C for 2hr. Prepare the blocking buffer by adding 0.5 ml of 
20% SDS to 100 ml Odyssey Blocking Buffer (LI-COR, Cat #927-40000) for a final SDS 
concentration of 0.1 %, add 5 ml into the tube and gently shake at room temperature for a 
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minimum of 120 minutes. Dilute the streptavidin-IRDye™ 800CW conjugate with 
Blocking Buffer to a concentration of 1:70,000. Remove old blocking buffer and add 5 
ml of diluted streptavidin-IRDye™ 800CW solution. Incubate 10-15 minutes at room 
temperature while shaking. Wash the blot 3 times in 1X PBST (0.1 % Tween-20) with 
shaking, for 10 min each, at room temperature. Follow with a rinse in 1X PBS, with 
shaking, for 5 minutes at room temperature. Results (dot signal density) were scanned 
using Odyssey® Infrared Imaging System and analyzed with the supplied software 
according to our previous description (468). 
4.2.3.7 In vitro T cell proliferation assay   
To assess the antigen presenting function of differentially stimulated CD4-8- DCOVA, 
we performed antigen specific T cell proliferation assay. Naive OVA-specific CD4+ T 
cells from OT II mice were obtained by passage of splenocytes through nylon wool 
columns (173). The T cells were fractionated by negative selection using anti-mouse CD8 
(Ly2) paramagnetic beads (Dynal Biotech) according to the manufacturer's protocols.  
OT I CD8+ T cells were purified by adopting the same method as for OT II CD4+, but 
using Dynabeads mouse CD4 (L3T4). The irradiated (3000 rad) CD4-8- DCOVA, and their 
twofold dilutions were cultured with a constant number of naive OT II CD4+ and OT I 
CD8+ T cells (1x105 cells/well), respectively. After culturing for 3 days, thymidine 
incorporation was determined by liquid scintillation counting (173). 
4.2.3.8 Cytokine analysis of activated OT II CD4+T cells 
Naive OVA-specific CD4+ T cells (2 x 105 cells/ml) from OT II were purified as 
described above and were stimulated for 3 days with freshly purified CD4-8-  DCOVA 
from overnight culture or then further treated with the above culture conditions (1 x 105 
cells/ml) in the presence of IL-2 (10 U/ml) and then isolated from Ficoll-Paque 
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(Amersham Biosciences) density gradients (173); cell culture supernatants were 
harvested and used for IL-17 analysis. Some cell culture was added with Golgistop® (BD 
biosciences) for the last six hours, cells were then harvested for intracellular staining of 
IL-17 with FITC-anti-IL-17 and PE-anti-CD4. The in vitro activated OT II T cells were 
further stimulated with LB27 pulsed with OVA II peptide for 24 h, and all the above 
culture supernatants were harvested for assay of IL-2, IL-4, IL-l0, IL-17, IFN-γ, TNF-α 
and TGF-β using ELISA kits from BD Biosciences and eBioscience (IL-17).  
4.2.3.9 Tetramer staining assay (In vivo antigen specific CTL proliferation) 
Six days after the immunization, 50 µL blood was taken from the tail of the 
immunized mice. Those blood samples were incubated with PE-conjugated 
H-2Kb/OVA257-264 tetramer (Beckman Coulter, Mississauga, Ontario, Canada) for 30 min 
first and then with FITCconjugated anti-CD8 antibody for another 30 min at room 
temperature. The erythrocytes were then lysed using lysis/fixed buffer (Beckman Coulter) 
according to the company instruction. The cells were washed and analyzed by flow 
cytometry (469). 
4.2.3.10 In vivo cytoxicity assay  
The in vivo cytotoxicity assay was performed with modification as described by (470). 
Briefly, splenocytes were harvested from naive mouse spleens and incubated with high 
(3.0 µM, CFSEhigh) or low (0.3 µM, CFSE1ow) concentrations of CFSE to generate 
differentially labeled target cells. The CFSEhigh cells were pulsed with OVA I peptide, 
whereas the CFSElow cells were pulsed with Mut l peptide and served as internal controls. 
These peptide pulsed target cells were washed extensively to remove free peptides and 
then i.v.-coinjected at a 1: 1 ratio into the above immunized mice 7-9 days after 
immunization. Sixteen hours after the target cell delivery, the spleens of immunized mice 
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were removed, and their respective fluorescence intensity of residual CFSEhigh and 
CFSElow target cells remaining in the recipients' spleens were analyzed by flow cytometry. 
To calculate specific lysis, the following formulas were used: ratio = (percentage 
CFSElow/percentage CFSEhigh); percentage specific lysis = (1 (ratio naive/ratio immunized) 
x 100) (471). 
4.2.3.11 Animal study  
For investigation of antitumor immunity, wild type C57BL/6, CD4-/-, CD8-/-, or 
IL-15R-/- mice (n = 8/group) were vaccinated s.c. with 0.5-1 x l06 differently prepared 
and OVA pulsed CD4-8- DCs from wild type B6 or IL-6-/- mice, respectively, and then 
challenged s.c. 10 days later with l x l05 BL6-10OVA tumor cells. Tumor growth and 
mouse survival were monitored daily for 60 days after tumor cell inoculation (106); for 
humanitarian reasons, all mice with tumors that achieved a size of 1.5 cm in diameter 
were sacrificed.  
 4.2.4 RESULTS 
 
4.2.4.1 CpG, LPS and anti-CD40 Ab treatment induce CD4-8- DC maturation 
The freshly prepared CD4-8- DCs from C57BL/6 mice expressed lower level of MHC 
class II, CD40, CD54, CD80 and CD86, indicating that they are relatively immature DCs 
(106). However, after culturing with CpG, LPS, anti-CD40 Ab for 8 hours, CD4-8- DCs 
up-regulated expression of the above molecules (Fig.4.2. lA), indicating that they become 
a more matured form of DCs upon CD40 and TLR signaling. In addition, all treatments 
completely blocked DC's TGF-β secretion (Fig.4.2. 1B). CpG treatment stimulated 
CD4-8- DCs to secrete higher amount of IL-6 (380 pg/ml), IL-10 (130 pg/ml), IL-15 (280 
pg/ml) and IFN-γ (130 pg/ml) than those for the other two stimuli. However, CD40 
signaling induced the highest level of IL-12 (320 pg/ml) secretion (Fig.4.2. 1B).  
4.2.4.1 DNA microarray analyses of gene expressions identified more Th1 
polarization molecules among CpG treated CD4-8-DCOVA  
 
Total RNAs were purified from stimulated DCs with RNeasy Mini kit(Qiagen), 
GEArray® S Series Mouse Dendritic & Antigen Presenting Cells Gene Array 
(Superarray Biosciences Corp., Frederick, MD)(comprising the cDNAs of  antigen 
presentation cells-related cytokines, chemokines and their receptors; antigen uptake; 
antigen presentation; cell surface receptors and signal transduction genes) were used to 
analyze the DC-related gene expression by using streptavidin-IRDye™ 800CW conjugate 
for detecting hybridization signal with Odyssey® Infrared Imaging System and methods 
as we described before (468). 
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     Among the 151 DC related genes,  96 were expressed in LPS-stimulated CD4-8- 
DCOVA and the mRNA expression level of 25 genes were higher in LPS group.  140 
were expressed in CpG-activated DCs and the mRNA expression level of 77 genes were 
higher in CpG group.  46 genes were expressed at a similar level in both groups (Table 
4.2. 1, 4.2. 2, 4.2. 3).  mRNA expression results confirmed our DC phenotype and 
cytokine profiles analyses. Although in LPS group, those genes expressed at higher level 
could not explicitly explain why this kind of stimulated DCs induced Th1 response much 
less efficiently than CpG-treated DCs,  CpG stimulation did increase the expression of 
many of Th1/Th17 polarization molecules such IL-1, IL-6, IL-12β (IL-23β), IL-15, 
IFN-γ, CCL-19, OX40L, 4-1BBL.  IL-1 and IL23 have been reported to be involved in 
the formation and/or maintenance of Th17 (472). 4-1BB costimulatory signals 
preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of 
cytotoxic T cell responses (48). OX40 ligand (OX40L) strongly inhibited the generation 
of IL-10-producing Tr1 cells and their IL-10 production and strongly inhibited 
suppressive function of differentiated IL-10-producing Tr1 cells (473). CCL19 could 
promote IFN-γ-dependent antitumor responses in a lung cancer model (474) and as an 
adjuvant for DNA vaccination, it induced a Th1-type T-cell response and enhanced 
antitumor immunity (475).  TRANCE, which is a DC-specific survival factor (476) and 
is beneficial to the formation of CTL in vivo (477), was also only expressed significantly 
in the CpG group, which further confirmed the previous report (478). This molecule’s 
expression perfectly explained the dilemma of why the CpG stimulated group has higher 
cell survival after the same length of stimulation compared with LPS group (data not 
shown). DCIR expression was down-regulated by signals inducing DC maturation such 
as CD40 ligand, LPS, or TNF-alpha. Thus, DCIR is differentially expressed on DCs 
depending on their origin and stage of maturation/activation. DCIR represents a novel 
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surface molecule expressed by Ag presenting cells, and of potential importance in 
regulation of DC function (479). 
 
4.2.4.3 CpG-treated CD4-8- DCs induce a mixture of CD4+ Th1/Th17 cell response 
To assess the in vitro stimulatory effect, we performed T cell proliferation assays.  8 
hr CpG-treated CD4-8- DCs more efficiently stimulated CD4+ and CD8+ T cell 
proliferation than the freshly prepared CD4-8- DCs (p<0.05), whereas the other two 
stimuli-treated ones had a similar stimulatory effect as the freshly prepared CD4-8- DCs 
(Fig.4.2. 2A).  In contrast to the freshly prepared CD4-8- DCs capable of stimulating 
IL-10/IFN-γ-expressing CD4+ Trl cell responses (106), CD4+ T cells stimulated by all 
three stimuli maintained its IFN-γ secretion, but significantly down-regulated IL-10 
expression (p<0.05) (Fig.4.2. 2B). Anti-CD40 Ab-treated DCs secreted TNF-α (500 
pg/ml), whereas CpG-treated DCs induced CD4+ T cells to secrete IL-17 (330 pg/ml) 
(Fig. 4.2. 2B). By analyzing the intracellular cytokine of CD4+ T cells, we found that 
there were three distinct CD4+ T cell populations that secreted IFN-γ only, IL-17 only, 
and both IL-17 and IFN-γ, respectively, indicating that CpG-treated DCs induced a 
mixture of CD4+ Th1 and Th17 cell responses.  
4.2.4.4 CpG-treated CD4-8- DCs induce the most efficient CD8+ CTL responses and 
antitumor immunity  
We previously demonstrated that the freshly prepared tolerogenic CD4-8- DCOVA 
suppressed OVA-specific CD8+ CTL responses and antitumor immunity (106). To assess 
the in vivo stimulatory effect, we performed tetramer staining assays using blood samples 
of mice immunized with the above treated DCOVA. As shown in Fig.4.2. 3A, vaccination 
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of mice with the original CD4-8- DCOVA did not induce any OVA-specific CD8+ CTL 
responses, whereas three stimuli-treated CD4-8- DCOVA all induced in vivo OVA-specific 
CD8+ CTL proliferation, accounting for 1.50% , 0.66%, 0.42% of the total CD8+ T cell 
population, respectively. Among them, CpG-treated CD4-8- DCOVA induced the highest 
CD8+ CTL responses (p<0.05). To assess the effector function of CD8+ T cells activated 
by these three stimuli-treated CD4-8- DCOVA, we performed in vivo cytotoxicity assays. 
As shown in Fig.4.2. 3B, vaccination of mice with the original CD4-8- DCOVA did not 
induce any OVA-specific CD8+ CTL responses against OVA I-pulsed target cells, 
whereas CpG-, LPS- and anti-CD40 Ab-treated CD4-8- DCOVA all stimulated 
OVA-specific CD8+ CTL responses leading to loss of OVA-specific target cells by 84% 
(CpG), 45% (LPS) and 37% (anti-CD40 Ab), respectively.  This confirmed that CpG- 
treated CD4-8- DCOVA induce the strongest CTL effector function (p<0.05). In addition, 
our animal studies further confirmed the results derived from the above in vivo CTL 
proliferation and cytotoxicity assays. As shown in Fig. 4.2. 3C, mice with inoculation of 
BL6-10OVA tumor cells in PBS-treated or freshly prepared tolerogenic CD4-8- DCOVA 
died within 25 days after tumor cell inoculation, similar to what we previously reported 
(106). However, the groups of mice immunized with three stimuli-treated OVA-pulsed 
CD4-8- DCOVA were all protected against OVA-expressing BL6-10OVA tumor cell 
challenge to various extents. Among them, vaccination of mice with CpG-treated CD4-8- 
DCOVA provided the strongest protection with 10 out of 10 (100%) mice surviving 
(p<0.05), while LPS and anti-CD40 groups only provided around 50% and 45% 
protection, respectively. To study the immune mechanism in the antitumor immunity, we 
immunized CD8-/- and CD4-/- mice lacking of CD8+ and CD4+ T cells with CpG-treated 
CD4-8- DCOVA and then challenged the mice with tumor cell inoculation.  As shown in 
Fig.4.2. 3D, we found that 100% and 75% of mice immunized the CpG-treated DCOVA 
lost immune protection against tumor challenge, respectively (p<0.05); indicating that 
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both CD8+ and CD4+ T cells are involved in CpG-treated DCOVA induced T cell 
responses. Taken together, our data indicate that CpG treatment completely converts the 
tolerogenic DCs into immunogenic ones capable of efficiently stimulating CD4+ T 
cell-dependent OVA-specific CD8+ CTL responses and antitumor immunity.  
4.2.4.5 IL-6 and IL-15 play an important role in CpG-treated CD4-8- 
DCOVA-induced Th1/Th17 responses  
It has been demonstrated that various cytokines including TGF-β, IL-6, IL-21 and 
IL-23 play a key role in inducing CD4+ Thl/Th17 cell responses (480). To assess the 
potential effect of IL-6 and IL-15 in CpG-treated CD4-8- DC-induced Thl/Th17 cell 
responses, we added anti-IL-6 and anti-IL-15 Abs to CpG-treated CD4-8- DCOVA culture, 
As shown in Fig. 4.2. 4A, interestingly, both IL-17 and IFN-γ secretion were decreased 
by around 50% for anti-IL-6 Ab group and 45% for anti-IL-15 Ab group (p<0.05), 
indicating that IL-6 and IL-15 secretion are involved in CpG-treated DC induced 
Thl/Thl7 immune responses. To assess whether Thl/Thl7 cells are involved in 
CpG-treated DC-induced antitumor immunity, as shown in Fig.4.2.4B, we used 
CpG-treated CD4-8- DCOVA derived from IL6-/- mice for immunization of wild-type 
C57BL/6 mice or used CpG-treated CD4-8- DCOVA derived from wild-type C57BL/6 
mice for immunization of IL-15R-/- mice as recipient mice. We found that 2/3 mice 
immunized with IL-6-/- mice-derived DCOVA lost animal protection compared with wild 
type DC, wild type mice derived DCOVA immunized IL-15R-/- mice could only protect 
mice from tumor challenge up to 50% (p<0.05), indicating that IL-6 and IL-15 secretion 
is critical to CpG-treated DCOVA-induced antitumor immunity.  
 4.2.5 DISCUSSION 
DCs are professional APCs that play a crucial role as initiators or modulators of 
adoptive immune responses. Although DC-based vaccines have been used successfully to 
generate CTL activity against tumor Ags, evidence has accumulated that DCs have also a 
potent ability to tolerize T cells in an Ag-specific manner (459). Immature DCs can 
mediate immune tolerance, presumably by induction of regulatory T cells (341, 342). 
They can stimulate CD4+ and CD8+ Tr cells and suppress autoimmune diseases (340, 481, 
482). Sometimes, mature DCs pulsed with specific antigen could expand the CD4+ T cells 
in vitro to suppress the development of autoimmune diabetes and restore normoglycemia 
in diabetic NOD mice when the latter were administrated in vivo (343, 344).  
Toll-like receptor (TLR) ligands have been widely reported to promote the maturation 
of DCs and induce Th1-polarized immune response which would benefit cancer 
immunotherapy (457). Synthetic oligodeoxynuc1eotides (ODNs) that contain 
immunostimulatory CpG motifs bind to TLR 9 on DC and trigger an immunomodulatory 
cascade that skews the host's immune milieu in favor of Th1 responses (483-485). Vicari 
et al firstly demonstrated the successful reversal of intratumoral tolerogenic DC paralysis 
by CpG ODNs and anti-IL 10 receptor antibody (Ab) (233). However, single use of either 
CpG or anti-IlL-l0R Ab was inactive. Recently, Guiducci et al confirmed their results 
with the treatment of CpG ODNs and anti-IL-10R Ab in another animal model (232). 
They demonstrated that treatment of CpG ODNs and anti-IL-10R Ab can convert 
tumor-infiltrating tolerogenic type 2 macrophages (M2) secreting immunosuppressive 
IL-10, TGF-β and prostaglandin E2 (PGE2) to immunogenic type 1 macrophages (M1) 
secreting inducible nitric oxide synthase, IL-12 and TNF-α, and thus eradicate established 
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tumors. When CpG or plus anti-IL-10 were injected inside the tumor, the tumor 
infiltrated immature DC could become matured and induced the regression of established 
tumor.  If the tumor cells were transfected with CCL20 (MIP-3α) or CCL 16, 
chemokines for immature DC, the antitumor immunity were even stronger than just those 
treatments alone (231, 232). Murine renal cell carcinoma (RENCA)-pulsed 
CpG-ODN-treated DCs were able not only to significantly reduce tumor growth but also 
to prevent tumor implantation in 60% of mice (230). Poly(I:C)- and CpGs- treated DCs, 
which secrete very high level of IL-12, loaded with B16 melanoma cells and injected into 
tumor-bearing mice induce Th1-skewed tumor-specific CD4+ T cells and a significant 
reduction in tumor growth (133). Among the spleen DCs, our specific DC CD4-8- DCs 
express TLRs from TLR1 to TLR 9, but CD4-8+ DCs and CD4+8- DCs don't have TLR7 
and TLR3, respectively (226).  This means that almost every kind of TLR ligands could 
be used to trigger and induce the maturation of CD4-8- DCs. 
   CD40, the receptor for CD40L (CD154), is expressed on APCs such as B cells, 
macrophages, and DCs with its expression increasing with maturation. CD40L is a 
member of the TNF family and is expressed primarily on activated Th cells. CD40 and 
CD40L interaction induces the maturation and activation of DCs and help TLR ligands to 
stimulate DCs to secrete cytokines such as IL-12, which is essential for the development 
of the Th1 response (217, 218). Agonistic anti-CD40 Ab can function as CD40L and 
modulate DC to drive naive CD8+ T cells, while ligation of CD40 on DC restores CTL 
activity in CD4+ depleted mice. In addition, mice treated with anti-CD40L Ab had 
impaired induction of Ag-specific CTLs. These data indicate that CD40-CD40L 
interactions play a key role in modulating APC function so that these cells can prime 
CD8+ T cells in vivo (219). CD40 ligand and TNF-α combination could antagonize the 
inhibitory effects of interleukin l0 on T cell stimulatory capacity of DCs (234).  
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 The cooperation of TLR ligands and CD40L or anti-CD40 in induction of DCs to 
secrete IL-12 is very important in generating CTL from naive polyclonal CD8+ T cells in 
vitro (219). CpG and PPD need the help of CD40L to stimulate the spleen DC mixture, 
CD4-8- DCs and CD4-8+  DCs, but not CD4+8- DCs to secrete IL-12. Peptide antigen 
could also enhance the IL-12 induction capacity of PPD (226). LPS could not efficiently 
stimulate bone marrow or monocyte-derived DCs to secrete IL-12 without the help of 
CD40L or T cell help (217, 436). Various TLR ligands combination such as R848+LPS, 
R848+poly (I:C), LPS+CpG, and LPS+ poly(I:C), which react with TLRs on the cell 
surface and inside cellular compartments at the same time but separately, have been 
reported to stimulate higher level of IL-12 secretion than single ligands and reach the 
similar level of IL-12 induced by TLR ligands +IFN-γ (144, 237, 486). DCs activated 
simultaneously through TLR-7 (and TLR 2/6,3,4, 7, 9 to some extent) and anti-CD40 
displayed 10-fold increases in their ability to stimulate CD8+ T cell responses over DCs 
activated through each individual receptor alone (53, 238). Synergistic activation of 
macrophages via CD40 and TLR9 also results in T cell independent antitumor effects 
(239). Simultaneous activation of TLR-3 and TLR-9 induced synergistic levels of nitric 
oxide, IL-12, TNF-α, and IL-6 production (240).  
 CD4-8- DCs has been reported to be tolerogenic DCs and induce Trl response to 
inhibit CD8+ CTL response, while the other two subsets CD4-8+ DC  and CD4+8- DC are 
immunogenic and stimulate strong antitumor response (106).   In this study, for the first 
time, we demonstrated that CpG, LPS and anti-CD40 Ab can all convert tolerogenic 
CD4-8- DC subset secreting immunosuppressive TGF-β into immunogenic ones secreting 
IL-12.  The Th1 cell response is favored when pulsed with low concentration of OVA 
(0.1 mg/ml) compared with the freshly isolated CD4-8- DCs. However, if the protection 
efficiency against tumor challenge among those groups were carefully analyze in detail, 
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we found that the IL-12 secretion level is not always proportional to the antitumor 
immunity; anti-CD40 group DCs boast highest level of IL-12, however, they only 
provided around 50% protection, while the CpG group DCs produce only 1/3 of IL-12 
compared with the above group but provided 100% protection (please refer to Fig.4.2. 
3C). Antigen presentation assay and in vivo CTL formation and cytotoxicity detection all 
indicated that CpG-treated CD4-8- DCs is the strongest Thl inducer among those three 
group stimuli (see Fig.4.2. 3, A and B).  
 IL-6 has been found to inhibit the function of regulatory T cells (150, 151); IL-6, 
IL-15, IL-21 and IL-23 are among those key cytokines involved in the development and 
maintenance of a new T cell subset, Th17 (115, 152, 480, 487). Th17 has been confirmed 
to be the major player in autoimmunity and anti-bacterial infection instead of Th1 (153), 
however, other reports found that Th17 still needs to synergize with Th1 to induce EAE 
(488) and Th1 and Th17 T cells are independently capable of inducing disease in two 
established models of autoimmunity(489, 490); Th17, which secrete IL-21 (155), has 
been indirectly linked to antitumor immunity, which indicate that Th1 and Th17 might 
cooperate in antitumor immunity. Hsp70-mediated induction of Th17 autoimmunity had 
been exploited to reject established prostate tumors (157). Very recently, tumor-specific 
Th17-polarized cells have been reported to eradicate large established melanomas (158). 
Although IL-12 is considered to a classic type I cytokine, dendritic cells-derived IL-12 
might not be critical for generation of CTLs in vivo under certain conditions whereas 
other cytokine(s) such as IL-15, IL-18 and IL-23, etc might be involved (145).  LPS has 
been described to induce the CD8- DC to activate MyD88 dependent Delta 4 Notch-like 
ligand expression and promote Th1 response independent of IL-12 (147). 
 We checked IL-6 and IL-15 secretion among those DCs and only the CpG group 
secretes these two cytokines. IL-6 has been reported to inhibit the development of 
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regulatory T cells and promote the formation of Th17 T cells (480). Our neutralization 
study found that IL-6 and IL-15 were necessary for the formation of Th17 T cells, 
because IL-17 secretion from those CpG-stimulated DC activated OT II CD4+ T cells 
were decreased more than 30-50% when either of the neutralization antibody were added 
to the coculture of dendritic and T cells.  IFN-γ secretion was also reduced, indicating 
that both cytokines were also involved in the Thl induction. In vivo IL-6 blockade has 
also been reported to inhibit the induction of myelin antigen-specific Th17 cells and Thl 
cells in experimental autoimmune encephalomyelitis (491). Then we used IL-6-/-and 
IL-15R-/- mice to carry out animal studies.  Compared with the wild type mice, in the 
absence of IL-6 secretion from DCs or impaired reaction to the DC derived IL-15, 
vaccinated mice lost 75% and 50% protection, respectively. When CD4 KO mice were 
used for animal study, 75% of those immunized mice lost their tumor growth inhibition 
capacity, which indicated that Th response is a major part of DC induced antitumor 
immunity. Our results provide the first direct evidence that Th17 cooperate with Thl to 
induce antitumor immunity and CpG is the best candidate for converting the tolerogenic 
CD4-8- DC into immunogenic ones stimulating Thl and Th17 mixed antitumor immune 
response.  
 
This manuscript will be submitted to the Journal of Immunology. 
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4.2.6 Figure legends for Manuscript 4.2 
 
Figure 4.2.1: Phenotype and cytokine analyses of differentially stimulated and fresh 
CD4-8-DCs. 
A, CD4-8-DCs were isolated as described in Material and Methods and cultured in 
AIM-V containing 10 ng/ml rmGM-CSF and 0.1 mg/ml with CpG (5 ug/ml), LPS (2 
ug/ml) or anti-CD40 (10 ug/ml) alone. After 8 hrs, cells were harvested and stained with 
FITC labeled anti-CD40, CD54, CD80, CD86, and I-Ab,  and analyzed by flow 
cytometry,  FITC labeled isotype IgGs (dotted line) were used as control. A 
representative example of three independent experiments is shown.  B, CD4-8-DCs were 
cultured as above, The supernatants were harvested after their culture. IL-6, IL-10, IL-12, 
IL-15, IFN-γ,TNF-α and TGF-β were measured using related ELISA kits from BD 
Biosciences, eBiosciences and R & D Systems. One of three similar experiments is 
shown. 
 
 
Figure 4.2.2: In vitro autologous T cell proliferation assays and activated CD4+ T 
cell cytokine secretion.  
A, Irradiated (4000 rad)  differentially treated CD4-8- DCOVA (0.1 x 106 cells/well) and 
their 2-fold dilutions were cultured with a constant number (0.1 x 106 cells/well) of 
autologous OT II CD4+ and OT I CD8+ T cells, respectively. After 72 h, thymidine 
incorporation was determined by liquid scintillation counting. *, p < 0.05 vs cohorts of 
LPS- and anti-CD40 Ab- treated CD4–8– DCs (Student’s t test). One representative 
experiment of three is depicted.  B,  OT II  CD4+ T cells were cultured in vitro for 3 
days with CD4-8- DCOVA treated by CpG, LPS or anti-CD40 antibody for 8hrs, 
respectively; then activated T cells were re-stimulated with LB27-OVAII for 48 hrs. All 
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the above culture supernatants were measured for IL-2, IL-4, IL-10, IL-17, IFN-γ, 
TNF-α, and TGF-β secretion by ELISA. *, p<0.5 vs cohorts of LPS-, anti-CD40 
Ab-treated and fresh CD4-8-DCs activated T cells.  One representative experiment of 
three is shown.  
 
 
Figure 4.2.3: In vivo CTL proliferation and cytotoxicity assay, and animal study. 
A, After vaccination s.c. with differentially treated CD4-8- DCOVA, collect 50 ul of mouse 
tail vein blood into 1.5 ml eppendorf tubes containing 50 ul 2 x heparin and gently mix 
well. Add 1.5 ul H2-Kb OVA I tetramer-PE reagents each sample and incubate at room 
temperature for 30 min in the dark place, and then add 1.5 ul anti-CD8-FITC for another 
30 min, add 500 ul lysis buffer and 12.5 ul fixative and lyse RBC for 30-60 min. Wash 
the cells with PBS for two times and suspend the cells in 500 ul PBS and run flow to 
detect the CD8 and tetramer double positive cells. The experiment shown is 
representative of two additional experiments.  B,  Differentially labeled CFSEhigh and 
CFSElow naïve C57B/L splenocytes were pulsed with OVAI peptide and DMEM only, 
respectively, then injected by tail vein into the PBS(○) and stimulated DC immunized 
mice 6-7 days before. 18-20 hrs later, the splenocytes of mice were collected to analyze 
the specific lysis of OVA I labeled CFSEhigh cells, as determined by live cells gated flow 
cytometry.  C, Mice were vaccinated with freshly  isolated CD4-8- DCs or cultured in 
media containing 15 ng/ml rmGM-CSF and 0.1 mg/ml OVA with CpG (5 ug/ml) (■) , 
LPS (2 ug/ml) (▲), or anti-CD40 antibody (10 ug/ml) (♦) for 8 hours, respectively; and 
ten days later were challenged s.c. with 1x105 BL6-10OVA tumor cells. Animal mortality 
was monitored daily up to 8 weeks. D, CpG-treated CD4-8- DCOVA   were used to 
immunize the CD4 (▼) and CD8 (▲) knock out mice as above, normal B6 mice (■) 
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were used as positive control. Then the animals were challenged and observed as above. 
The data are representative of three experiments with similar results for b and c. 
 
 
Figure 4.2.4: IL-6 and IL-15 were the crucial cytokine for inducing Th1/Th17 
antitumor immunity.  
 
A, OT II  CD4+ T cells were cultured in vitro for 3 days with CpG-treated CD4-8- 
DCOVA only, or with 10 ug/ml anti-IL-6, or anti-IL-15 neutralization Ab, respectively; All 
the above culture supernatants were measured for IL-2, IL-4, IL-10, IL-17, IFN-γ, 
TNF-α, and TGF-β secretion by ELISA. One representative experiment of three is 
shown. B, CpG-treated CD4-8- DCOVA  isolated from IL-6-/- mice (□) were used to 
vaccinate normal B6  mice  and wild type B6 derived CpG-treated CD4-8- DCOVA   
were  used to immunize IL-15Rα-/- mice(∆) and normal B6 mice(■) , respectively.  Ten 
days later were challenged s.c. with 1x105 BL6-10OVA tumor cells. Animal mortality was 
monitored daily up to 8 weeks. The data are representative of three experiments with 
similar results. 
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Figure 4.2. 1: Phenotype and cytokine analyses of differentially stimulated and 
fresh CD4-8- DCs. 
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Figure 4.2. 2: In vitro autologous T cell proliferation assays and activated CD4+ T cell 
cytokine secretion.  
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        Figure 4.2. 3: In vivo CTL proliferation and cytotoxicity assay, and animal study. 
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Figure 4.2. 4: IL-6 and IL-15 were the crucial cytokines for inducing Th1/Th17 
antitumor immunity.  
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4.2.7 Tables for Manuscript 4.2 
            Table 4.2. 1: List of genes that were expressed at similar levels in CpG- and LPS-treated CD4-8- DCs 
Gene GeneBank Acession No. CpG 
Group 
(EL) 
LPS 
group(EL) 
DE
Cytokines, Chemokines and Their Receptors     
CCL3 NM_011337  5.89  4.83 <2 
CCL5 NM_013653 11.27 10.73 <2 
CCR2 NM_009915  1.07  1.37 <2 
CCR7 NM_007719  3.39  5.43 <2 
IFN-α1 NM_010502  6.46  3.68 <2 
IFN-γR NM_010511  0.87  1.27 <2 
IL-18 NM_008360  0.93  0.88 <2 
TNF-α NM_013693  1.26  1.72 <2 
Antigen Uptake     
CDC42 NM_009861  3.06  5.55 <2 
DCP1B XM_284227  1.39  1.77 <2 
Icosl NM_015790  1.37  2.38 <2 
Igsf6 NM_030691  1.54  2.61 <2 
Marcks NM_008538  2.49  1.83 <2 
Pfn1 NM_011072  3.36  5.86 <2 
Prg NM_011157  4.95  7.51 <2 
Tral NM_011631  5.32  3.03 <2 
Antigen Presentation     
CD52 NM_013706  7.82  7.63 <2 
CD80 NM_009855  1.63  0.86 <2 
Clecsf8 NM_010819  1.29  1.99 <2 
DC-LAMP NM_177356  1.55  1.52 <2 
H-2DMa NM_010386  0.79  1.19 <2 
H-2DMb2 NM_010388  7.91  4.53 <2 
Cell Surface Receptors     
CD47 NM_010581  1.45  1.33 <2 
DEC205 NM_013825  1.70  1.23 <2 
FcεR1A NM_010814  2.99  3.54 <2 
Fcγr2b NM_010187  1.17  0.81 <2 
FcγR3(CD16) NM_010188  2.63  1.69 <2 
Lrp1 NM_008512  1.91  1.97 <2 
TLR1 NM_030682  2.58  1.90 <2 
TLR2 NM_011905  1.17  1.38 <2 
Signal Transduction     
CD11b NM_008401  1.48  2.41 <2 
CREB-2 NM_009716  1.57  2.57 <2 
EBi3 NM_015766  1.85  2.03 <2 
Ifi30 NM_023065  4.02  3.58 <2 
IFI44 NM_133871  2.75  3.26 <2 
Ifit1 NM_008331  2.25  2.59 <2 
Ifit3 NM_010501  2.67  2.12 <2 
Isg15 NM_015783  2.43  1.97 <2 
M-CSFR NM_007779 15.23 19.85 <2 
Mst1 NM_021420  1.68  2.34 <2 
NF-κB1 NM_008689  4.84  3.30 <2 
RELA NM_009045  5.23  3.03 <2 
S100a4 NM_011311  4.39  4.52 <2 
S100b NM_009115  3.89  2.88 <2 
Vcl NM_009502  1.30  1.43 <2 
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The expression level (EL) value represents the normalized signal to background 
(S/B) ratio of each DNA array signal. The differential expression (DE) value 
represents the fold change of gene between CpG- and LPS- activated DCs. 
CpG/LPS- activated CD4-8- DCOVA value of <2 are considered to be similar 
expression in the two groups of T cells. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. 2: List of genes that were expressed at higher levels in LPS- than CpG-treated CD4-8- DCs 
Gene   GenBank Acession No.   LPS group 
(EL)      
CpG group 
(EL)       
DE 
Cytokines, Chemokines and Their 
Receptors 
    
IL-12a   NM_008351            3.70          0.49           7.61 
CXCR4  NM_009911            6.38          2.09           3.04 
CCR3  NM_009914            1.25          -  
CCR5  NM_009917            2.33          -  
CCR6 NM_009835            2.96          -  
Antigen Uptake     
ICAM-2  NM_010494            1.43          0.09           14.66 
Abcb3(Tap2)  NM_011530            3.35          0.24           13.86
Pim2   NM_145737            4.27          0.51            8.33
Lip1  NM_021460            5.39          1.38            3.91
DCTN2  NM_027151            3.68          1.24            2.98
ICAM-1  NM_010493            2.83          1.25            2.27
Pnrc1  XM_131355            2.71          1.25            2.17
Abcb2(Tap1) NM_013683            2.39          1.11            2.15
ICOS  NM_017480            3.37          -  
CD68  NM_009853            0.75          -  
Antigen Presentation     
CD86   NM_019388            6.02          2.14            2.81
Cell Surface Receptors     
Plaur   NM_011113            2.24          -  
Signal Transduction     
Isg20 NM_020583            1.69          0.56            3.03
F13a  NM_028784            4.69          1.60            2.93
CDKI(p21) NM_007669            4.03          1.72            2.34
Btg1  NM_007569            6.79          2.98            2.28
Casper(Flip)  NM_009805            5.19          2.33            2.23
CD18        NM_008404            4.69          2.20            2.13
Up-regulated gene expression was based on that the DE value for the LPS-activated 
DCs relative to the CpG-activated DCs was ≥2, or that the LPS-activated DCs 
expressed the designated gene, while the CpG-activated DCs did not (indicated as “-”, 
below the detection limits for EL). A total of 25 genes are up-regulated in the LPS- 
activated DCs, but those with EL values of less than 0.70 are not listed in the above 
table 
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Table 4.2. 3: List of genes that were expressed at higher levels in CpG- than LPS-treated CD4-8- DCs   
Gene   GenBank Acession 
No.      
CpG group 
(EL)       
LPS group 
(EL)      
DE 
Cytokines, Chemokines and Their Receptors     
CCL19 NM_011888         2.18          0.07           31.18
IL-1β NM_008361 1.35          0.09           14.75
CX3CL1 NM_009142         1.57          0.12           13.67
IFN-β  NM_010510         1.46          0.23            6.29
IL-6    NM_031168          2.87          0.61            4.67
IL-16 NM_008360         2.48          0.54            4.56
IL-1α  NM_010554         2.72          0.62            4.39
CCL22 NM_009137         1.05          0.24            4.28
L-17            NM_010552         0.96          0.25            3.86
IL-10  NM_010548         3.09          0.91            3.40
CXCL16  NM_023158         5.11          1.98            2.58
IL-12β NM_008352         2.59          -  
OX40L NM_009452         2.22          -             
IL-2 NM_008366         1.89          -  
HVEM-1         NM_019418         1.63          -  
IFN-γ   NM_008337         1.56          -  
IL-15 NM_008357         1.32          -    
TRANCE(TNFSF11) NM_011613         1.25          -       
IL-4  NM_021283          1.09         -  
4-1BBL  NM_009404          1.07         -       
CCL17            NM_011332         0.76          -  
Antigen Uptake     
Rac1             XM_132485         3.74          0.25           14.96
Pscdbp   NM_139200         3.97          0.83            4.74
NADPH P450   NM_008898         1.73          0.84            2.06
CD44   XM_130536         3.75          -             
Nr3c2    XM_356093         2.53          -      
Mx1    NM_010846         2.52          -      
Mlp  NM_010807 2.05          -    
Rnase6    XM_127690         1.82          -             
MIF   NM_010798        1.79          -      
B3Bwg0562e NM_177664         1.57          -  
Prkra    NM_011871         1.47          -             
Map4k3  XM_128800         1.34          -  
SOD2             NM_013671         1.17          -  
Mx2  NM_013606         1.02          -    
Mtrf1    NM_145960         0.80          -             
Antigen Presentation     
CD1d1    NM_007639          2.13          0.84            2.53
CD83 NM_009856         15.38          7.16            2.15
CD-207  NM_144943         1.17          0.58            2.00
Dectin  NM_ 020008        4.89          -      
DCIR             NM_011999         1.60          -  
CD2  NM_013486         0.86          -  
CD-209a           NM_133238         0.79          -        
Cell Surface Receptors     
CD40  NM_011611 2.27          0.19           11.69
CD36  NM_007643         1.64          0.65            2.52
TLR9  NM_031178         2.18          -      
TLR5 NM_016928         1.77          -             
TLR4    NM_021297         1.55          -             
TLR3   NM_126166         1.46          -             
Fcrl3   NM_144599         1.34          -  
FcεR2A(CD23)     NM_013517         1.27          -  
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FcεR1γ  NM_010185         1.09          -  
FcγR1  NM_010186         1.07          -  
Signal Transduction     
Gbp2  NM_010260         2.78          0.02         174.55
IFP35  NM_027320         1.68          0.07           24.48
Cystatin C NM_009976         2.20          0.19           11.07
Zfp398    NM_173034         1.94          0.29            6.71
Arhgdib NM_007486         10.05          2.65            3.79
Gbp3  NM_018734         1.49          0.59            2.51
NF-κB2 NM_019408         4.18          2.01            2.08
AIM2-est   XM_357160         6.13          -  
Cct6a    NM_009838         3.82          -        
CHD4   NM_145979          2.46         -  
Ifi204  NM_015766         1.97          -      
Fscn3   NM_019569         1.90          -  
Fragilis            NM_025378         1.32          -  
Acpp  NM_019807         1.17          -  
Ifit2    NM_008332         1.11          -      
C1qrf  NM_011795         1.01          -  
Adar              NM_019655         0.73          -  
Up-regulated gene expression was based on that the DE value for the CpG-activated 
DCs relative to the LPS-activated DCs was ≥2, or that the CpG-activated DCs 
expressed the designated gene, while the LPS-activated DCs did not (indicated as “-”, 
below the detection limits for EL). A total of 77 genes are up-regulated in the 
CpG-activated DCs, but those with EL values of less than 0.70 are not listed in the 
above table. 
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Our first two manuscripts indicated that DCs are not functionally homogeneous and 
contain different subsets and induce antitumor immunity or immunotolerance. Our results also 
demonstrated that one way of provoking immunotolerance is through formation of regulatory 
T cells (Tr).  However, the mechanism for Tr antigen specificity acquisition is still 
controversial. Some reports indicated that Tr might get the antigen specificity during their 
development. Other results have shown that Tr antigen specificity is induced in vitro or during 
the immune response in vivo. Our lab recently found that CD4+ and CD8+ can acquire pMHC 
I (OVA I peptide and MHC I) complex to become antigen specific APC. We are interested in 
whether pMHCI could confer the antigen specificity to Tr. During our study, CD8+CD25+ Tr 
were found to be easily expanded in vitro and rarely studied, thus this type of Tr was used as a 
model cell in our project.  
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4.3.1 ABSTRACT 
   Natural nonspecific CD8+CD25+ regulatory T (Tr) cells play important roles in 
maintenance of self-tolerance and control of autoimmunity. We previously demonstrated 
that the nonspecific CD4+ T cells can acquire antigen-specific DC-released exosomes 
(EXO) and these CD4+ T cells with acquired exosomal pMHC I can stimulate 
antigen-specific CD8+ CTL responses. To assess whether the nonspecific CD8+CD25+ Tr 
cells can acquire antigen-specificity via acquired exosomal pMHC I, we purified 
CD8+CD25+ Tr cells from wild-type C57BL/6 mice and OVA-pulsed DCOVA-released 
EXOOVA expressing pMHC I complexes. We demonstrated that the nonspecific 
CD8+CD25+ Tr cells expressing Foxp3, CTLA-4, GITR, FasL and granzyme B inhibited 
in vitro T cell proliferation and in vivo OVA-specific CD4+ T cell-dependent and 
independent CD8+ CTL responses and antitumor immunity. CD8+CD25+  Tr cells’ 
suppressive effect is possibly mediated by its inhibition of DC maturation, 
down-regulation of secretion of Thl polarization cytokines by DCs and its induction of T 
cell anergy via cell-to-cell contact. The nonspecific CD8+CD25+ Tr cells acquired antigen 
specificity by uptake of DCOVA-released EXOOVA expressing pMHC I and enhanced its 
effect on inhibition of OVA-specific CD8+ T cell responses and antitumor immunity by 
10- folds. The principles elucidated in this study may have significant implications not 
only in antitumor immunity, but also in other sectors of immunology (e.g, autoimmunity 
and transplantation).  
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 4.3.2 INTRODUCTION 
   Natural self-antigen (Ag)-reactive CD4+CD25+ and CD8+CD25+ regulatory T (Tr) 
cells expressing forkhead box P3 (Foxp3) (380, 412, 421, 424) play important roles in 
maintenance of self-tolerance and control of autoimmunity (492). They develop in the 
thymus and then enter peripheral tissues, where they suppress the activation of 
self-reactive T effector cells in a non-antigen-specific manner (493, 494). The 
mechanisms by which CD4+CD25+ Tr cells exert their suppressive effect have been 
extensively reported. It has been shown that CD4+CD25+ Tr cells’ suppressive effect is 
dependent upon the production of suppressive cytokines such as interleukin-10 (IL-10) 
and transformation growth factor-beta (TGF-β) (495-500).  However, in contrast to 
these findings, most reports indicated that CD4+CD25+ Tr cells exerted their immune 
suppression via cell-to-cell contact fashion, in which the Tr cell-surface cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4) was involved (501-503).  In comparison, 
the mechanisms responsible for CD8+CD25+ Tr cells’ inhibition of the immune responses 
are less well studied (504).  
   DCs process exogenous antigens (Ags) in endosomal compartments such as 
multivesicular endosomes (345) which can fuse with plasma membrane, thereby 
releasing Ag presenting vesicles called "exosomes" (EXO) (346, 347). Exosomes (EXO) 
are 50-90 nm diameter vesicles containing Ag presenting (MHC class I, class II, CD1, 
hsp70-90), tetraspan (CD9, CD63, CD81), adhesion (CDllb, CD54) and co stimulatory 
(CD80 and CD86) molecules (348, 349), i.e. the necessary machinery required for 
generating potent immune responses. Kennedy et al previously demonstrated that CD4+ T 
cells can acquire antigen presenting cell (APC) membrane molecules in vivo, and induce 
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memory cytotoxic T lymphocyte (CTL) responses (433).  We have recently 
demonstrated that CD4+ T cells derived from (ovalbumin) OVA-specific T cell receptor 
(TCR) transgenic OT II mice uptook DCOVA released EXOOVA via MHC/TCR and 
CD54/LFA-1 interactions, and these CD4+ T cells with acquired exosomal pMHC I and 
co stimulatory molecules stimulated central memory CD8+ CTL responses (469, 477).  
Interestingly, the stimulatory effect of CD4+ T cells was found to be specifically targeted 
to CD8+ T cells in vivo via acquired exosomal pMHC I complexes. However, whether the 
non-specific CD8+CD25+ regulatory T cells can also get Ag specificity via uptake of 
Ag-specific DC released EXO remains illusive.  
   In this study, we investigated the suppressive effect of CD8+CD25+ Tr cells and its 
molecular immune mechanisms responsible for its suppressive effect in a 
well-established OVA-specific animal model. We first purified CD8+CD25+ Tr cells from 
wild-type C57BL/6 mice. We then investigated its suppressive effect on in vitro T cell 
proliferation and DC maturation and in vivo OVA-specific CD8+ T cell responses and 
antitumor immunity. In addition, we also investigated whether the non-specific 
CD8+CD25+ Tr cells can get their OVA Ag specificity via uptake of OVA-specific 
DCOVA-released EXOOVA leading to enhancement of its inhibition in OVA-specific CD8+ 
CTL responses and antitumor immunity.  
 
4.3.3 MATERIALS AND METHODS 
 
4.3.3.1 Reagents, cell lines and animals  
   Ovalbumin (OVA) was obtained from Sigma (St. Louis, MO). OVA I (SIINFEKL) 
and OVA II (lSQAVHAAHAEINEAGR), which are OVA peptides specific for H-2Kb 
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and I-Ab, respectively (440, 505). Mutl (FEQNTAQP) peptide is specific for H-2Kb of an 
irrelevant 3LL lung carcinoma (506).  All peptides were synthesized by Multiple 
Peptide Systems (San Diego, CA). Biotin-labeled, PE or FITC-Iabeled antibodies (Abs) 
specific for H-2Kb (AF6-88.5), lab (AF6-120.1), CD4 (GK1.5), CD8 (53-6.7), CDllc 
(HL3), CD25 (7D4), CD28 (37.51), CD30 (mCD30.1), CD40 (3/23), CD54 (3E2), 
CD62L (MEL-14), CD69 (I:I1.2F3), CD80 (16-10Al), FasL (CDI78, MFL3), GITR 
(DTA-1), CTLA-4 (9H10), perforin (δG9),  and Va2V~5+ TCR (MR9-4) as well as 
FITC-conjugated streptavidin were all obtained from BD Biosciences(Mississauga, ON, 
Canada).Biotin-labeled antibodies for TLR-4 (UT41), FITC-anti-mouse FR4 (Folate 
receptor, 12A5), PE–anti-CD73 (TY/11.8) and mouse regulatory T cells staining kit 
(88-8815) were purchased from eBiosciences (Cornerstone Court West, San Diego, CA). 
PE anti-granzyme B (GBll) was bought from AbD Serotec (Raleigh, NC).  Rat 
anti-TGF-β McAb was purified from culture supernatant of related hybridoma in our lab. 
PE anti-mouse TRAIL (CD253) (N2B2) was bought from Cedarlane Laboratories 
Limited, Burlington, Ontario, Canada) The anti-LFA-l Ab, the cytotoxic T 
lymphocyte-associated Ag (CTLA)-4/Ig fusion protein, the recombinant mouse IL-4 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) were purchased from 
R&D Systems Inc (Minneapolis, MN). Dynal mouse CD3/CD28 T cell expander were 
bought from Invitrogen (Burlington, ON, Canada). The highly lung metastasis 
OVA-transfected BL6-10OVA melanoma cell line was generated in our own laboratory 
(461).  Female OVA-specific TCR-transgenic OT I and OT II mice, H-2Kb and I-Ab 
gene knockout (KO) mice were obtained from the Jackson Laboratory (Bar Harbor, MA). 
All mice were treated according to animal care committee guidelines of the University of 
Saskatchewan.  
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4.3.3.2 Spleen APCOVA preparation  
   This protocol is a modified version (106) of that originally described by Livingstone 
and Kuhn (441).  Briefly, spleens were injected with Dulbecco's modified Eagle’s 
medium (DMEM) containing 1 mg/ml collagenase (Worthington Biochemical, NJ), cut 
into small fragments, and digested in the above-described enzyme solution for 45-60 min 
at 37°C. Single-cell suspension was prepared by pressing the digested tissues through a 
stainless mesh. After the red blood cells were lysed with Tris-NH4CI, the spleen cells 
were washed once in phosphate buffered saline (PBS) and re-suspended in AIM-V® 
medium (serum-free lymphocyte medium; Invitrogen Life Technologies) plus OVA 
protein (Sigma-Aldrich) (0.2 mg/ml), recombinant mouse granulocyte 
macrophage-colony stimulating factor (rmGM-CSF) (10 ng/ml) and 50 μM 2-ME, and 
incubated at 37°C in 100 x 20-mm petri dishes (one spleen equivalent per dish). After 90 
min at 37°C, nonadherent cells were removed by gentle washing three times with 
pre-warmed normal saline, the used medium were kept for next step. Adherent cells were 
cultured for 3-4 hrs in the above AIM-V medium. Nonadherent cells were harvested by 
vigorously pipetting, washed with PBS for two times and used for animal study. Those 
cells were termed spleen antigen presentating cells (SpAPCOVA).  
4.3.3.3 Spleen and Bone marrow dendritic cells preparation  
   For spleen DCs, the first several steps were the same as SpAPCoVA preparation, only 
OVA were omitted and medium were replaced with 10%FCS-RPMI (Roswell Park 
Memorial Institute Media) with 50 μM 2-ME (2-mercaptoethanol), and after first time 
incubation on plate, attached cells were harvested by vigorously pipetting with PBS and 
washed twice, and then cells were incubated with biotin-anti-CDllc and anti-biotin 
MACS® beads sequentially before loading onto LS for positively selecting CD11c+ 
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cells-splenic DCs (SpDC). The generation of bone marrow-derived mature DCs (mDC) 
under high-dose of GM-CSF/IL-4 (20 ng/ml) has been described previously (173). DCs 
at day 6 of culture were further pulsed with OVA protein (0.3 mg/ml) in fetal calf 
serum-free AIM-V medium (Invitrogen, Burlington, Canada) for overnight culture and 
termed DCOVA. DCOVA derived from H-2Kb and I-Ab gene KO mice were termed 
(Kb-/-)DCOVA and (I-Ab-/-)DCOVA. 
4.3.3.4 Exosome preparation  
   Preparation and purification of exosomes (EXO) derived from the culture 
supernatants of DCOVA were previously described (351).  EXO derived from DCOVA 
were termed EXOOVA. Similar to DCOVA, EXOOVA also expressed MHC class I (H-2Kb) 
and class II (I-Ab), CDllc, CD40, CD54, CD80 and pMHC I complex (OVA I peptide and 
H-2Kb), but in a less content, compared to DCOVA(351). EXO derived from (Kb-/-)DCOVA 
were termed EXOOVA(Kb-/-). To generate 5-carboxy-fluorescein diacetate succinimidyl 
ester (CFSE)-labeled EXO, DCOVA were stained with 10 μM CFSE at 37°C for 20 
minutes (507) and washed three times with PBS, and then pulsed with OVA protein in 
AIM-V serum-free medium for overnight. The CFSE-labeled EXO (EXOCFSE) was 
harvested and purified from the culture supernatants as previously described above (351).  
4.3.3.5 CD8+CD25+ regulatory T cell preparation, expansion and characterization   
   Naive CD8+ T cells were isolated from normal B6 mouse spleens, enriched by 
passage through nylon wool columns (C&A Scientific, Manassas, VA), and then purified 
by negative selection using anti-mouse CD4 (L3T4) paramagnetic beads (Invitrogen, 
Burlington, ON, Canada) to yield populations that were >98% CD8+ (461). Naive CD8+ 
T cells were used to purify CD25+ cells by incubating with biotin-labeled anti-CD25 
antibody (7D4) and anti-biotin MACS beads (Miltenyi Biotech, Auburn, CA)(508) and 
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pass through LS column. The positively selected T cells were naive CD8+CD25+ 
regulatory T cells (Tr), the range of yield is between 0.1 to 0.3 x 106 cells/mouse. Those T 
cells were cultured in RPMI 1640 medium containing IL-2 (20 U/ml) and CD3/CD28 T 
cell expander beads (1:1) for 5 to 7 days for expansion and activation, After removing 
CD3/CD28 beads, those T cells were used for FACS analysis and exosome pulsing for 
animal study; some cells were also re-stimulated with CD3/CD28 beads for 24-48 hrs, the 
supernatant were collected for cytokine profile analysis (including IL-2, IL-4, IL-I0, 
IFN-γ, TGF-β and TNF-α). Regulatory T cell staining kit #3 (PE-anti-CD25 (clone 
PC61.5), FITC-CD4 (clone GK1.5) and ECD-Foxp3 (clone FJK-16S)) (eBioscience, San 
Diego, CA), FITC-CD8 (53-6.7) and biotin-anti-CD25 (7D4) with PE-Streptavidin were 
used to analyze the regulatory T cell distribution in spleens.  
4.3.3.6 Exosomal molecule uptake by CD8+CD25+ regulatory T cells  
   Firstly, the CD8+CD25+ Tr cells were incubated with EXOCFSE [10-30 μg/1 x106 T 
cells in 100 μl of AIM-V serum-free medium containing IL-2 (20 U/ml)] at 37°C for 1, 2, 
3, and 4hr, and then assessed by confocal fluorescence microscopy. To further determine 
the transfer of exosomal molecules to T cells, CD8+CD25+ T cells were incubated with 
EXOOVA, and then analyzed for expression of H-2Kb, CD40, CD54, CD80 and pMHC I 
by flow cytometry. The CD8+CD25+ T cells co-cultured with EXOOVA were Tr/E cells. 
For blocking assays, CD8+CD25+T cells were incubated with anti-H-2Kb, anti-I-Ab and 
anti-LFA-I Abs (50 μg/ml) or CTLA-4/lg (50 μg/ml), respectively, on ice for 30 min, 
then were co-cultured with EXOCFSE for 4h at 37°C. The cells was harvested and 
analyzed for CFSE expression by confocal fluorescence microscopy.  
4.3.3.7 Inhibition assay for T cell proliferation and spleen dendritic cell maturation  
   To assess the inhibition effect of CD8+CD25+ T cells, we performed in vitro T cell 
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proliferation assay. T cells depleted APC were harvested by pushing the cell out with a 
syringe plunger from splenocytes loaded nylon column after eluting the unattached T 
cells. CD8+CD25+ T cells (1 xl 05 cells/well) cells and their 2-fold dilutions were cultured 
with a constant number of 1 μM/ml CFSE labeled naive CD4+ or CD8+ T cells (l x 105 
cells/well) in presence of T cells depleted APC derived from CS7BL/6 mice (2 x 105 
cells/well) and anti-CD3 (2ug/ml). To examine the molecular mechanism, a panel of 
reagents including TGF-β (100 μg/ml), IL-10 and CTLA -4 (each 10 μg/ml) antibodies, 
and a mixture of isotype-matched irrelevant Abs (as control reagents) were added to the 
cell cultures, respectively. After culturing for 5 days, cell division and CD25 expression 
was detected by flow cytometry (424); cell proliferation is detected by 3H-incorporation 
assay using CD3/CD28 beads as stimulatant. For the DC maturation assay, freshly 
isolated immature CD11c+ spleen DCs were incubated with CD8+CD25+ Tr with or 
without naive T cells for overnight, and then Tr were removed by incubating the cell 
suspension with biotin-anti-CD3 Abs and anti-biotin microbeads, respectively, and 
running through LS column, negatively purified DCs were stained with DC related 
markers and analysis by flow cytometry (509), or cultured overnight with 1 ug/ml LPS 
and rmGM-CSF in AIM-V medium and then their supernatants were harvested for 
cytokine analyses. In in vivo OVA-specific CD8+ T cell proliferation inhibition assay, 
C57BL/6 mice (8 mice per group) were i.v. immunized with irradiated (4,000 rads) 
DCOVA (l  x 106 cells/mouse) or recombinant Listeria monocytogenes expressing OVA 
(rLmOVA) (510) alone or together with CD8+CD25+ Tr cells (3 x 106 cells/mouse). For 
evaluation of in vivo OVA-specific CD8+ T cell proliferation, the tail blood samples 
derived from mice 6 days after immunization were incubated with PE-H-2Kb/OVAI 
tetramer and FITC-anti-CD8 Ab (Beckman Coulter) and analyzed by flow cytometry 
(351).  
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4.3.3.8 In vivo cytotoxicity inhibition assay  
   In vivo cytotoxicity assay was performed as previously described (461). Briefly, 
C57BL/6 mice (8 mice per group) were i.v. immunized with irradiated (4,000 rad) DCOVA 
alone or together with CD8+CD25+ Tr cells (3 x 106 cells/mouse). Splenocytes were 
harvested from naive mouse spleens and incubated with either high (3.0 μM, CFSEhigh) or 
low (0.3 μM, CFSElow) concentrations of CFSE, to generate differentially labeled target 
cells. The CFSEhigh cells were pulsed with OVA I peptide, whereas the CFSElow cells 
were pulsed with unrelated peptide Mut1 or medium only and served as internal controls. 
These pulsed target cells were washed extensively to remove free peptides, and then i.v. 
co-injected at 1: 1 ratio into the immunized mice 7-10 days after immunization. Sixteen 
hrs after the target cells delivery, the spleens of injected mice were removed and residual 
CFSEhigh and CFSElow target cells remaining in the recipients' spleens were analyzed by 
flow cytometry.  
4.3.3.9 Animal studies 
   To examine immunosuppression of antitumor protective immunity conferred by 
CD8+CD25+ T cells. Wild-type C57BL/6 mice (n=8) were injected i.v. with irradiated 
(4,000 rad) spleen APCOVA (2 x 106 cells/mouse) with or without co-injection of 
CD8+CD25+ Tr cells (0.3-3 x 1 06 cells/mouse). The mice injected with PBS were used as 
a control. To assess the antitumor immunity, the immunized mice were challenged s.c. 
with 0.1 x 106 BL6-10OVA tumor cells ten days subsequent to the immunization. Animal 
mortality was monitored daily for up to 10 wk; for humanitarian reasons, all mice with 
tumors that achieved a size of 1.5 cm in diameter were sacrificed.  
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4.3.4 RESULTS 
 
4.3.4.1 CD8+CD25+ regulatory T cells express CD28, Foxp3, CTLA-4, GITR, 
perforin and granzyme B  
   We first analyzed the presence of CD4+CD25+ and CD8+CD25+  regulatory T (Tr) 
cells in wild-type C57BL/6 mice by using e-Biosciences Regulatory T cell kits. As shown 
in Fig. 4.3. 1A, CD4+CD25+ and CD8+CD25+ Tr cells accounted for 5.51% and 1.38% of 
the total T cell population in mouse splenocytes, respectively, which is consistent with 
some previous reports (424, 511).  Both CD4+CD25+ and CD8+CD25+ Tr cells 
expressed Foxp3 with the former expressing higher amount of Foxp3 than the latter. 
These CD8+CD25+ Tr cells were expanded in vitro by using anti-CD3/CD28 Ab-coupled 
beads (512), and then analyzed by flow cytometry. Naive CD8+ CD25- T cells did not 
express T cell activation markers CD25 and CD69, but displayed a high level of 
cell-surface CD62L and GITR, and intracellular CTLA-4 (Fig.4.3. 1B). CD8+CD25+ Tr 
cells, however, expressed a high level of CD25 and CD69, indicating that they are active 
T cells. They also expressed a high level of cell-surface CD28 and GITR, and 
intracellular CTLA-4 and Foxp3, but had low or no expression of TGF-β, CD30, CD62L 
and TLR-4, indicating that they are CD8+CD28+ Tr cells, but not CD8+CD28- and 
TLR-4-expressing CD4+CD25+ Tr cells (513). Since CD8+ Tr cells may have some 
characteristics that are attributed to cytotoxic T cells (405, 420),  we also assessed 
expression of a number of cytotoxicity-related molecules such as FasL, TRAIL, perforin 
and granzyme B by flow cytometry. As shown in Figure 1b, CD8+CD25+ Tr cells 
expressed both the intracellular perforin and granzyme B, but not the cell-surface TRAIL 
and FasL. However, we found that CD8+CD25+ Tr cells derived from OVA-specific TCR 
transgenic OT I mice did not show any killing activity to OVA I-pulsed splenocytes or 
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OVA-expressing BL6-10OVA tumor cells (data not shown). In addition, these CD8+CD25+ 
Tr cells secreted immune suppressive cytokines such as IL-10 (1.5 ng/ml/l06 cells/24 hr) 
and TGF-β (0.8 ng/ml/l06 cells/24 hr) as well as inflammatory cytokines such as IFN-γ 
(4.0 ng/ml/l06 cells/24 hr) and TNF-α (3.0 ng/ml/106 cells/24 hr), but no IL-4 (Fig.4.3. 
1B), indicating that CD8+CD25+ Tr cells also share some features of Trl cells such as 
secretion of both IL-1 0 and IFN-γ (424).  
 
4.3.4.2 CD8+CD25+ Tr cells inhibit dendritic cell maturation  
   Fresh immature mouse SpDCs become mature ones through overnight culturing in 
presence of GM-CSF (107, 108). CD4+CD25+ regulatory T cells have also been reported 
to play inhibitory role via reducing the DC maturation (396, 509). To assess the in vitro 
inhibitory effect of CD8+CD25+ Tr cells, we incubated splenic DCs with CD8+CD25+ Tr 
cells, and then analyzed DCs after incubation by flow cytometry. As shown in Figure 2a, 
DCs greatly down-regulated expression of DC maturation markers such as CD80, CD86, 
and I-Ab, but also down-regulated that of PD-L1 (B7-H1), PD-L2 (B7-DC) and only 
slightly increase that of B7-H3 and B7-H4 after incubation with CD8+CD25+ Tr cells, 
indicating that CD8+CD25+ Tr cells could inhibit spontaneous DC maturation. It has been 
demonstrated that presence of naive T cells(Tn) is necessary for mouse CD4+ Tr cells to 
exert its immune suppressive effect, while Tr themselves weakly promote the DC 
maturation (509).  To assess whether CD8+CD25+ Tr cells also inhibit naive T 
cell-induced DC maturation, we incubated DCs with CD8+CD25+ Tr cells in presence of 
naive CD4+ T cells, and then phenotypically analyzed DCs by flow cytometry. We found 
that DCs also greatly down-regulated expression of DC maturation markers (Fig.4.3. 2A), 
indicating that CD8+CD25+ Tr cells could also inhibit naive T cell-induced DC 
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maturation.  
4.3.4.3 CD8+CD25+ Tr cells induce dendritic cell tolerogenicity 
   To further characterize CD8+CD25+ Tr cell-treated DCs, we then analyzed the 
cytokine secretion of Tr-treated DCs. After stimulation with LPS, SpDC only secreted 
high level of IL-6 (840 pg/ml), IFN-γ (1069 pg/ml), and TNF-α (883 pg/ml), but very low 
level of IL-10 (80 pg/ml); in the presence of Tn, SpDC also secreted significant amount 
of the above mention cytokines (IL-6, 372 pg/ml; IFN-γ, 696 pg/ml; and TNF-α, 451 
pg/ml), although with much lower level compared with SpDC only, but with a little 
higher level of IL-10 (200 pg/ml). However, the Tr-treated DCs secreted much lower 
level of IL-6, IFN-γ and TNF-α (all below 10 pg/ml), the IL-10 secretion change was 
only and almost doubly increased in DC-Tr only (152 pg/ml) culture group (Fig.4.3. 2B). , 
indicating that CD8+CD25+ Tr cells induce DC tolerogenicity. Our results were also 
indirectly supported by those reports that CD4+CD25+ Tr cells inhibited DCs by 
increasing its own secretion of IL-10 and decreasing IL-6 secretion (393, 394). 
4.3.4.4 CD8+CD25+ Tr cells inhibit in vitro T cell proliferation via cell-to-cell contact 
   To assess the in vitro inhibition effect, we performed CFSE-labeled T cell 
proliferation assay by using CD8+CD25+ Tr cells. As shown in Figure 3a, CD8+CD25+ Tr 
cells suppressed the in vitro proliferation of both CD4+ and CD8+ T cells in a 
dose-dependent manner. At a ratio (CD8+25+ Tr cell and responder T cell) of 1:1, 
CD8+CD25+ Tr cells completely (100%) and prominently (75%) suppressed CD4+ and 
CD8+ T cell proliferation. We also found that their inhibition of T cell proliferation was 
not affected by the blocking reagents including CTLA-4-IgFc, anti-IL-10 and anti-TGF-β 
Abs (Fig.4.3. 3B), indicating that its inhibition is not dependent upon CD28/CD80 
interactions and secretion of immune suppressive cytokines IL-10 and TGF-β, which is 
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consistent with some previous reports (503, 514). However, the in vitro transwell 
experiments suggest that the suppressive activity of CD8+CD25+ Tr cells requires 
cell-to-cell contact because CD8+CD25+ Tr cells separated by transwell membrane did 
not show any inhibitory effect. Our data are also consistent with some previous reports 
(503, 514).  
4.3.4.5 CD8+CD25+ Tr cells induce in vitro T cell anergy 
CD4+CD25+ regulatory T cells have also been reported to play inhibitory role via 
inducing T cell anergy (389).  To assess the potential effect of CD8+CD25+ Tr cells, we 
purified naive CD4+ T cells and pre-incubated them with CD8+CD25+ Tr cells, and then 
phenotypically characterized them by flow cytometry. As shown in Fig.4.3. 3C, they did 
not express T cell activation marker CD25, but express high level of CD73 and FR-4, 
indicating that CD8+CD25+ Tr cells are capable of inducing T cell anergy (515). To 
functionally characterize them, we tested CD4+ T cell proliferation using CD3/CD28 
beads as stimuli in 3H-thymidine incorporation assay. As shown in Fig. 4.3. 3D, the 
primary naive T cells proliferated upon stimulation derived from CD3/CD28 beads in a 
dose-dependent manner. However, the naive T cells after incubation with CD8+CD25+ Tr 
cells lost their proliferative capacity.  
4.3.4.6 CD8+CD25+ Tr cells inhibit both CD4+ Th cell-dependent and -independent 
CD8+ T cell responses in vivo  
   To assess whether CD8+CD25+ Tr cells inhibit CD8+ T cell responses in vivo, we 
performed tetramer staining assay using blood samples of mice immunized with 
rLmOVA and DCOVA. Both the bacteria rLmOVA and DCOVA stimulated proliferation of 
H-2Kb/OVAI tetramer-positive CD8+ T cells accounting for 12.02% and 1.53% of the 
total CD8+ T cell population in wild-type C57BL/6 mice (Fig.4.3. 4A). However, only 
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the bacteria rLmOVA (8.23%), but not the DCOVA (0.03%) stimulated in vivo 
OVA-specific CD8+ T cell responses in I-Ab gene KO mice lacking CD4+ Th cells, 
indicating that DCOVA and bacteria rLmOVA stimulate CD4+ Th cell-dependent and 
CD4+ Th cell-independent CD8+ T cell responses, respectively. To assess in vivo 
inhibitory effect of CD8+CD25+ Tr cells in CD4+ Th cell-dependent and CD4+ Th 
cell-independent CD8+ CTL responses, we performed another tetramer staining assay by 
using the peripheral blood samples from mice immunized with both DCOVA/ rLmOVA 
and CD8+CD25+ Tr cells. As shown in Fig.4.3. 4B, the stimulation of DCOVA- and 
rLmOVA-induced proliferation of H-2Kb/OVAI tetramer-positive CD8+ T cells in 
presence of CD8+CD25+ Tr cells in wild-type C57BL/6 mice significantly dropped from 
3.05% and 11.98% to 1.74% and 6.05% of the total CD8+ T cell population, respectively 
(p<0.05), indicating that CD8+CD25+ Tr cells are capable of suppressing both CD4+ Th 
cell-dependent and CD4+ Th cell-independent CD8+ CTL responses.  
4.3.4.7 CD8+CD25+ Tr cells inhibit in vivo effector CD8+ CTL responses and 
antitumor immunity 
   To assess whether CD8+CD25+ Tr cells suppress CD8+ T cell differentiation into 
effector CD8+ cytotoxic T cells, we adoptively transferred OVA I peptide-pulsed 
splenocytes that had been strongly labeled with CFSE (CFSEhigh), as well as the control 
peptide Mut1-pulsed splenocytes that had been weakly labeled with CFSE (CFSE1ow), 
into the recipient mice that had been injected with DCOVA alone or DCOVA and 
CD8+CD25+ Tr cells, respectively. The mice immunized with DCOVA had larger loss of 
CFSEhigh target cells (85%) (Fig.4.3. 4C), indicating that DCOVA can most efficiently 
stimulate CD8+ T cell differentiation into CTL effectors. As expected, the injection of 
CD8+CD25+ Tr cells significantly reduced the loss of CFSEhigh target cells (55%) in 
DCOVA-immunized mice, indicating that CD8+CD25+ Tr cells efficiently inhibit in vivo 
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effector CD8+ CTL responses. To assess whether CD8+CD25+ Tr cells also suppress 
antitumor immunity, we performed animal studies. As shown in Fig.4.3. 4D, all PBS 
control mice died of tumor within 4 weeks after inoculation of OVA-expressing 
BL6-l0OVA tumor cells. Most of SpAPCOVA-immunized mice (75%) were protected from 
BL6-10OVA tumor cell challenge. However, CD8+CD25+ Tr cell administration 
significantly reduced SpAPCOVA-induced antitumor immunity and 4/8 (50%) of mice 
died of tumor (p<0.05), indicating that CD8+CD25+ Tr cells also suppress in vivo 
antitumor immunity.  
4.3.4.8 CD8+CD25+ Tr cells uptake DCOVA-released exsomes via TCR/MHC I and 
CD28/CD80 interaction 
   We previously demonstrated that CD4+ T cells can uptake OVA-specific 
DCOVA-released exosomes (EXOOVA) expressing pMHC I (469, 477). In this study, Fig. 
4.3. 5A demonstrates that EXOOVA released from wild-type C57BL/6 (B6) DCOVA, but 
not EXOOVA(Kb-/-) released from H-2Kb-/- mouse (Kb-/-)DCOVA displayed pMHC I 
expression. To assess uptake of OVA-specific DCOVA-released EXOOVA by CD8+CD25+ 
Tr cells, CD8+CD25+ Tr cells derived from B6 mice were incubated with CFSE-Iabeled 
DCOVA-released exosomes (EXOCFSE) at different doses and for various times, and then 
analyzed by confocal microscopy. The CFSE dye was apparently detectable on 
CD8+CD25+ Tr cells by confocal microscopy after incubation with EXOCFSE. As shown 
in Fig.4.3. 5A, the uptake of EXOCFSE by CD8+CD25+ Tr cells increased with dose of 
EXOCFSE. When CD8+CD25+ Tr cells incubated with EXOCFSE at a concentration of 30 
μg/ml, 82% of CD8+CD25+ Tr cells became CFSE-positive. The uptake of EXOCFSE by 
CD8+CD25+ Tr cells also increased with incubation time and reached a maximal level 
(80% CFSE-positive cells) after 3 hr incubation (Fig.4.3. 5B). The CFSE-positive cells 
declined with the time when culturing them in medium, but were still detectable more 
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than 3 days in culture (Fig.4.3. 5B), indicating that the uptaken exosomal molecules on 
CD8+CD25+ Tr cells are quite stable, which is consistent with a previous report by 
Undale et al (516).  Therefore, we regularly used EXOOVA-pulsed CD8+CD25+ Tr cells 
by incubation of CD8+CD25+ Tr cells with EXOOVA (30 μg/ml) for 3 hr in this study. To 
elucidate the molecular pathway involved in EXO uptake, we used a panel of reagents in 
the blocking assay. We demonstrated that the anti-H-2Kb Ab and CTLA-4/Ig fusion 
protein, but not the anti-LFA-l and anti-I-Ab Abs were able to significantly reduce 
EXOCFSE uptaking (p<0.05), indicating that the nonspecific CD8+CD25+ Tr cells uptake 
OVA-specific DCOVA-released EXOOVA via TCR-H-2Kb and CD28/CD80 interactions, 
which is consistent with a previous report on exosome uptake of CD8+ T cells by Hwang 
et al (517).  
4.3.4.9 CD8+CD25+ Tr/E cells with uptake of exosomes acquire functional exosomal 
pMHC I 
   We previously demonstrated that OVA-pulsed DCOVA and EXOOVA released from 
DCOVA also expressed pMHC I complexes (477). To assess whether CD8+CD25+ Tr cells 
with uptake of EXOOVA also express exosomal pMHC I, we performed flow cytometric 
analysis. As shown in Fig.4.3. 5A, the original CD8+CD25+ Tr cells did not express 
pMHC I. However, they became pMHC I-positive after incubation of EXOOVA, 
indicating that CD8+CD25+ Tr/E cells acquire the exosomal pMHC I complexes. To 
confirm it, we also incubated CD8+CD25+ Tr cells with (Kb-/-)DCOVA-released 
EXOOVA(Kb-/-) without pMHC I expression and analyzed these CD8+CD25+ Tr/E(Kb-/-) 
cells by flow cytometry. In addition, As shown in Fig.4.3. 5A, these CD8+CD25+ 
Tr/E(Kb-/-)  cells then became pMHC I negative, confirming that CD8+CD25+ Tr/E cells 
express acquired exosomal pMHC I complexes. To assess whether the acquired exosomal 
pMHC I complexes are functional, we performed IL-2 secretion assay. As shown in 
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Fig.4.3. 6A, pMHC I-expressing DCOVA and CD8+CD25+ Tr/E cells stimulated 
OVA-specific TCR-expressing RF3370 cells to secreted IL-2, respectively. On the 
contrary, pMHC I-negative CD8+CD25+ Tr/E(Kb-/-) cells derived from CD8+CD25+ Tr 
cells with uptake of (Kb-/-)DCOVA-released EXOOVA(Kb-/-) failed in stimulation of RF3370 
cells to secrete IL-2, indicating that the acquired exosomal pMHC I complexes on 
CD8+CD25+ Tr/E cells are functional.  
4.3.4.10 CD8+CD25+ Tr/E cells with acquired exosomal pMHC I enhance its 
suppressive effect on CD8+ T cell responses and antitumor immunity  
   We previously demonstrated that the nonspecific CD4+ T cells can acquire antigen 
specificity via uptake of antigen-specific DC-released EXO (469). To assess whether the 
nonspecific CD8+CD25+ Tr cells can also become OVA Ag-specific Tr cells via uptake 
of OVA-specific DCOVA-released EXOOVA, we performed the tetramer staining, in vivo 
cytotoxicity assay and animal studies by using CD8+CD25+ Tr/E cells  expressing 
acquired exosomal pMHC I. As shown in Fig.4.3. 6B, the stimulation of DCOVA-induced 
proliferation of H-2Kb/OVAI tetramer-positive CD8+ T cells in presence of CD8+CD25+ 
Tr/E cells accounted for only 1.32% of the total CD8+ T cell population (Fig.4.3. 6B), 
which is significantly lower than that (1.78%) in presence of CD8+CD25+ Tr cells 
without pMHC I expression(p<0.05) indicating that the acquisition of exosomal pMHC I 
greatly enhances the suppressive effect of CD8+CD25+ Tr cells. To our surprise, 
CD8+CD25+ Tr/E almost completely inhibited the rLmOVA induced in vivo CTL 
proliferation, indicated that CD8+CD25+ Tr/E cells have stronger capacity of inhibiting 
the CD4+ T cell-independent CTL response. To confirm it, we repeated the above 
tetramer staining assay by using pMHC I-negative CD8+CD25+ Tr/E(Kb-/-) cells. As 
shown in Fig4.3. 6B, the stimulation of DCOVA induced proliferation of H-2Kb/OVAI 
tetramer-positive CD8+ T cells resume to the level when CD8+CD25+ Tr cells were used, 
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confirming that the acquisition of exosomal pMHC I does greatly enhance the 
suppressive effect of CD8+CD25+ Tr cells. As expected, the injection of CD8+CD25+ 
Tr/E cells significantly reduced the loss of CFSEhigh target cells in DCOVA-immunized 
mice, with 71 % of the target cells left alive, while the un-pulsed CD8+CD25+ Tr group 
only has around 44% left alive (Fig4.3. 6C), indicating that CD8+CD25+ Tr/E cells more 
efficiently inhibit in vivo effector CD8+ CTL responses. Again like the tetramer assay, 
CD8+CD25+ Tr/E(Kb-/-) lost their superiority to the CD8+CD25+ Tr, with 43% target cells 
left alive, further confirmed that it's the pMHC I mediated antigen specificity enhanced 
the suppression power of CD8+CD25+ Tr cells in our model. Similarly in the animal 
studies, all mice died of tumor within 4 weeks after inoculation of OVA-expressing 
BL6-10OVA tumor cells (Fig.4.3. 6D). SpAPCOVA-immunized mice were mostly (75%) 
protected from BL6-10OVA tumor cell challenge. However, CD8+CD25+ Tr/E cells 
administration significantly reduced SpAPCOVA-induced antitumor immunity and 7/8 
(87.5% verse 45% for CD8+CD25+ Tr) of mice died of tumor, indicating that 
CD8+CD25+ Tr/E cells also show stronger suppression in vivo antitumor immunity than 
its un-plused counterparts. We also did the dose curve study of this specific Tr (Fig.4.3. 
6D) and found that 0.3 x l06 CD8+CD25+ Tr/E could reach the effects of 3 x 106 
CD8+CD25+ Tr; 0.6 x l06 and more CD8+CD25+ Tr/E showed the same extent of 
inhibition of animal protection induced with SpAPCOVA vaccination in our model; while 
CD8+CD25+ Tr cells dose was decreased to 0.3 x 106, their inhibitory function could not 
be demonstrated here. The above study indicated that CD8+CD25+ Tr/E were at least 10 
times more powerful than CD8+CD25+ Tr cells without acquisition of pMHC- I complex, 
indicating that the important role of acquired exosomal pMHC I complexes on 
CD8+CD25+ Tr/E cells in targeting Tr's suppression to CD8+ T cells in vivo. In order to 
test whether IL-l0 of CD8+CD25+ Tr cells play any role in the inhibition, we compared 
IL-10-/- and wild type C57BL/6 mice derived CD8+CD25+ Tr cells (Fig.4.3. 6D), no 
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significant differences (p>0.05) were found between these two groups in this model.  
4.3.5 DISCUSSION 
   CD8+ Tr cells have been originally found in models of autoimmune diseases, 
transplantation and cancer in 1970s and early 1980s (405, 406).  However, because of 
lacking defining markers and difficulties in isolating these cells, the suppressive 
mechanisms in these earlier reports have been discredited or ignored. Recently CD8+ Tr 
cells have been primarily reported to be essential in vivo in prevention of experimental 
autoimmune encephalomyelitis and in participation of oral tolerance (518-520). In human 
both natural self-antigen (Ag)-reactive CD4+CD25+ and CD8+CD25+ Tr expressing 
forkhead box P3 (Foxp3) (380, 421) play a unique role in restoring immune homeostasis 
and in maintaining immune privileged sites (502, 521). They develop in the thymus and 
then enter peripheral tissues, where they suppress the activation of self-reactive T effector 
cells in a non-Ag-specific manner (427).  In contrast to the natural nonspecific 
CD8+CD25+ regulatory T cells derived from thymus, adoptive CD8+ Tr cells developed 
in the peripheral tissues have been reported to be antigen specific. Mouse CD8+CD25+ Tr 
have been reported in I-Ab-/- gene KO mouse thymus and in mouse periphery during 
ontogeny (424). In this study, we demonstrated that there were small amount of 
CD8+CD25+ Tr cells accounting for 1.35% of the total CD8+ T cell population in the 
spleen of wild-type C57BL/6 mice compared to a larger amount (5.51 %) of CD4+CD25+ 
Tr cells in total CD4+ T cells.  
   The first fully characterized CD8+ Tr cells were CD8+CD28- by in vitro culture 
peripheral blood mononuclear cell with multiple rounds of stimulation with allogenic, 
xenogenic or antigen-pulsed syngenic APCs (522). However, the mechanisms 
responsible for CD8+ Tr cell's inhibition of the immune responses are still controversial 
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(504).  Some kinds of CD8+ Tregs involved soluble TGF-β and IL-10 in their inhibition 
of T cell proliferation (27, 523), whereas most other reports indicated that cell-contact is 
important in CD8+ Tr cell's inhibitory effect through CTLA-4, membrane-bound TGF-β 
and granzyme B or even tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
(409, 504).  CD8+CD28- Tr up-regulated the expression of immunoglobulin-like 
transcript (ILT) 3 and ILT4 on monocytes and DCs, rendering these APCs tolerogenic 
with reduced expression of CD80 and induction of antigen-specific unresponsiveness in 
CD4+ T helper cells (524). The human CD8+CD25+ Tr cells isolated from thymus 
suppress the proliferation of autologous CD25- T cells via cell-contact through CTLA-4 
and TGF-β (421).  In this study, we found that CD8+CD25+ Tr cells significantly 
inhibited in vitro CD4+ and CD8+ T cell proliferation via cell-contact mechanism. Unlike 
the human thymus-derived CD8+CD25+ Tr cells, which don't proliferate and secrete 
cytokines (374), the mouse peripheral CD8+CD25+ Tr cells proliferate vigorously in vitro 
under stimulation of CD3/CD28 T cell expander beads, and express CTLA-4 and secrete 
high level of IL-10 and TGF-β. However, none of them is involved in the mechanism of 
their suppression. Mouse CD4+CD25+ Tr cells which slightly promoted DC maturation 
could suppress the naive T cell-induced DC maturation (509).  In this study, we found 
that CD8+CD25+ Tr cells could not only impaired DC spontaneous maturation, but also 
inhibited the naive T cell-induced DC maturation, indicating that CD8+CD25+ Tr cells are 
superior to CD4+CD25+ Tr cells in suppressing DC maturation. In addition, they also 
induced CD4 T cell anergy. Although CD4+CD25+ Tr cells could increase expression of 
the inhibitory molecule B-7H4 on monocyte-derived DC through up-regulating their own 
secretion of IL-10 (393), or down –regulating their secretion of  IL-6 (394), we didn't 
find any CD8+CD25+ Tr cells-mediated change on IL-10 and B7-H4 expression. 
However we did find that CD8+CD25+ Tr cells almost completely inhibited secretion of 
the two Thl-polarizing cytokines (IFN-γ and TNF-α) besides down-regulation of IL-6 
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secretion, indicating that CD8+CD25+ Tr cells might employ even more wide inhibitory 
mechanism.  
   Peripheral adaptive CD8+ Tr cells, which are antigen specific, are induced by unique 
antigen presenting cells during viral infections or tumor development (521). Glatiramer 
acetate (GA)-induced CD8+ Tr cells which are cytotoxic can directly kill CD4+ T cells in 
a GA-specific manner by cell contact-dependent mechanisms (525).  The killing was 
enhanced by pre-activation of the target CD4+ T cells and may depend on presentation of 
GA through HLA - E. Tang et al demonstrated that CD8αα+ Tr cells can kill CD4+ T cells 
with a dynamic expression of TCR peptide/Qa-l complexes within a narrow window of 
time (420).  Several other groups reported the acquisition of antigen specificity by CD8+ 
Tr cells via MHC molecules such as HLA-G (431),  Qa-l (420) and HLA-A2 (375).  
We have recently demonstrated that CD4+ T cells derived from OVA-specific T cell 
receptor (TCR) transgenic OT II mice uptook DCOVA released EXOOVA via MHC/TCR 
and CD54/LFA-I interactions, and these CD4+ T cells with acquired exosomal pMHC I 
and costimulatory molecules stimulated central memory CD8+ CTL responses (469, 477). 
Interestingly, the stimulatory effect of CD4+ T cells was found to be specifically targeted 
to CD8+ T cells in vivo via acquired exosomal pMHC I complexes. In this study, we 
found that the nonspecific CD8+CD25+ Tr cells acquired antigen specificity by uptake of 
antigen-specific exosomal pMHC I and enhanced its inhibitory effect by l0-folds, 
confirming the Ag-specific targeting role of acquired exosomal pMHC I complexes on 
CD8+CD25+ Tr cells. 
   Taken together, our data demonstrated that nonspecific CD8+CD25+ Tr cells 
expressing Foxp3, CTLA-4, GITR, perforin and granzyme B inhibited in vitro T cell 
proliferation via cell-to-cell contact and in vivo OVA-specific CD4+ T cell-dependent 
and -independent CD8+ CTL responses and antitumor immunity. CD8+CD25+ Tr cells’ 
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suppressive effect is mediated by its inhibition of DC maturation, induction of DC 
tolerogenecity and T cell anergy. The nonspecific CD8+CD25+ Tr cells acquired OVA 
antigen specificity by uptake of DCOVA-released EXOOVA expressing pMHC I and 
enhanced its effect on inhibition of OVA-specific CD8+ T cell responses and antitumor 
immunity by 10-folds. The principles elucidated in this study may have significant 
implications not only in antitumor immunity, but also in other sectors of immunology 
(e.g, autoimmunity and transplantation).  
 
This manuscript will be submitted to the Journal of Leukocyte Biology. 
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 4.3.6 Figure legends for Manuscript 4.3 
Figure 4.3.1: Characterization of CD8+CD25+ Tr(Tr) in spleen. 
 A, Distribution of CD4+CD25+ and CD8+CD25+ Tr. Naïve splenocytes were harvested 
by pressing the spleen through mesh to get the single cell suspension and lysed the RBC 
with 0.83% NH4Cl-Tris, and were stained with FITC-anti-CD4 or -CD8, 
anti-CD25-Biotin(7D4)/ streptavidin-PE, and anti-Foxp3-ECD(FJK-16S); double positive  
CD4+CD25+ and CD8+CD25+ were gated and analyzed for the expression of Foxp3 by 
flow cytometry. B, Cytokine profile of CD8+CD25+ Tr. In vitro cultured CD8+CD25+ Tr 
were restimulated with CD3CD28 dynal beads for 24 hrs. The supernatants were 
harvested after their culture. IL-2, IL-4, IL-10, IFN-γ, TNF-α, and TGF-β were measured 
using related ELISA kits from BD Pharmingen and R & D Systems. One of three similar 
experiments is shown. C, Phenotypic analyses of activated CD8+CD25+ Tr. Purified 
CD8+CD25+ Tregs  and naive CD8 Tcells were culture in medium containing the same 
number of CD3CD28 beads as the cells for 5-7 days. The cells were stained with 
Anti-CD8, CD25, CD28, CD30, CD62L, CD69, CD80, CTLA-4, Foxp3, FasL, GITR, 
granzyme B, perforin, TLR-4, TRAIL, TGF-β, and their corresponding control were 
prepared. A representative example of three independent experiments is shown. Note: the 
dotted lines were the corresponding control.   
 
Figure 4.3.2: Influences of CD8+CD25+ Tr (Tr) on splenic DCs.  
 A, Tr inhibit the maturation of splenic DC. Fresh immature splenic DCs were purified 
as described in Materials and Methods and cultured with same number of Tr, and/or with 
naive T cells for overnight; splenic DCs were negatively purified with biotin-anti-CD3 
and anti-biotin MCAS beads and stained for CD80, 86, I-Ab, B7-H1, B7-DC, B7-H3, and 
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B7-H4, respectively. Numbers in graph were their expression level as MFI. B, Tr inhibit 
Th1 polarization cytokine secretion. The above cocultured splenic DC were stimulated 
with LPS overnight and their supernatants were harvested for analyses of  IL-6, IL-10, 
IL-12, IFN-γ, TNF-α, and TGF-β secretion. 
 
Figure 4.3.3: Influences of CD8+CD25+ Tr (Tr) on naive T cells. 
 A, Dose-dependent suppression of T cell proliferation by Tr. CFSE labeled naïve CD4+ 
or CD8+ T cells (1×105/well) were cultured  with 2 μg/ml anti-CD3 Ab in the presence 
of 2×105 irradiated T cell depleted splenocytes and decreasing amounts of  activated Tr 
(at indicated ratios). After 5 days of culture, proliferation was measured based on CFSE 
signal. A representative CFSE profile from one experiment of three is shown. B, Tr cells 
mediate suppression by cell contact, not by CTLA-4, IL-10 and TGF-β. For the 
mechanism study, the ratio of T cells to Tr is from1:1 to1:8 and all the results were 
similar; only 1:1 results were shown.  C, Tr induced T cell anergy. After culturing with 
Tr  overnight,  CD4 T cells  were purified for CD73 and FR-4 expression,  and  
simulated with different ratios of CD3CD28 dynal beads for 3 days, 3H-tymidine was 
added for last 12 hrs of culture for tritium incorporation assay,  then cells were analyzed 
for their CD25 expression by flow cytometry or proliferation by β-counter.   
 
Figure 4.3.4: CD8+CD25+ Tr (Tr) effects on antitumor immunity. 
 A, DCOVA and rLmOVA induced   CD4+-dependent and independent CTL response, 
respectively. The tail-vein blood was collected after vaccination of wild type and I-Ab-/- 
B6 mice with DCOVA and LmOVA for  6 and 9 days, respectively, and stained with 
PE-H-2-Kb/OVAI tetramer and FITC-CD8 Ab for flow cytometry analysis. Double 
positive T cells were OVAI-specific CTL. B,  Tr inhibit the DCOVA and LmOVA induced 
CTL response. B6 mice were treated with vaccination only, 3x106Tr only, or with Tr (iv), 
 143
OVAI specific CTL were detected as described above. C, Tr inhibited DCOVA induced in 
vivo cytotoxicity. Splenocytes from C57BL/6 mice were pulsed with OVA I peptide and 
strongly stained with CFSE (CFSEhigh), or pulsed with control Mut1 peptide and weakly 
stained with CFSE (CFSElow).  These labeled cells were then i.v. injected at ratio of 1:1 
into mice after immunization for 8-10 days, 16-20 hrs later, the relative proportions of 
CFSEhigh and CFSElow cells remaining in the spleens of the recipient mice were assessed 
by flow cytometry. The values in each panel represent the percentage of CFSEhigh cells 
(+/- the standard deviation) and CFSElow cells remaining in the spleens. D, Tr inhibited 
SpAPCOVA induced anti-tumor immunity. The naïve B6 mice (4 per group) were 
immunized with 0.2 mg/ml OVA pulsed SpAPC or with 3x106 Tr cells, 10 day later, 
mice were challenged with 0.1x106 BL6-10OVA tumor cells s.c., and were sacrificed when 
their tumor growth reached 1-1.2cm in diameter. One representative result of three 
experiments (for a, b, c, and d) is shown. 
Figure 4.3.5: Exosome uptake by CD8+CD25+ Tr (Tr) cells. 
 A. BM DCOVA derived exosomes express pMHCI. EXOOVA, EXOOVA(Kb-/-), Tr, Tr/E, 
and Tr/E(Kb-/-) were stained with biotin-anti-pMHCI and FITC-streptavidin, and analyzed 
by flow cytometry(solid dark line for pMHCI, dotted line for the isotype control, Tr/E 
means Tr pulsed with related exosomes).  B, Kinetic study of exosomes uptake by Tr 
cells. Activated Tr cells (30 x 106 cells/3 ml) were incubated with CFSE labeled 
exosomes (EXOCFSE)  (30 µg/1×106 cells) in AIM-V containing IL-2 (10U/ml) at 37°C, 
5×106 cells were taken out after 1, 2, 3, and 4 hrs of incubation, respectively; cells were 
washed and fixed right away. CFSE-positive T cells were detected by confocal 
microscopy and the average percentages of CFSE-positive T cells were calculated from 
three different areas. C, Dose curve. Tr were pulsed as above, but with different 
concentration, respectively, and detected as b.  D, Blocking assay.  5×106 cells were 
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used for each experiment under the same condition as above with 50 ug/ml of each 
reagent, cells were treated as above after 4 hrs culture. d. Stability assay.  Activated Tr 
cells with incubation of EXOCFSE for 4 h were cultured in AIM-V containing IL-2 (10 
U/ml) at 37°C for different times after extensively washing. CFSE-positive T cells were 
detected by confocal microscopy and the percentages of CFSE-positive T cells were 
calculated after different period of culture. Note:  
Figure 4.3.6: Characterization of exosome pulsed CD8+CD25+ Tr (Tr/E).  
 A, MHC I presentation of OVA I to RF3370 hybridoma cells by Tr/E. The amount of 
IL-2 secretion of stimulated RF3370 in examined wells was substracted by the amount of 
IL-2 in wells containing DCOVA, Tr/E, Tr/E(Kb-/-), or RF3370, respectively.  B,  In 
OVA-specific CD8+ T cell proliferation inhibition assay, the tail blood samples from 
mice immunized with irradiated DCOVA, and rLmOVA, either alone or together with Tr , 
Tr(IL-10-/-), Tr/E or Tr/E(Kb-/-) cells (3×106 cells per mouse) were stained with 
PE-H-2Kb/OVAI tetramers and FITC-anti-CD8 Ab, and then analyzed by flow 
cytometry.  C, In vivo CD8+ T cell cytotoxicity assay. Splenocytes from C57BL/6 mice 
were pulsed with OVA I peptide and strongly stained with CFSE (CFSEhigh), or pulsed 
with control Mut1 peptide and weakly stained with CFSE (CFSElow).  These labeled 
cells were then i.v. injected at ratio of 1:1 into mice immunized with irradiated DCOVA, or 
DCOVA plus various Tr cells as in panel 6b (above). Sixteen hours later, the relative 
proportions of CFSEhigh and CFSElow cells remaining in the spleens of the recipient mice 
were assessed by flow cytometry. The values in each panel represent the percentage of 
CFSEhigh cells (The value in parentheses represents the standard deviation) and CFSElow 
cells remaining in the spleens. *, representing p<0.05 versus cohorts of immunized mice 
treated with Tr1, Tr1(IFN-γ-/-) and Tr1(vivo) cells, respectively,  (Student’s t test).  D, 
and E,  Tr/E  showed stronger inhibition on in vivo antitumor immunity induced by 
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SpAPCOVA than Tr itself.  Wild-type C57BL/6 mice (n=8) were either injected s.c. with 
SpAPCOVA alone or in conjunction with i.v.-injected 3×106 or other number of  Tr, Tr/E, 
Tr(IL-10-/-), or Tr/E(Kb-/-) cells, respectively.  9-11 days later the mice were given 
0.1×106 BL6-10OVA tumor cells s.c., then mouse survival was monitored daily for up to 6 
weeks.   One representative experiment of three for b, c, d, and e is depicted. Note: The 
number after Tr or Tr/E means number of million cells. Tr(IL-10-/-): Tr from IL-10 knock 
out mice. 
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Figure 4.3. 1: Characterization of CD8+CD25+ Tr (Tr) in spleen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147
  
Figure 4.3. 2: Influences of CD8+CD25+ Tr (Tr) on splenic DCs. 
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 Figure 4.3. 3: Influences of CD8+CD25+ Tr (Tr) on naive T cells. 
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Figure 4.3. 4: CD8+CD25+ Tr (Tr) effects on antitumor immunity. 
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 Figure 4.3. 5: Exosome uptake by CD8+CD25+ Tr (Tr) cells. 
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Figure 4.3. 6: Characterization of exosome pulsed CD8+CD25+ Tr (Tr/E). 
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